• Abdo AA, Bain VG, Kichian K, Lee SS. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology 36: 1393-1399 (2002). *

• Abe M, Thomson AW. Dexamethasone preferentially suppresses plasmacytoid dendritic cell differentiation and enhances their apoptotic death. Clin. Immunol. 118: 300-306 (2006). *

• Aboian E, Winter DC, Metcalf DR, Wolff BG. Perineal hernia after proctectomy: prevalence, risks, and management. Dis. Colon Rectum 49: 1564-1568 (2006). *

• Abraham SC, Freese DK, Ishitani MB, Krasinskas AM, Wu TT. Significance of central perivenulitis in pediatric liver transplantation. Am. J. Surg. Pathol. 32: 1479-1488 (2008).

• Adams DH, Afford SC. Effector mechanisms of nonsuppurative destructive cholangitis in graft-versus-host disease and allograft rejection. Semin. Liver Dis. 25: 281-297 (2005).

• Adams RW, Chapman RL, Smallwood GA. Steroid withdrawal in liver transplant recipients. Prog. Transplant. 11: 217-223 (2001).

• Adorini L. New trends in clinical and experimental immunosuppression - fourth international conference. IDrugs 3: 496-498 (2000).

• Aggarwal C, Gupta S, Hahn T, Smiley S, Padmanabhan S, McCarthy PL Jr, Battiwalla M. Human leukocyte antigen DR4 is associated with inferior progression-free survival following allogeneic hematopoietic stem cell transplantation for lymphoid malignancies. Leuk. Lymphoma 49: 1494-1500 (2008).

• Ahluwalia M, Gotlieb V, Damerla V, Saif MW. Aggressive Burkitt-like lymphoma of colon in a patient with prior celiac disease. Yale J. Biol. Med. 79: 173-175 (2006). *

• Aithal GP, Mansfield JC. Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment. Aliment. Pharmacol. Ther. 15: 1101-1108 (2001). *

• Akalin E. Posttransplant immunosuppression in highly sensitized patients. Contrib. Nephrol. 162: 27-34 (2009).

• Akashi S, Sho M, Kashizuka H, Hamada K, Ikeda N, Kuzumoto Y, Tsurui Y, Nomi T, Mizuno T, Kanehiro H, Hisanaga M, Ko S, Nakajima Y. A novel small-molecule compound targeting CCR5 and CXCR3 prevents acute and chronic allograft rejection. Transplantation 80: 378-384 (2005).

• Aksamit AJ. Progressive multifocal leukoencephalopathy. Curr. Treat. Options Neurol. 10: 178-185 (2008).

• Aksamit AJ. Review of progressive multifocal leukoencephalopathy and natalizumab. Neurologist 12: 293-298 (2006).

• Al Shammeri O, Duerksen DR. Celiac crisis in an adult on immunosuppressive therapy. Can. J. Gastroenterol. 22: 574-576 (2008). *

• Al-Chalabi T, Heneghan MA. Remission in autoimmune hepatitis: what is it, and can it ever be achieved? Am. J. Gastroenterol. 102: 1013-1015 (2007). *

• Al-Za'abi AM, Ghazarian D, Greenberg GR, Shaw JC. Eruptive tufted angiomas in a patient with Crohn's disease. J. Clin. Pathol. 58: 214-216 (2005). *

• Ali M, Duerksen DR. Ulcerative colitis and Sweet's syndrome: a case report and review of the literature. Can. J. Gastroenterol. 22: 296-298 (2008). *

• Allam R, Anders HJ. The role of innate immunity in autoimmune tissue injury. Curr. Opin. Rheumatol. 20: 538-544 (2008).

• Alvarez F. Round table: controversies in the treatment of autoimmune liver diseases in children. Cyclosporine indication in “autoimmune hepatitis (AIH)”. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 95-96 (2004). *

• Anastasiadis A, Margaritis D, Kotsianidis I, Spanoudakis E, Christoforidou A, Kostopoulos I, Tsatalas C. Pure red cell aplasia as first manifestation of splenic marginal zone lymphoma-successful treatment with rituximab: a case report. Cases J. 2: 6913 (2009). *

• Anderson NG, Garcia-Valenzuela E, Martin DF. Hypopyon uveitis and relapsing polychondritis: a report of 2 patients and review of autoimmune hypopyon uveitis. Ophthalmology 111: 1251-1254 (2004).

• Annicchiarico BE, Siciliano M, Avolio AW, Agnes S, Bombardieri G. Orthotopic liver transplantation after successful treatment with anti-CD20 monoclonal antibody (rituximab) for severe steroid-resistant autoimmune hemolytic anemia: a case report. Transplant. Proc. 41: 1380-1382 (2009). *

• Ansari A, Elliott T, Fong F, Arenas-Hernandez M, Rottenberg G, Portmann B, Lucas S, Marinaki A, Sanderson J. Further experience with the use of 6-thioguanine in patients with Crohn's disease. Inflamm. Bowel Dis. 14: 1399-1405 (2008). *

• Ansari AA, Pattanapanyasat K. Chapter 33. Immunological tolerance in allo- and xenografts. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 433-449 (2007). *

• Ansorge S, Bank U, Heimburg A, Helmuth M, Koch G, Tadje J, Lendeckel U, Wolke C, Neubert K, Faust J, Fuchs P, Reinhold D, Thielitz A, Tager M. Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin. Chem. Lab. Med. 47: 253-261 (2009).

• Anstey A, Lear JT. Azathioprine: clinical pharmacology and current indications in autoimmune disorders. BioDrugs 9: 33-47 (1998).

• Antoine C. Transplantation strategies in immunized and hyperimmunized patients. Nephrol. Ther. 4 Suppl. 3: S174-S178 (2008).

• Antonelli A, Ferri C, Galeazzi M, Giannitti C, Manno D, Mieli-Vergani G, Menegatti E, Olivieri I, Puoti M, Palazzi C, Roccatello D, Vergani D, Sarzi-Puttini P, Atzeni F. HCV infection: pathogenesis, clinical manifestations and therapy. Clin. Exp. Rheumatol. 26: S39-S47 (2008).

• Aoki T, Umehara Y, Ferraresso C, Sugiyama N, Middleton Y, Avital I, Inderbitzin D, Demetriou AA, Rozga J. Intrasplenic transplantation of encapsulated cells: a novel approach to cell therapy. Cell Transplant. 11: 553-561 (2002).

• Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, Mariette C, Chaput N, Mira JP, Delaloge S, Andre F, Tursz T, Kroemer G, Zitvogel L. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol. Rev. 220: 47-59 (2007). *

• Appay V, Voelter V, Rufer N, Reynard S, Jandus C, Gasparini D, Lienard D, Speiser DE, Schneider P, Cerottini JC, Romero P, Leyvraz S. Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma. J. Immunother. 30: 240-250 (2007).

• Appel GB, Waldman M. The IgA nephropathy treatment dilemma. Kidney Int. 69: 1939-1944 (2006). *

• Araujo MB, Leonardi LS, Leonardi MI, Boin IF, Magna LA, Donadi EA, Kraemer MH. Prospective analysis between the therapy of immunosuppressive medication and allogeneic microchimerism after liver transplantation. Transpl. Immunol. 20: 195-198 (2009).

• Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 50: 3161-3169 (2004). *

• Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, Steiner G, Smolen JS. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 48: 1451-1454 (2009).

• Armenti VT, Herrine SK, Moritz MJ. Reproductive function after liver transplantation. Clin. Liver Dis. 1: 471-485 (1997).

• Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment. Pharmacol. Ther. 17: 1451-1457 (2003). *

• Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients. Am. J. Gastroenterol. 103: 2308-2313 (2008). *

• Ashamiss F, Wierzbicki Z, Chrzanowska A, Scibior D, Pacholczyk M, Kosieradzki M, Lagiewska B, Porembska Z, Rowinski W. Clinical significance of arginase after liver transplantation. Ann. Transplant. 9: 58-60 (2004).

• Asherson RA, Giampaolo D, Strimling M. A case of adult-onset Satoyoshi syndrome with gastric ulceration and eosinophilic enteritis. Nat. Clin. Pract. Rheumatol. 4: 439-444 (2008).

• Ashwell JD, Lu FW, Vacchio MS. Glucocorticoids in T cell development and function. Annu. Rev. Immunol. 18: 309-345 (2000). *

• Assy N, Adams PC, Myers P, Simon V, Minuk GY, Wall W, Ghent CN. Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid. Transplantation 83: 1571-1576 (2007).

• Atalar K, Afzali B, Lord G, Lombardi G. Relative roles of Th1 and Th17 effector cells in allograft rejection. Curr. Opin. Organ Transplant. 14: 23-29 (2009).

• Atar M, Korperich EJ. Systemic disorders and their influence on the development of dental hard tissues: a literature review. J. Dent. Dec 14 [Epub ahead of print] (2009).

• Atkins GJ, Cosby SL. Is an improved measles-mumps-rubella vaccine necessary or feasible? Crit. Rev. Immunol. 23: 323-338 2003.

• Aubareda A, Mulero MC, Perez-Riba M. Functional characterization of the calcipressin 1 motif that suppresses calcineurin-mediated NFAT-dependent cytokine gene expression in human T cells. Cell. Signal. 18: 1430-1438 (2006). *

• Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270: 286-290 (1995). *

• Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J. Hepatol. 51: 156-160 (2009).

• Ayala A, Chaudry IH. Dietary n-3 polyunsaturated fatty acid modulation of immune cell function before or after trauma. Nutrition 11: 1-11 (1995).

• Babu S, Blauvelt CP, Kumaraswami V, Nutman TB. Regulatory networks induced by live parasites impair both Th1 and Th2 pathways in patent lymphatic filariasis: implications for parasite persistence. J. Immunol. 176: 3248-3256 (2006). *

• Badina L, Taddio A, Ventura A. Early combined immunosuppression in Crohn's disease. Lancet 371: 1995 (2008). *

• Bahrle S, Szabo G, Stiehl A, Theilmann L, Dengler TJ, Zimmermann R, Kubler W. Adjuvant treatment with ursodeoxycholic acid may reduce the incidence of acute cardiac allograft rejection. J. Heart Lung Transplant. 17: 592-598 (1998).

• Baker BS, Owles AV, Fry L. A possible role for vaccination in the treatment of psoriasis? G. Ital. Dermatol. Venereol. 143: 105-117 (2008).

• Baker JF, Ghio AJ. Iron homoeostasis in rheumatic disease. Rheumatology (Oxford) 48: 1339-1344 (2009).

• Bakke AC, Purtzer MZ, Wildin RS. Prospective immunological profiling in a case of immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX). Clin. Exp. Immunol. 137: 373-378 (2004). *

• Balan V, Abu-Elmagd K, Demetris AJ. Autoimmune liver diseases. Recurrence after liver transplantation. Surg. Clin. North Am. 79: 147-152 (1999).

• Balan V, Batts KP, Porayko MK, Krom RA, Ludwig J, Wiesner RH. Histological evidence for recurrence of primary biliary cirrhosis after liver transplantation. Hepatology 18: 1392-1398 (1993).

• Balan V, Ruppert K, Demetris AJ, Ledneva T, Duquesnoy RJ, Detre KM, Wei YL, Rakela J, Schafer DF, Roberts JP, Everhart JE, Wiesner RH. Long-term outcome of human leukocyte antigen mismatching in liver transplantation: results of the national institute of diabetes and digestive and kidney diseases liver transplantation database. Hepatology 48: 878-888 (2008). *

• Balandraud N, Guis S, Baptiste Meynard J, Auger I, Roudier J, Roudier C. Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase Epstein-Barr virus load in patients with rheumatoid arthritis. Arthritis Rheum. 57: 762-767 (2007). *

• Balato A, Unutmaz D, Gaspari AA. Natural killer T cells: an unconventional T-cell subset with diverse effector and regulatory functions. J. Invest. Dermatol. 129: 1628-1642 (2009). *

• Balfour Sartor R. Bacteria in Crohn's disease: mechanisms of inflammation and therapeutic implications. J. Clin. Gastroenterol. 41 Suppl. 1: S37-S43 (2007).

• Bandyopadhyay G, De A, Laudanski K, Li F, Lentz C, Bankey P, Miller-Graziano C. Negative signaling contributes to T-cell anergy in trauma patients. Crit. Care Med. 35: 794-801 (2007).

• Banga JP, Nielsen CH, Gilbert JA, El Fassi D, Hegedus L. Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trials. Thyroid 18: 973-981 (2008).

• Bao J, Miao S, Kayser F, Kotliar AJ, Baker RK, Doss GA, Felix JP, Bugianesi RM, Slaughter RS, Kaczorowski GJ, Garcia ML, Ha SN, Castonguay L, Koo GC, Shah K, Springer MS, Staruch MJ, Parsons WH, Rupprecht KM. Potent Kv1.3 inhibitors from correolide-modification of the C18 position. Bioorg. Med. Chem. Lett. 15: 447-451 (2005). *

• Barber A, Rynda A, Sentman CL. Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment. J. Immunol. 183: 6939-6947 (2009).

• Barber MD, Fearon KC, Ross JA. Eicosapentaenoic acid modulates the immune response but has no effect on a mimic of antigen-specific responses. Nutrition 21: 588-593 (2005). *

• Bardet V, Junior AP, Coste J, Lecoq-Lafon C, Chouzenoux S, Bernard D, Soubrane O, Lacombe C, Calmus Y, Conti F. Impaired erythropoietin production in liver transplant recipients: the role of calcineurin inhibitors. Liver Transpl. 12: 1649-1654 (2006). *

• Baroco AL, Oldfield EC. Gastrointestinal cytomegalovirus disease in the immunocompromised patient. Curr. Gastroenterol. Rep. 10: 409-416 (2008).

• Barreiro-de Acosta M, Magro F, Carpio D, Lago P, Echarri A, Cotter J, Pereira S, Goncalves R, Lorenzo A, Carvalho L, Castro J, Barros L, Dias JA, Rodrigues S, Portela F, Dias C, da Costa-Pereira A. Ulcerative colitis in northern Portugal and Galicia in Spain. Inflamm. Bowel Dis. Nov 18 [Epub ahead of print] (2009). *

• Bartosik W, Egan JJ, Soo A, Remund KF, Nolke L, McCarthy JF, Wood AE. A review of the lung transplantation programme in Ireland 2005-2007. Eur. J. Cardiothorac. Surg. 35: 807-811 (2009).

• Barve S, Joshi-Barve S, Song Z, Hill D, Hote P, Deaciuc I, McClain C. Interactions of cytokines, S-adenosylmethionine, and S-adenosylhomocysteine in alcohol-induced liver disease and immune suppression. J. Gastroenterol. Hepatol. 21 Suppl. 3: S38-S42 (2006). *

• Beaugerie L, Sokol H, Seksik P. Noncolorectal malignancies in inflammatory bowel disease: more than meets the eye. Dig. Dis. 27: 375-381 (2009).

• Beckebaum S, Cicinnati V, Broelsch CE. Liver transplantation, rejection and disease recurrence. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 55-56. October 15-16 (2003). *

• Beckebaum S, Cicinnati VR, Broelsch CE. Advances and limitations of liver transplantation in Germany. Verh. Dtsch. Ges. Pathol. 88: 45-50 (2004).

• Beckebaum S, Sotiropoulos GC, Klein CG, Broelsch CE, Saner F, Paul A, Gerken G, Cicinnati VR. Predictive factors of outcome in patients transplanted for hepatitis B. Transplantation 87: 872-881 (2009).

• Befeler AS, Lissoos TW, Schiano TD, Conjeevaram H, Dasgupta KA, Millis JM, Newell KA, Thistlethwaite JR, Baker AL. Clinical course and management of inflammatory bowel disease after liver transplantation. Transplantation 65: 393-396 (1998).

• Bellone M, Mondino A, Corti A. Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer. Trends Immunol. 29: 235-241 (2008). *

• Belloni Fortina A, Piaserico S, Zattra E, Alaibac M. Dermoscopic features of eruptive melanocytic naevi in an adult patient receiving immunosuppressive therapy for Crohn's disease. Melanoma Res. 15: 223-224 (2005).

• Ben M'rad M, Gherissi D, Mouthon L, Salmon-Ceron D. Tuberculosis risk among patients with systemic diseases. Presse. Med. 38: 274-290 (2009).

• Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin. Cancer Biol. 16: 38-52 (2006). *

• Bennett JL. Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis. Neurol. Res. 28: 291-298 (2006).

• Benseler V, McCaughan GW, Schlitt HJ, Bishop GA, Bowen DG, Bertolino P. The liver: a special case in transplantation tolerance. Semin. Liver Dis. 27: 194-213 (2007).

• Beretta C, Leoni V, Rossi MR, Jankovic M, Patroniti N, Foti G, Biagi E. Prolonged extracorporeal membrane oxygenation therapy for severe acute respiratory distress syndrome in a child affected by rituximab-resistant autoimmune hemolytic anemia: a case report. J. Med. Case Reports 3: 6443 (2009). *

• Bergasa NV, Mason A, Floreani A, Heathcote J, Swain MG, Jones DE, Lindor KM, Bassendine MF, Worman HJ. Primary biliary cirrhosis: report of a focus study group. Hepatology 40: 1013-1020 (2004). *

• Berger CL, Vasquez JG, Shofner J, Mariwalla K, Edelson RL. Langerhans cells: mediators of immunity and tolerance. Int. J. Biochem. Cell Biol. 38: 1632-1636 (2006). *

• Berggren MA, Heinlen L, Isaksson A, Nystrom U, Ricksten A. EBNA1 expression in a lung transplant recipient with hypocomplementemic urticarial vasculitis syndrome. J. Med. Virol. 79: 963-969 (2007).

• Berney T, Ferrari-Lacraz S, Buhler L, Oberholzer J, Marangon N, Philippe J, Villard J, Morel P. Long-term insulin-independence after allogeneic islet transplantation for type 1 diabetes: over the 10-year mark. Am. J. Transplant. 9: 419-423 (2009). *

• Bhat S, Milner S. Antimicrobial peptides in burns and wounds. Curr. Protein Pept. Sci. 8: 506-520 (2007).

• Bhattacharyya S, Brown DE, Brewer JA, Vogt SK, Muglia LJ. Macrophage glucocorticoid receptors regulate Toll-like receptor-4-mediated inflammatory responses by selective inhibition of p38 MAP kinase. Blood 109: 4313-4319 (2007). *

• Bianchi FB, Muratori L. Primary and secondary autoimmunity in hepatology. Ann. Ital. Med. Int. 15: 56-62 (2000).

• Bilbao I, Dopazo C, Lazaro JL, Castells L, Escartin A, Lopez I, Sapisochin G, Balsells J, Margarit C. Our experience in liver transplantation in patients over 65 yr of age. Clin. Transplant. 22: 82-88 (2008). *

• Binks M, Passweg JR, Furst D, McSweeney P, Sullivan K, Besenthal C, Finke J, Peter HH, van Laar J, Breedveld FC, Fibbe WE, Farge D, Gluckman E, Locatelli F, Martini A, van den Hoogen F, van de Putte L, Schattenberg AV, Arnold R, Bacon PA, Emery P, et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann. Rheum. Dis. 60: 577-584 (2001). *

• Bird MD, Kovacs EJ. Organ-specific inflammation following acute ethanol and burn injury. J. Leukoc. Biol. 84: 607-613 (2008). *

• Biswas R, Ghosh P, Banerjee N, Das J, Sau T, Banerjee A, Roy S, Ganguly S, Chatterjee M, Mukherjee A, Giri A. Analysis of T-cell proliferation and cytokine secretion in the individuals exposed to arsenic. Hum. Exp. Toxicol. 27: 381-386 (2008).

• Biswas SK, Lopez-Collazo E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol. 30: 475-487 (2009). *

• Bjelakovic G, Beninati S, Pavlovic D, Kocic G, Jevtovic T, Kamenov B, Saranac LJ, Bjelakovic B, Stojanovic I, Banic J. Glucocorticoids and oxidative stress. J. Basic Clin. Physiol. Pharmacol. 18: 115-127 (2007).

• Black M, Mignogna M, Scully C. Pemphigus vulgaris. Oral Dis. 11: 119-130 (2005). *

• Blanchard TG, Drakes ML, Czinn SJ. Helicobacter infection: pathogenesis. Curr. Opin. Gastroenterol. 20: 10-15 (2004).

• Blauwet LA, Cooper LT. Myocarditis. Prog. Cardiovasc. Dis. 52: 274-288 (2010).

• Bleau C, Monges A, Rashidan K, Laverdure JP, Lacroix M, Van Calsteren MR, Millette M, Savard R, Lamontagne L. Intermediate chains of exopolysaccharides from Lactobacillus rhamnosus RW-9595M increase IL-10 production by macrophages. J. Appl. Microbiol. Jun 30 [Epub ahead of print] (2009). *

• Bleday R, Lee E, Jessurun J, Heine J, Wong WD. Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease. Dis. Colon Rectum 36: 908-912 (1993).

• Bobadilla NA, Gamba G. New insights into pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone. Am. J. Physiol. Renal Physiol. 293: F2-F9 (2007). *

• Bocelli-Tyndall C, Bracci L, Spagnoli G, Braccini A, Bouchenaki M, Ceredig R, Pistoia V, Martin I, Tyndall A. Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. Rheumatology (Oxford) 46: 403-408 (2007). *

• Bodingbauer M, Kramar R, Wekerle T, Bohmig GA, Berlakovich G, Saemann MD, Steininger R, Perco P, Oberbauer R, Horl W, Muhlbacher F. Present status at the Vienna Transplantation Center after four thousand renal transplantations. Clin. Transpl. 2007: 69-80 (2007).

• Bogdanos D, Vergani D, Mieli-Vergani G. Overlap syndromes from pediatrics to adulthood. J. Gastroenterol. Hepatol. 19: S284-S286 (2004). *

• Bohm M, Luger TA, Schneider M, Schwarz T, Kuhn A. New insight into immunosuppression and treatment of autoimmune diseases. Clin. Exp. Rheumatol. 24: S67-S71 (2006).

• Boillot O, Mayer DA, Boudjema K, Salizzoni M, Gridelli B, Filipponi F, Trunecka P, Krawczyk M, Clavien PA, Ducerf C, Margarit C, Margreiter R, Pallardo JM, Hoeckerstedt K, Pageaux GP. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. Liver Transpl. 11: 61-67 (2005). *

• Boltin D, Vilkin A, Levi Z, Elkayam O, Niv Y. JC virus T-antigen DNA in gastrointestinal mucosa of immunosuppressed patients: a prospective, controlled study. Dig. Dis. Sci. Oct 3 [Epub ahead of print] (2009). *

• Bonfioli AA, de Miranda SS, Campos WR, Orefice F. Tuberculosis. Semin. Ophthalmol. 20: 169-175 (2005).

• Borner C, Warnick B, Smida M, Hartig R, Lindquist JA, Schraven B, Hollt V, Kraus J. Mechanisms of opioid-mediated inhibition of human T cell receptor signaling. J. Immunol. 183: 882-889 (2009).

• Borza DB, Chedid MF, Colon S, Lager DJ, Leung N, Fervenza FC. Recurrent Goodpasture's disease secondary to a monoclonal IgA1-kappa antibody autoreactive with the alpha1/alpha2 chains of type IV collagen. Am. J. Kidney Dis. 45: 397-406 (2005).

• Bosso MC, Marchesa PE, Ricchiuti A, Giacardi A, Cocchis D, Campi M, Palisi M, Salizzoni M. Proctocolectomy for ulcerative colitis after liver transplantation for primary sclerosing cholangitis. Transplant. Proc. 41: 1390-1392 (2009). *

• Bournia VK, Vlachoyiannopoulos PG, Selmi C, Moutsopoulos HM, Gershwin ME. Recent advances in the treatment of systemic sclerosis. Clin. Rev. Allergy Immunol. 36: 176-200 (2009). *

• Bozorgzadeh A, Jain A, Ryan C, Ornt D, Zand M, Mantry P, Lansing K, Orloff M. Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus. Transplantation 77: 1066-1070 (2004).

• Bradstock KF, Hertzberg MS, Kerridge IH, Svennilson J, McGurgan M, Huang G, Antonenas V, Gottlieb DJ. Unrelated umbilical cord blood transplantation for adults with haematological malignancies: results from a single Australian centre. Intern. Med. J. 36: 355-361 (2006). *

• Brandtzaeg P. 'ABC' of mucosal immunology. Nestle Nutr. Workshop Ser. Pediatr. Program 64: 23-43 (2009).

• Brandtzaeg P. Impact of immunodeficiency on immunological hoemostasis in the gut. Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 61-62. September 12 - 13 (2003). *

• Bratchikov OI, Lazarev AI, Siplivyi GV, Kukureka AV, Karlov PM, Siplivaia LE, Shumakova EA. Immunometabolic activity of fluoroquinolones immobilized into cell carriers in toxic lesion of the kidneys due to staphylococcal infection. Urologiia 2: 13-18 (2009).

• Braumann C, Menenakos C, Jacobi CA. Pneumatosis intestinalis - a pitfall for surgeons? Scand. J. Surg. 94: 47-50 (2005).

• Braun A, Sis J, Max R, Mueller K, Fiehn C, Zeier M, Andrassy K. Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases. Scand. J. Rheumatol. 36: 291-298 (2007). *

• Braun J, Targan SR. Multiparameter analysis of immunogenetic mechanisms in clinical diagnosis and management of inflammatory bowel disease. Adv. Exp. Med. Biol. 579: 209-218 (2006).

• Bremner AR, Beattie RM. Recent advances in the medical therapy of Crohn's disease in childhood. Expert Opin. Pharmacother. 8: 2553-2568 (2007).

• Briand JP, Muller S. Emerging peptide therapeutics for inflammatory autoimmune diseases. Curr. Pharm. Des. Dec 23 [Epub ahead of print] (2009).

• British Society of Gastroenterology. Antibiotic prophylaxis in gastrointestinal endoscopy. BSG Guidelines in Gastroenterology, p. 1-10, January (2001). *

• Brodsky RA, Jones RJ. Aplastic anaemia. Lancet 365: 1647-1656 (2005). *

• Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB. Interleukin-10 determines viral clearance or persistence in vivo. Nat. Med. 12: 1301-1309 (2006). *

• Broughton SS, Meyerhoff WE, Cohen SB. Immune-mediated inner ear disease: 10-year experience. Semin. Arthritis Rheum. 34: 544-548 (2004). *

• Bucuvalas JC, Anand R; Studies of Pediatric Liver Transplantation Research Group. Treatment with immunoglobulin improves outcome for pediatric liver transplant recipients. Liver Transpl. 15: 1564-1569 (2009).

• Bucuvalas JC, Zeng L, Anand R, The Studies of Pediatric Liver Transplantation (SPLIT) Research Group. Predictors of length of stay for pediatric liver transplant recipients. Liver Transpl. 10: 1011-1017 (2004). *

• Buniel MC, Geelan-Hansen K, Weber PC, Tuohy VK. Immunosuppressive therapy for autoimmune inner ear disease. Immunotherapy 1: 425-434 (2009).

• Burra P. Hepatitis C. Semin. Liver Dis. 29: 53-65 (2009).

• Burt AD. Spectrum of liver pathology in immune mediated liver diseases. J. Gastroenterol. Hepatol. 19: S353-S355 (2004). *

• Burt RK, Traynor A, Statkute L, Barr WG, Rosa R, Schroeder J, Verda L, Krosnjar N, Quigley K, Yaung K, Villa Bs M, Takahashi M, Jovanovic B, Oyama Y. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 295: 527-535 (2006). *

• Burt RK, Traynor AE, Cohen B, Karlin KH, Davis FA, Stefoski D, Terry C, Lobeck L, Russell EJ, Goolsby C, Rosen S, Gordon LI, Keever-Taylor C, Brush M, Fishman M, Burns WH. T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients. Bone Marrow Transplant. 21: 537-541 (1998).

• Burt RK, Traynor AE, Pope R, Schroeder J, Cohen B, Karlin KH, Lobeck L, Goolsby C, Rowlings P, Davis FA, Stefoski D, Terry C, Keever-Taylor C, Rosen S, Vesole D, Fishman M, Brush M, Mujias S, Villa M, Burns WH. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood 92: 3505-3514 (1998). *

• Bushell A, Wood K. GITR ligation blocks allograft protection by induced CD25(+)CD4(+) regulatory T cells without enhancing effector T-cell function. Am. J. Transplant. 7: 759-768 (2007). *

• Bushell A, Wood KJ. Permanent survival of organ transplants without immunosuppression: experimental approaches and possibilities for tolerance induction in clinical transplantation. Expert Rev. Mol. Med. 1: 1-31 (1999). *

• Busuttil RW, Lake JR. Role of tacrolimus in the evolution of liver transplantation. Transplantation 77: S44-S51 (2004).

• Bynoe MS, Viret C. Foxp3(+)CD4(+) T cell-mediated immunosuppression involves extracellular nucleotide catabolism. Trends Immunol. 29: 99-102 (2008). *

• Cabrijan L, Lipozencic J, Batinac T, Lenkovic M, Stanic Zgombic Z. Influence of PUVA and UVB radiation on expression of ICAM-1 and VCAM-1 molecules in psoriasis vulgaris. Coll. Antropol. 32 Suppl. 2: 53-56 (2008).

• Caforio AL, Iliceto S. Genetically determined myocarditis: clinical presentation and immunological characteristics. Curr. Opin. Cardiol. 23: 219-226 (2008).

• Caforio AL, Tona F, Bottaro S, Vinci A, Dequal G, Daliento L, Thiene G, Iliceto S. Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy. Autoimmunity 41: 35-45 (2008).

• Caforio AL, Vinci A, Iliceto S. Anti-heart autoantibodies in familial dilated cardiomyopathy. Autoimmunity 41: 462-469 (2008).

• Cagatay T, Aydin M, Sunmez S, Cagatay P, Gulbaran Z, Gul A, Artim B, Kilicaslan Z. Follow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis. Rheumatol. Int. Oct 21 [Epub ahead of print] (2009). *

• Calabuig E, Salavert M. Infectious risk. Actas Dermosifiliogr. 99 Suppl. 4: 14-22 (2008).

• Calder PC. Use of fish oil in parenteral nutrition: rationale and reality. Proc. Nutr. Soc. 65: 264-277 (2006). *

• Calder PC. n-3 Fatty acids, inflammation, and immunity - relevance to postsurgical and critically ill patients. Lipids 39: 1147-1161 (2004).

• Calder PC. The 2008 ESPEN Sir David Cuthbertson lecture: fatty acids and inflammation - from the membrane to the nucleus and from the laboratory bench to the clinic. Clin. Nutr. Nov 18 [Epub ahead of print] (2009).

• Callan MF. Epstein-Barr virus, arthritis, and the development of lymphoma in arthritis patients. Curr. Opin. Rheumatol. 16: 399-405 (2004).

• Calmus Y. Immunosuppression after liver transplantation. Presse. Med. 38: 1307-1313 (2009).

• Cals-Grierson MM, Ormerod AD. Nitric oxide function in the skin. Nitric Oxide 10: 179-193 (2004). *

• Campbell MS, Rai J, Kozin E, Bloom RD, Markmann JF, Olthoff KM, Shaked A, Rajender Reddy K. Effects of sirolimus vs. calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation. Clin. Transplant. 21: 377-384 (2007). *

• Campbell PM, Senior PA, Salam A, Labranche K, Bigam DL, Kneteman NM, Imes S, Halpin A, Ryan EA, Shapiro AM. High risk of sensitization after failed islet transplantation. Am. J. Transplant. 7: 2311-2317 (2007). *

• Campbell S, Ghosh S. Combination immunomodulatory therapy with cyclosporine and azathioprine in corticosteroid-resistant severe ulcerative colitis: the Edinburgh experience of outcome. Dig. Liver Dis. 35: 546-551 (2003).

• Campise M. Post-transplant diabetes mellitus: diagnosis and treatment. G. Ital. Nefrol. 24: 547-557 (2007).

• Campos M, Jouzdani E, Sempoux C, Buts JP, Reding R, Otte JB, Sokal EM. Sclerosing cholangitis associated to cryptosporidiosis in liver-transplanted children. Eur. J. Pediatr. 159: 113-115 (2000).

• Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Mandell S, Kam I. Sirolimus and liver transplantation: clinical implications for hepatocellular carcinoma. Expert Opin. Pharmacother. 8: 1275-1282 (2007).

• Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Steinberg T, Kam I. Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl. 14: 181-185 (2008). *

• Canivet C, Bohler T, Galvani S, Therville N, Salvayre R, Durand D, Thomsen M, Rostaing L, Kamar N. T-cell function in maintenance renal transplant patients receiving mycophenolate mofetil and steroids with or without tacrolimus. Transplant. Proc. 40: 3422-3423 (2008). *

• Cao Q, Wang L, Du F, Sheng H, Zhang Y, Wu J, Shen B, Shen T, Zhang J, Li D, Li N. Downregulation of CD4+CD25+ regulatory T cells may underlie enhanced Th1 immunity caused by immunization with activated autologous T cells. Cell Res. 17: 627-637 (2007). *

• Capello E, Saccardi R, Murialdo A, Gualandi F, Pagliai F, Bacigalupo A, Marmont A, Uccelli A, Inglese M, Bruzzi P, Sormani MP, Cocco E, Meucci G, Massacesi L, Bertolotto A, Lugaresi A, Merelli E, Solari A, Filippi M, Mancardi GL, et al. Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. Neurol. Sci. 26 Suppl. 4: s200-s203 (2005). *

• Capron A, Lerut J, Verbaandert C, Mathys J, Ciccarelli O, Vanbinst R, Roggen F, De Reyck C, Lemaire J, Wallemacq PE. Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in liver biopsies after hepatic transplantation: correlation with histopathologic staging of rejection. Ther. Drug Monit. 29: 340-348 (2007).

• Carbone J, Lanio N, Gallego A, Sarmiento E. Immune monitoring to predict the development of infections after immunosuppression for solid organ transplantation and autoimmune diseases. Curr. Drug Saf. 3: 91-99 (2008).

• Cardoso CC, Pinto AC, Marques PR, Gayer CR, Afel MI, Coelho MG, Sabino KC. Suppression of T and B cell responses by Pterodon pubescens seeds ethanolic extract. Pak. J. Biol. Sci. 11: 2308-2313 (2008).

• Carter JD, Chen M, Ellett JD, Smith KM, Nadler JL, Yang Z. Impact of donor immune cells in pancreatic islet transplantation. Transplant. Proc. 36: 2866-2868 (2004). *

• Castellaneta A, Di Leo A, Francavilla R, Margiotta M, Barone M, Amoruso A, Troiani L, Thomson AW, Francavilla A. Functional modification of CD11c(+) liver dendritic cells during liver regeneration after partial hepatectomy in mice. Hepatology 43: 807-816 (2006). *

• Cattral MS, Lilly LB, Levy GA. Immunosuppression in liver transplantation. Semin. Liver Dis. 20: 523-531 (2000). *

• Cavaletti G. Current status and future prospective of immunointervention in multiple sclerosis. Curr. Med. Chem. 13: 2329-2343 (2006).

• Ceballos-Viro J, Lopez-Picazo JM, Perez-Gracia JL, Sola JJ, Aisa G, Gil-Bazo I. Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer. World J. Gastroenterol. 15: 2290-2292 (2009). *

• Celik S, Doesch A, Erbel C, Blessing E, Ammon K, Koch A, Katus HA, Dengler TJ. Beneficial effect of omega-3 fatty acids on sirolimus- or everolimus-induced hypertriglyceridemia in heart transplant recipients. Transplantation 86: 245-250 (2008).

• Cencioni MT, Chiurchiu V, Catanzaro G, Borsellino G, Bernardi G, Battistini L, Maccarrone M. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB(2) receptors. PLoS One 5: e8688 (2010). *

• Certad G, Arenas-Pinto A, Pocaterra L, Ferrara G, Castro J, Bello A, Nunez L. Cryptosporidiosis in HIV-infected Venezuelan adults is strongly associated with acute or chronic diarrhea. Am. J. Trop. Med. Hyg. 73: 54-57 (2005).

• Chaklader M, Morris-Larkin L, Gulliver W, McGrath J. Cyclosporine in the management of esophageal lichen planus. Can. J. Gastroenterol. 23: 686-688 (2009).

• Chamberlain G, Wright K, Rot A, Ashton B, Middleton J. Murine mesenchymal stem cells exhibit a restricted repertoire of functional chemokine receptors: comparison with human. PLoS ONE 3: e2934 (2008). *

• Chan TM. Lupus nephritis: induction therapy. Lupus 14 Suppl. 1: s27-s32 (2005).

• Chang YC, Chen TC, Lee CT, Yang CY, Wang HW, Wang CC, Hsieh SL. Epigenetic control of MHC-II expression in tumor-associated macrophages by decoy receptor 3. Blood 111: 5054-5063 (2008). *

• Chapman RW. The management of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 5: 9-17 (2003).

• Charach G, Grosskopf I, Weintraub M. Development of Crohn's disease in a patient with multiple sclerosis treated with copaxone. Digestion 77: 198-200 (2008). *

• Charlton M. Obesity, hyperlipidemia, and metabolic syndrome. Liver Transpl. 15: S83-S89 (2009).

• Chase K, Sargan D, Miller K, Ostrander EA, Lark KG. Understanding the genetics of autoimmune disease: two loci that regulate late onset Addison's disease in Portuguese water dogs. Int. J. Immunogenet. 33: 179-184 (2006). *

• Chatenoud L. Progress towards the clinical use of CD3 monoclonal antibodies in the treatment of autoimmunity. Curr. Opin. Organ Transplant. 14: 351-356 (2009).

• Chatenoud L. CD3-specific antibodies restore self-tolerance: mechanisms and clinical applications. Curr. Opin. Immunol. 17: 632-637 (2005).

• Chatenoud L, Bach JF. Resetting the functional capacity of regulatory T cells: a novel immunotherapeutic strategy to promote immune tolerance. Expert Opin. Biol. Ther. 5 Suppl. 1: S73-S81 (2005).

• Chen H, Cowan MJ, Hasday JD, Vogel SN, Medvedev AE. Tobacco smoking inhibits expression of proinflammatory cytokines and activation of IL-1R-associated kinase, p38, and NF-kappaB in alveolar macrophages stimulated with TLR2 and TLR4 agonists. J. Immunol. 179: 6097-6106 (2007). *

• Chen W, Gluud C. Bile acids for liver transplanted patients. Cochrane Database Syst. Rev. 2: CD004384 (2004). *

• Chew GY, Gatenby PA. Inflammatory myositis complicating hypocomplementemic urticarial vasculitis despite on-going immunosuppression. Clin. Rheumatol. 26: 1370-1372 (2007). *

• Chinnakotla S, Smith DM, Domiati-Saad R, Agura ED, Watkins DL, Netto G, Uemura T, Sanchez EQ, Levy MF, Klintmalm GB. Acute graft-versus-host disease after liver transplantation: role of withdrawal of immunosuppression in therapeutic management. Liver Transpl. 13: 157-161 (2007). *

• Chiu WC, Wang YC, Chien YW, Hou YC, Hu YM, Yeh SL. Effects of dietary fish oil supplementation on cellular adhesion molecule expression and tissue myeloperoxidase activity in hypercholesterolemic mice with sepsis. J. Nutr. Biochem. 20: 254-260 (2009). *

• Cho EH, Suh KS, Yang SH, Lee HW, Cho JY, Cho YB, Yi NJ, Lee KU. Acute graft versus host disease following living donor liver transplantation: first Korean report. Hepatogastroenterology 54: 2120-2122 (2007).

• Cho ML, Min SY, Chang SH, Kim KW, Heo SB, Lee SH, Park SH, Cho CS, Kim HY. Transforming growth factor beta 1(TGF-beta1) down-regulates TNFalpha-induced RANTES production in rheumatoid synovial fibroblasts through NF-kappaB-mediated transcriptional repression. Immunol. Lett. 105: 159-166 (2006).

• Cholongitas E, Shusang V, Papatheodoridis GV, Marelli L, Manousou P, Rolando N, Patch D, Rolles K, Davidson B, Burroughs AK. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 14: 138-143 (2008). *

• Chong BF, Wong HK. Treatment of psoriasis with etanercept in a patient with a history of primary B-cell lymphoma. Clin. Exp. Dermatol. 34: e11-e13 (2009). *

• Chung L, Berry GJ, Chakravarty EF. Giant cell myocarditis: a rare cardiovascular manifestation in a patient with systemic lupus erythematosus. Lupus 14: 166-169 (2005).

• Church NI, Pereira SP, Deheragoda MG, Sandanayake N, Amin Z, Lees WR, Gillams A, Rodriguez-Justo M, Novelli M, Seward EW, Hatfield AR, Webster GJ. Autoimmune pancreatitis: clinical and radiological features and objective response to steroid therapy in a UK series. Am. J. Gastroenterol. 102: 2417-2425 (2007). *

• Clark B, Unsworth DJ. HLA and kidney transplantation. J. Clin. Pathol. 63: 21-25 (2010).

• Clark RA, Huang SJ, Murphy GF, Mollet IG, Hijnen D, Muthukuru M, Schanbacher CF, Edwards V, Miller DM, Kim JE, Lambert J, Kupper TS. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J. Exp. Med. 205: 2221-2234 (2008). *

• Cobbold SP. New trends in immunosuppression. Int. Immunopharmacol. 5: 1-5 (2005).

• Cobbold SP, Adams E, Graca L, Daley S, Yates S, Paterson A, Robertson NJ, Nolan KF, Fairchild PJ, Waldmann H. Immune privilege induced by regulatory T cells in transplantation tolerance. Immunol. Rev. 213: 239-255 (2006). *

• Cohran VC, Heubi JE. Treatment of pediatric cholestatic liver disease. Curr. Treat. Options Gastroenterol. 6: 403-415 (2003).

• Colic-Hadzic B, Mladina N, Hadzic D. Humoral immunity in children with immunodeficiency and immunosuppression. Med. Arh. 63: 9-12 (2009).

• Collins BH, Pirsch JD, Becker YT, Hanaway MJ, Van der Werf WJ, D'Alessandro AM, Knechtle SJ, Odorico JS, Leverson G, Musat A, Armbrust M, Becker BN, Sollinger HW, Kalayoglu M. Long-term results of liver transplantation in older patients 60 years of age and older. Transplantation 70: 780-783 (2000).

• Collins PW. Treatment of acquired hemophilia A. J. Thromb. Haemost. 5: 893-900 (2007). *

• Colvin GA, Berz D, Ramanathan M, Winer ES, Fast L, Elfenbein GJ, Quesenberry PJ. Nonengraftment haploidentical cellular immunotherapy for refractory malignancies: tumor responses without chimerism. Biol. Blood Marrow Transplant. 15: 421-431 (2009).

• Conrad C, Trueb RM. Pyoderma gangrenosum. J. Dtsch. Dermatol. Ges. 3: 334-342 (2005).

• Contreras AM, Monteon FJ, Flores MR, Mendoza-Sanchez F, Ruiz I. Drug-related hepatotoxicity in a renal transplant recipient with long-term survival and hepatitis C. Ann. Hepatol. 6: 70-73 (2007). *

• Cooper SC, Olliff SP, McCafferty I, Wigmore SJ, Mirza DF. Polyarteritis nodosa, presenting as life-threatening gastrointestinal hemorrhage in a liver transplant recipient. Liver Transpl. 14: 151-154 (2008). *

• Cope AP, Schulze-Koops H, Aringer M. The central role of T cells in rheumatoid arthritis. Clin. Exp. Rheumatol. 25: S4-S11 (2007).

• Court FG, Wemyss-Holden SA, Dennison AR, Maddern GJ. Bioartificial liver support devices: historical perspectives. ANZ J. Surg. 73: 739-748 (2003). *

• Craig DG, Lee A, Hayes PC, Simpson KJ. Review article: the current management of acute liver failure. Aliment. Pharmacol. Ther. 31: 345-358 (2010). *

• Creange A, Farge-Bancel D. Immunoablation and autologous hematopoietic stem cell transplantation (AHSCT) in multiple sclerosis. Rev. Neurol. (Paris) 164: 207-215 (2008).

• Cucchiara S, Escher JC, Hildebrand H, Amil-Dias J, Stronati L, Ruemmele FM. Pediatric inflammatory bowel diseases and the risk of lymphoma: should we revise our treatment strategies? J. Pediatr. Gastroenterol. Nutr. 48: 257-267 (2009).

• Cuffari C, Hunt S, Bayless TM. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment. Pharmacol. Ther. 14: 1009-1014 (2000). *

• Cui H, Tucker-Burden C, Cauffiel SM, Barry AK, Iwakoshi NN, Weber CJ, Safley SA. Long-term metabolic control of autoimmune diabetes in spontaneously diabetic nonobese diabetic mice by nonvascularized microencapsulated adult porcine islets. Transplantation 88: 160-169 (2009).

• Cullen S, Chapman R. Aetiopathogenesis of primary sclerosing cholangitis. Best Pract. Res. Clin. Gastroenterol. 15: 577-589 (2001). *

• Cunha BA, Gouzhva O, Nausheen S. Severe cytomegalovirus (CMV) community-acquired pneumonia (CAP) precipitating a systemic lupus erythematosus (SLE) flare. Heart Lung 38: 249-252 (2009).

• Czaja AJ. Treatment of autoimmune hepatitis. Semin. Liver Dis. 22: 365-378 (2002). *

• Czaja AJ. Emerging treatments for autoimmune hepatitis. Curr. Drug Targets Inflamm. Allergy 1: 317-326 (2002).

• D'Alessandro AM, Knechtle SJ, Chin LT, Fernandez LA, Yagci G, Leverson G, Kalayoglu M. Liver transplantation in pediatric patients: twenty years of experience at the University of Wisconsin. Pediatr. Transplant. 11: 661-670 (2007). *

• D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ, Coche JC, van der Woude J, Ochsenkuhn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371: 660-667 (2008). *

• D'Haens G, Feagan B, Stitt L. Early combined immunosuppression in Crohn's disease - authors' reply. Lancet 371: 1996-1997 (2008). *

• Dai Z, Turtle CJ, Booth GC, Riddell SR, Gooley TA, Stevens AM, Spies T, Groh V. Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus. J. Exp. Med. 206: 793-805 (2009). *

• Daikeler T, Kotter I, Bocelli Tyndall C, Attarbaschi A, Apperley J, Guardiola P, Gratwohl A, Jantunen E, Marmont A, Porretto F, Musso M, Maurer B, Rinaldi N, Saccardi R, Tyndall A. Haematopoietic stem cell transplantation for vasculitis including Behcet's disease and polychondritis. A retrospective analysis of patients recorded to the European Bone Marrow Transplantation (EBMT) and European League Against Rheumatism (EULAR) … Ann. Rheum. Dis. 66: 202-207 (2007). *

• Dalekos GN, Zachou K, Liaskos C, Gatselis N. Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview. Eur. J. Intern. Med. 13: 293-303 (2002).

• Dalgic A, Ozcay F, Arslan G, Emiroglu R, Sozen H, Moray G, Karakayali H, Bilgin N, Haberal M. Living-related liver transplantation in pediatric patients. Transplant. Proc. 37: 3133-3136 (2005).

• Damian DL, Kim YJ, Dixon KM, Halliday GM, Javeri A, Mason RS. Topical calcitriol protects from UV-induced genetic damage but suppresses cutaneous immunity in humans. Exp. Dermatol. Sep 16 [Epub ahead of print] (2009).

• Danese S, Peyrin-Biroulet L. Early combined immunosuppression in Crohn's disease. Lancet 371: 1996 (2008). *

• Darmanin S, Chen J, Zhao S, Cui H, Shirkoohi R, Kubo N, Kuge Y, Tamaki N, Nakagawa K, Hamada J, Moriuchi T, Kobayashi M. All-trans retinoic acid enhances murine dendritic cell migration to draining lymph nodes via the balance of matrix metalloproteinases and their inhibitors. J. Immunol. 179: 4616-4625 (2007). *

• Davis GL, Czaja AJ. Current concepts in the diagnosis and management of hepatitis B surface antigen-positive chronic active hepatitis. J. Clin. Gastroenterol. 3: 381-388 (1981).

• Day MJ. Canine sino-nasal aspergillosis: parallels with human disease. Med. Mycol. 47 Suppl. 1: S315-S323 (2009). *

• de Boer NK, van Nieuwkerk CM, Aparicio Pages MN, de Boer SY, Derijks LJ, Mulder CJ. Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine. Eur. J. Gastroenterol. Hepatol. 17: 457-461 (2005).

• De Bosscher K, Vanden Berghe W, Haegeman G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J. Neuroimmunol. 109: 16-22 (2000).

• de Groot K, Schnabel A. Pulmonary-renal syndrome. Internist (Berl.) 46: 769-782 (2005).

• de Oliveira RA, Fechine LM, Neto FC, Nicodemus JM, Silva GB Jr, Silva LS. Posterior reversible encephalopathy syndrome (PRES) induced by cyclosporine use in a patient with collapsing focal glomeruloesclerosis. Int. Urol. Nephrol. 40: 1095-1098 (2008).

• De'Oliviera J, Gaskin G, Dash A, Rees AJ, Pusey CD. Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am. J. Kidney Dis. 25: 380-389 (1995).

• Debat Zoguereh D, Ruiz JM. Immunosuppression and vaccinations. Sante 10: 211-219 (2000).

• Debniak T, Kurzawski G, Huzarski T, Byrski T, Gronwald J, Debniak B, Rozmiarek A, Dziuba I, Zlowocka E, Suchy J, Gorski B, Cybulski C, Mierzejewski M, Masojc B, Medrek K, Oszurek O, Lubinski J. NOD2 variants and the risk of malignant melanoma. Eur. J. Cancer Prev. 14: 143-146 (2005).

• Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment. Pharmacol. Ther. 18: 1113-1120 (2003). *

• Dejica D. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy. Roum. Arch. Microbiol. Immunol. 60: 183-201 (2001).

• Del Pozo JL. Update and actual trends on bacterial infections following liver transplantation. World J. Gastroenterol. 14: 4977-4983 (2008). *

• Del Rio ML, Lucas CL, Buhler L, Rayat G, Rodriguez-Barbosa JI. HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation. J. Leukoc. Biol. Dec 14 [Epub ahead of print] (2009). *

• DeLuca HF, Zierold C. Mechanisms and functions of vitamin D. Nutr. Rev. 56: S4-S10 (1998).

• Demetris AJ. Evolution of hepatitis C virus in liver allografts. Liver Transpl. 15: S35-S41 (2009).

• Demirkiran A, Kok A, Kwekkeboom J, Kusters JG, Metselaar HJ, Tilanus HW, van der Laan LJ. Low circulating regulatory T-cell levels after acute rejection in liver transplantation. Liver Transpl. 12: 277-284 (2006). *

• Denys A, Hichami A, Khan NA. Eicosapentaenoic acid and docosahexaenoic acid modulate MAP kinase (ERK1/ERK2) signaling in human T cells. J. Lipid Res. 42: 2015-2020 (2001). *

• Descotes J. Immunotoxicology: role in the safety assessment of drugs. Drug Saf. 28: 127-136 (2005).

• Descotes J, Gouraud A. Clinical immunotoxicity of therapeutic proteins. Expert Opin. Drug Metab. Toxicol. 4: 1537-1549 (2008).

• Dhabhar FS. Enhancing versus suppressive effects of stress on immune function: implications for immunoprotection and immunopathology. Neuroimmunomodulation 16: 300-317 (2009).

• Dhillon MS, Rai JK, Gunson BK, Olliff S, Olliff J. Post-transplant lymphoproliferative disease in liver transplantation. Br. J. Radiol. 80: 337-346 (2007). *

• Diamond B. Autoimmunity. Immunol. Rev. 204: 5-8 (2005). *

• Dieckgraefe BK, Korzenik JR. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet 360: 1478-1480 (2002). *

• Dieckgraefe BK, Korzenik JR, Anant S. Growth factors as treatment options for intestinal inflammation. Ann. N. Y. Acad. Sci. 1072: 300-306 (2006). *

• Dikow R, Degenhard M, Kraus T, Sauer P, Schemmer P, Uhl W, Buchler M, Zeier M. Blood pressure profile and treatment quality in liver allograft recipients-benefit of tacrolimus versus cyclosporine. Transplant. Proc. 36: 1512-1515 (2004). *

• Dinarello CA. Anti-cytokine therapy from the bench to the bedside. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 84-86 (2005). *

• Dirosario J, Divers E, Wang C, Etter J, Charrier A, Jukkola P, Auer H, Best V, Newsom DL, McCarty DM, Fu H. Innate and adaptive immune activation in the brain of MPS IIIB mouse model. J. Neurosci. Res. 87: 978-990 (2009).

• Ditschkowski M, Einsele H, Schwerdtfeger R, Bunjes D, Trenschel R, Beelen DW, Elmaagacli AH. Improvement of inflammatory bowel disease after allogeneic stem-cell transplantation. Transplantation 75: 1745-1747 (2003).

• Dmitrewski J, Hubscher SG, Mayer AD, Neuberger JM. Recurrence of primary biliary cirrhosis in the liver allograft: the effect of immunosuppression. J. Hepatol. 24: 253-257 (1996). *

• Dmitrienko S, Hoar DI, Balshaw R, Keown PA. Immune response gene polymorphisms in renal transplant recipients. Transplantation 80: 1773-1782 (2005).

• Doctor P, Sultan A, Syed S, Christen W, Bhat P, Quinones K, Foster S. Infliximab for the treatment of refractory scleritis. Br. J. Ophthalmol. Dec 2 [Epub ahead of print] (2009).

• Doganis D, Baka M, Pourtsidis A, Bouhoutsou D, Varvoutsi M, Stamos G, Anastasiou N, Androulakakis E, Vasilatou-Kosmidis H. Successful combination of antifungal agents and surgical resection for pulmonary aspergillosis in a child with Hodgkin disease: review of the literature. Pediatr. Hematol. Oncol. 24: 631-638 (2007).

• Doherty SD, Van Voorhees A, Lebwohl MG, Korman NJ, Young MS, Hsu S. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J. Am. Acad. Dermatol. 59: 209-217 (2008).

• Dolle L, Best J, Mei J, Al Battah F, Reynaert H, van Grunsven LA, Geerts A. The quest for liver progenitor cells: a practical point of view. J. Hepatol. 52: 117-129 (2010). *

• Domagk D, Fegeler W, Conrad B, Menzel J, Domschke W, Kucharzik T. Biliary tract candidiasis: diagnostic and therapeutic approaches in a case series. Am. J. Gastroenterol. 101: 2530-2536 (2006). *

• Drake AL, Walling HW. Variations in presentation of squamous cell carcinoma in situ (Bowen's disease) in immunocompromised patients. J. Am. Acad. Dermatol. 59: 68-71 (2008).

• Dubinsky MC. Optimizing immunomodulator therapy for inflammatory bowel disease. Curr. Gastroenterol. Rep. 5: 506-511 (2003).

• Dubinsky MC, Fleshner PP. Treatment of Crohn's disease of inflammatory, stenotic, and fistulizing phenotypes. Curr. Treat. Options Gastroenterol. 6: 183-200 (2003).

• Duclos-Vallee JC. Recurrence of autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis after liver transplantation. Acta Gastroenterol. Belg. 68: 331-336 (2005).

• Dufour C, Ferretti E, Bagnasco F, Burlando O, Lanciotti M, Ramenghi U, Saracco P, Van Lint MT, Longoni D, Torelli GF, Pillon M, Locasciulli A, Misuraca A, La Spina M, Bacigalupo A, Pistoia V, Corcione A, Svahn J. Changes of cytokine profile pre and post immunosuppression in acquired aplastic anemia. Haematologica 94: 1743-1747 (2009). *

• Dufour C, Giacchino R, Ghezzi P, Tonelli R, Ferretti E, Pitto A, Pistoia V, Lanza T, Svahn J. Etanercept as a salvage treatment for refractory aplastic anemia. Pediatr. Blood Cancer 52: 522-525 (2009).

• Dunkelberg JC, Trotter JF, Wachs M, Bak T, Kugelmas M, Steinberg T, Everson GT, Kam I. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl. 9: 463-468 (2003). *

• Dvorchik I, Subotin M, Demetris AJ, Fung JJ, Starzl TE, Wieand S, Abu-Elmagd KM. Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology 35: 380-384 (2002). *

• Dwarakanath AD, Nash J, Rhodes JM. 'Conversion' from ulcerative colitis to Crohn's disease associated with corticosteroid treatment. Gut 35: 1141-1144 (1994). *

• Edelbauer M, Jungraithmayr T, Zimmerhackl LB. Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression. Case report. Pediatr. Nephrol. 20: 811-813 (2005). *

• Eibl MM. History of immunoglobulin replacement. Immunol. Allergy Clin. North Am. 28: 737-764 (2008).

• Ejrnaes M, von Herrath MG, Christen U. Cure of chronic viral infection and virus-induced type 1 diabetes by neutralizing antibodies. Clin. Dev. Immunol. 13: 67-77 (2006). *

• Ejrnaes M, von Herrath MG, Christen U. Cure of chronic viral infection and virus-induced type 1 diabetes by neutralizing antibodies. Clin. Dev. Immunol. 13: 337-347 (2006). *

• El-Shanawany TM, Williams PE, Jolles S. Response of refractory ITP in a patient with common variable immunodeficiency (CVID) to treatment with rituximab. J. Clin. Pathol. 60: 715-716 (2007). *

• Elisa Bohmer A, Ribeiro Correa AM, de Souza DG, Knorr L, Hansel G, Gustavo Corbellini L, Driemeier D, Valmor Portela L, Onofre Souza D. Long-term cyclosporine treatment: evaluation of serum biochemical parameters and histopathological alterations in Wistar rats. Exp. Toxicol. Pathol. Nov 23 [Epub ahead of print] (2009). *

• Encke J, Uhl W, Stremmel W, Sauer P. Immunosuppression and modulation in liver transplantation. Nephrol. Dial. Transplant. 19 Suppl. 4: iv22-iv25 (2004). *

• Erdelyi DJ, Kamory E, Zalka A, Semsei AF, Csokay B, Andrikovics H, Tordai A, Borgulya G, Magyarosy E, Galantai I, Fekete G, Falus A, Szalai C, Kovacs GT. The role of ABC-transporter gene polymorphisms in chemotherapy induced immunosuppression, a retrospective study in childhood acute lymphoblastic leukaemia. Cell. Immunol. 244: 121-124 (2006). *

• Ermisch B, Kirste G, Brandis M, Zimmerhackl LB. Improvement of liver function in a paediatric patient with biliary cirrhosis after triple immunosuppression with mycophenolate following renal transplantation. Nephrol. Dial. Transplant. 13: 1325 (1998).

• Eroglu Y, Duzovali O, Kavukcu S, Irken G, Buyukgebiz B. Combination of steroid with azathioprine in treatment of giant cell autoimmune hepatitis. Turk. J. Pediatr. 39: 565-571 (1997).

• Escarcega RO, Garcia-Carrasco M, Fuentes-Alexandro S, Jara LJ, Rojas-Rodriguez J, Escobar-Linares LE, Cervera R. Insulin resistance, chronic inflammatory state and the link with systemic lupus erythematosus-related coronary disease. Autoimmun. Rev. 6: 48-53 (2006).

• Esteve Comas M, Loras Alastruey C, Fernandez-Banares F. How do we manage vaccinations in patients with inflammatory bowel disease? Dig. Dis. 27: 370-374 (2009).

• Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 53: 1363-1365 (2004). *

• Etxagibel A, Julia MR, Brotons A, Company MM, Dolz C. Drug-induced hepatitis superimposed on the presence of anti-SLA antibody: a case report. J. Med. Case Reports 2: 25 (2008). *

• Evans HM, Kelly DA, McKiernan PJ, Hubscher S. Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology 43: 1109-1117 (2006). *

• Evans HM, McKiernan PJ, Kelly DA. Mycophenolate mofetil for renal dysfunction after pediatric liver transplantation. Transplantation 79: 1575-1580 (2005).

• Everson GT, Trotter JF, Kugelmas M, Forman L. Immunosuppression in liver transplantation. Minerva Chir. 58: 725-740 (2003).

• Ezernitchi AV, Vaknin I, Cohen-Daniel L, Levy O, Manaster E, Halabi A, Pikarsky E, Shapira L, Baniyash M. TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J. Immunol. 177: 4763-4772 (2006). *

• Fagiuoli S, Bruni F, Bravi M, Candusso M, Gaffuri G, Colledan M, Torre G. Cyclosporin in steroid-resistant autoimmune hepatitis and HCV-related liver diseases. Dig. Liver Dis. 39 Suppl. 3: S379-S385 (2007).

• Falagas ME, Snydman DR, Ruthazer R, Griffith J, Werner BG, Freeman R, Rohrer R. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. Clin. Transplant. 11: 432-437 (1997).

• Fan LY, Zhou Z, Zhong S, Ling N, Wang ZY, Shi XF, Zhang DZ, Ren H. Nucleos(t)ides as prophylaxis for the reactivation of hepatitis B virus in immunosuppressed patients. Zhonghua Gan Zang Bing Za Zhi 17: 429-433 (2009).

• Faraj W, Dar F, Bartlett A, Vilca Melendez H, Marangoni G, Mukherji D, Mieli Vergani G, Dhawan A, Heaton N, Rela M. Auxiliary liver transplantation for acute liver failure in children. Ann. Surg. Jan 5 [Epub ahead of print] (2010).

• Fararjeh M, Mohammad MK, Bustanji Y, Alkhatib H, Abdalla S. Evaluation of immunosuppression induced by metronidazole in Balb/c mice and human peripheral blood lymphocytes. Int. Immunopharmacol. 8: 341-350 (2008).

• Farges O, Saliba F, Farhamant H, Samuel D, Bismuth A, Reynes M, Bismuth H. Incidence of rejection and infection after liver transplantation as a function of the primary disease: possible influence of alcohol and polyclonal immunoglobulins. Hepatology 23: 240-248 (1996). *

• Farghali H, Masek K. Immunopharmacologic agents in the amelioration of hepatic injuries. Int. J. Immunopharmacol. 20: 125-139 (1998).

• Fassas A, Kazis A. High-dose immunosuppression and autologous hematopoietic stem cell rescue for severe multiple sclerosis. J. Hematother. Stem Cell Res. 12: 701-711 (2003).

• Faust TW. Recurrent primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis after transplantation. Semin. Liver Dis. 20: 481-495 (2000). *

• Feagan BG. Management of perianal and fistulizing disease. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, p. 37 (2005). *

• Feist E, Hermann KG, Filimonow S, Ruckert RI, Dorner T, Hiepe F. Benefit of immunosuppression for severe Takayasu's arteritis and coincident primary biliary cirrhosis. Ann. Rheum. Dis. 63: 889-890 (2004). *

• Feld J, Heathcote E. Epidemiology of autoimmune liver disease. J. Gastroenterol. Hepatol. 18: 1118-1128 (2003). *

• Felizardo M, Gomes A, Sousa M, Teixeira A, Freitas J, Tavares A, Vaz Patto J, Gomes M. Immunosuppression and tuberculosis. Rev. Port. Pneumol. 13: S23-S24 (2007).

• Felley C, Mottet C, Hess J, Maillard MH, Delarive J, Michetti P. Main therapeutic advances in IBD in 2008. Rev. Med. Suisse. 5: 185-186, 188-190, 192-194 (2009).

• Fernando MM, Isenberg DA. Conversion of discoid lupus to antiphospholipid syndrome and SLE. Nat. Clin. Pract. Rheumatol. 4: 106-110 (2008).

• Ferraro D, Pizzillo P, Di Marco V, Vultaggio A, Iannitto E, Venezia G, Craxì A, Di Stefano R. Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B virus profile reliable? Liver Int. 29: 1171-1177 (2009).

• Ferreira AR, Roquete ML, Penna FJ, Toppa NH. Autoimmune hepatitis in children and adolescents: clinical study, diagnosis and therapeutic response. J. Pediatr. (Rio. J.) 78: 309-314 (2002). *

• Ferreyra HA, Jayasundera T, Khan NW, He S, Lu Y, Heckenlively JR. Management of autoimmune retinopathies with immunosuppression. Arch. Ophthalmol. 127: 390-397 (2009). *

• Fiel MI, Agarwal K, Stanca C, Elhajj N, Kontorinis N, Thung SN, Schiano TD. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl. 14: 861-871 (2008). *

• Fijak M, Meinhardt A. The testis in immune privilege. Immunol. Rev. 213: 66-81 (2006). *

• Filaci G, Fravega M, Fenoglio D, Rizzi M, Negrini S, Viggiani R, Indiveri F. Non-antigen specific CD8+ T suppressor lymphocytes. Clin. Exp. Med. 4: 86-92 (2004). *

• Filaci G, Pelli N, Sacco T, Contini P, Lanza L, Picciotto A, Scudeletti M, Puppo F, Castiglioni G, Indiveri F. S-Adenosyl-L-methionine is able to reverse the immunosuppressive effects of chenodeoxycholic acid in vitro. Int. J. Immunopharmacol. 19: 157-165 (1997).

• Fildes JE, Yonan N, Keevil BG. Melatonin - a pleiotropic molecule involved in pathophysiological processes following organ transplantation. Immunology 127: 443-449 (2009). *

• Fink S, Schilsky ML. Inherited metabolic disease of the liver. Curr. Opin. Gastroenterol. 23: 237-243 (2007).

• Fiocchi C. Susceptibility genes and overall pathogenesis of inflammatory bowel disease: where do we stand? Dig. Dis. 27: 226-235 (2009).

• First MR. Tacrolimus based immunosuppression. J. Nephrol. 17 Suppl. 8: S25-31 (2004).

• First MR, Fitzsimmons WE. Modified release tacrolimus. Yonsei Med. J. 45: 1127-1131 (2004). *

• Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene 23: 6524-6534 (2004). *

• Fleischer B. Superantigens produced by infectious pathogens: molecular mechanism of action and biological significance. Int. J. Clin. Lab. Res. 24: 193-197 (1994).

• Flohe S, Flohe SB, Schade FU, Waydhas C. Immune response of severely injured patients - influence of surgical intervention and therapeutic impact. Langenbecks Arch. Surg. 392: 639-648 (2007). *

• Flohe SB, Flohe S, Schade FU. Invited review: deterioration of the immune system after trauma: signals and cellular mechanisms. Innate Immun. 14: 333-344 (2008). *

• Floreani A, Niro G, Rosa Rizzotto E, Antoniazzi S, Ferrara F, Carderi I, Baldo V, Premoli A, Olivero F, Morello E, Durazzo M. Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment. Pharmacol. Ther. 24: 1051-1057 (2006).

• Floreani A, Rizzotto ER, Ferrara F, Carderi I, Caroli D, Blasone L, Baldo V. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am. J. Gastroenterol. 100: 1516-1522 (2005). *

• Florin TH, Pandeya N, Radford-Smith GL. Epidemiology of appendicectomy in primary sclerosing cholangitis and ulcerative colitis: its influence on the clinical behaviour of these diseases. Gut 53: 973-979 (2004). *

• Flotte TR, Laube BL. Gene therapy in cystic fibrosis. Chest 120: 124S-131S (2001). *

• Focosi D, Maggi F, Ceccherini-Nelli L, Marchi S, Petrine M. Progressive multifocal leukoencephalopathy in autoimmune disorders. Gut 58: 605 (2009).

• Forbes A, Blanshard C, Gazzard B. Natural history of AIDS related sclerosing cholangitis: a study of 20 cases. Gut 34: 116-121 (1993). *

• Foroncewicz B, Mucha K, Paczek L, Oldakowska-Jedynak U, Gornicka B, Zieniewicz K, Nyckowski P, Krawczyk M. Anti-CD25 and tacrolimus therapy may not prevent early primary biliary cirrhosis recurrence after liver transplantation: two case reports. Transplant. Proc. 35: 2310-2312 (2003). *

• Forrest G. Gastrointestinal infections in immunocompromised hosts. Curr. Opin. Gastroenterol. 20: 16-21 (2004).

• Fouillard L, Gorin NC, Laporte JP, Leon A, Brantus JF, Miossec P. Control of severe systemic lupus erythematosus after high-dose immunusuppressive therapy and transplantation of CD34+ purified autologous stem cells from peripheral blood. Lupus 8: 320-323 (1999).

• Fousteri G, Hayek A, von Herrath M. Stopping diabetes in its tracks: autologous non-myeloablative stem cell transplantation. Regen. Med. 2: 845-851 (2007).

• Francis G, Duggan A. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance. Gastroenterology 135: 2156-2157 (2008). *

• Franco J, Saeian K. Biliary tract inflammatory disorders: primary sclerosing cholangitis and primary biliary cirrhosis. Curr. Gastroenterol. Rep. 1: 95-101 (1999).

• Fraser CK, Blake SJ, Diener KR, Lyons AB, Brown MP, Hughes TP, Hayball JD. Dasatinib inhibits recombinant viral antigen-specific murine CD4(+) and CD8(+) T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Exp. Hematol. 37: 256-265 (2009).

• Frazier WJ, Hall MW. Immunoparalysis and adverse outcomes from critical illness. Pediatr. Clin. North Am. 55: 647-668 (2008).

• Freeman AF, Holland SM. Antimicrobial prophylaxis for primary immunodeficiencies. Curr. Opin. Allergy Clin. Immunol. 9: 525-530 (2009).

• Freeman HJ, Davis JE, Prest ME, Lawson EJ. Granulomatous bronchiolitis with necrobiotic pulmonary nodules in Crohn's disease. Can. J. Gastroenterol. 18: 687-690 (2004). *

• Freeman K, Shao Z, Remzi FH, Lopez R, Fazio VW, Shen B. Impact of orthotopic liver transplant for primary sclerosing cholangitis on chronic antibiotic refractory pouchitis. Clin. Gastroenterol. Hepatol. 6: 62-68 (2008).

• Fridell JA, Vianna R, Kwo PY, Howenstine M, Sannuti A, Molleston JP, Pescovitz MD, Tector AJ. Simultaneous liver and pancreas transplantation in patients with cystic fibrosis. Transplant. Proc. 37: 3567-3569 (2005). *

• Friman S, Persson H, Schersten T, Svanvik J, Karlberg I. Adjuvant treatment with ursodeoxycholic acid reduces acute rejection after liver transplantation. Transpl. Int. 5 Suppl. 1: S187-S189 (1992).

• Frumento G, Piazza T, Di Carlo E, Ferrini S. Targeting tumor-related immunosuppression for cancer immunotherapy. Endocr. Metab. Immune Disord. Drug Targets 6: 233-237 (2006).

• Fry JW, Wood KJ. Gene therapy: potential applications in clinical transplantation. Expert Rev. Mol. Med. 1: 1-20 (1999). *

• Fuchs S, Feferman T, Meidler R, Margalit R, Sicsic C, Brenner T, Laub O, Souroujon MC. Immunosuppression of EAMG by IVIG is mediated by a disease-specific anti-immunoglobulin fraction. Ann. N. Y. Acad. Sci. 1132: 244-248 (2008). *

• Fujii R, Kanai T, Nemoto Y, Makita S, Oshima S, Okamoto R, Tsuchiya K, Totsuka T, Watanabe M. FTY720 suppresses CD4+CD44highCD62L- effector memory T cell-mediated colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 291: G267-G274 (2006). *

• Fujita M, Hatachi S, Yagita M. Immunohistochemically proven cytomegalovirus gastrointestinal diseases in three patients with autoimmune diseases. Clin. Rheumatol. 27: 1057-1059 (2008). *

• Fukushima K, Ueno Y, Kanegane H, Yamagiwa Y, Inoue J, Kido O, Nagasaki F, Kogure T, Kakazu E, Nakagome Y, Matsuda Y, Obara N, Kimura O, Shimosegawa T. A case of severe recurrent hepatitis with common variable immunodeficiency. Hepatol. Res. 38: 415-420 (2008). *

• Fung J, Eghtesad B, Patel-Tom K, DeVera M, Chapman H, Ragni M. Liver transplantation in patients with HIV infection. Liver Transpl. 10: S39-S53 (2004). *

• Fung J, Kelly D, Kadry Z, Patel-Tom K, Eghtesad B. Immunosuppression in liver transplantation: beyond calcineurin inhibitors. Liver Transpl. 11: 267-280 (2005). *

• Furst B, Glatz M, Kerl H, Mullegger RR. The impact of immunosuppression on erythema migrans. A retrospective study of clinical presentation, response to treatment and production of Borrelia antibodies in 33 patients. Clin. Exp. Dermatol. 31: 509-514 (2006). *

• Gagne DJ, Papasavas PK, Dovec EA, Urbandt JE, Caushaj PF. Effect of immunosuppression on patients undergoing bariatric surgery. Surg. Obes. Relat. Dis. 5: 339-345 (2009).

• Gamblin TC, Krasinskas AM, Slivka AS, Tublin ME, Demetris J, Shue E, Caro S, Marsh JW, James Moser A. Fibroinflammatory biliary stricture: a rare bile duct lesion masquerading as cholangiocarcinoma. J. Gastrointest. Surg. 13: 713-721 (2009). *

• Ganea D, Gonzalez-Rey E, Delgado M. A novel mechanism for immunosuppression: from neuropeptides to regulatory T cells. J. Neuroimmune Pharmacol. 1: 400-409 (2006).

• Ganschow R, Schulz T, Meyer T, Broering DC, Burdelski M. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients. J. Pediatr. Gastroenterol. Nutr. 38: 198-203 (2004). *

• Gao LH, Zheng SS, Zhu YF, Wang YL, Wei GQ, Qian SQ, Jiang WJ. A rat model of chronic allograft liver rejection. Transplant. Proc. 37: 2327-2332 (2005). *

• Gao ZH, McAlister VC, Wright JR, McAlister CC, Peltekian K, MacDonald AS. Immunoglobulin-G subclass antidonor reactivity in transplant recipients. Liver Transpl. 10: 1055-1059 (2004). *

• Garcia RF, Garcia CE, McMaster P. Chronic rejection of the liver: the role of immunosuppression. BioDrugs 14: 283-297 (2000).

• Garcia-Torres ML, Primo J, Ortuno JA, Martinez M, Anton MD, Zaragoza A, Gonzalez O, Devesa F, Merino C, Del Olmo JA. A clinical study of adult autoimmune hepatitis in Valencia, Spain. Rev. Esp. Enferm. Dig. 100: 400-404 (2008).

• Garrick V, Atwal P, Barclay AR, McGrogan P, Russell RK. Successful implementation of a nurse-led teaching programme to administer methotrexate in the community setting to children with Crohn's disease. Aliment. Pharmacol. Ther. 29: 90-96 (2009). *

• Gaur LK. Nonhuman primate models for islet transplantation in type 1 diabetes research. ILAR J. 45: 324-333 (2004).

• Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl. 12: 1813-1824 (2006). *

• Gavaler JS, Delemos B, Belle SH, Heyl AE, Tarter RE, Starzl TE, Gavaler C, van Thiel DH. Ulcerative colitis disease activity as subjectively assessed by patient-completed questionnaires following orthotopic liver transplantation for sclerosing cholangitis. Dig. Dis. Sci. 36: 321-328 (1991).

• Gaynor JJ, Moon JI, Kato T, Nishida S, Selvaggi G, Levi DM, Island ER, Pyrsopoulos N, Weppler D, Ganz S, Ruiz P, Tzakis AG. A cause-specific hazard rate analysis of prognostic factors among 877 adults who received primary orthotopic liver transplantation. Transplantation 84: 155-165 (2007).

• Gdynia HJ, Mogel H, Kuhnlein P, Dorst J, Osterfeld N, von Arnim CA, Sperfeld AD. Diagnosis and differential diagnosis of granulomatous myositis. Nervenarzt. 79: 470-474 (2008).

• Geissler EK, Schlitt HJ. Immunosuppression for liver transplantation. Gut 58: 452-463 (2009).

• Geissler K. Current status of clinical development of interleukin-10. Curr. Opin. Hematol. 3: 203-208 (1996).

• Georgiadou SP, Dalekos GN. Which level of immunosuppression is harmful for occult hepatitis B virus infection?: 'a million dollar' answer. Liver Int. 29: 1127-1128 (2009).

• Georgiadou SP, Zachou K, Liaskos C, Gabeta S, Rigopoulou EI, Dalekos GN. Occult hepatitis B virus infection in patients with autoimmune liver diseases. Liver Int. 29: 434-442 (2009).

• Gerber DA, Green M, Jaffe R, Greenberg D, Mazariegos G, Reyes J. Cryptosporidial infections after solid organ transplantation in children. Pediatr. Transplant. 4: 50-55 (2000).

• Ghai S, Pattison J, Ghai S, O'Malley ME, Khalili K, Stephens M. Primary gastrointestinal lymphoma: spectrum of imaging findings with pathologic correlation. Radiographics 27: 1371-1388 (2007). *

• Gheuens S, Pierone G, Peeters P, Koralnik IJ. Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression. J. Neurol. Neurosurg. Psychiatry Oct 14 [Epub ahead of print] (2009).

• Ghio M, Contini P, Ubezio G, Mazzei C, Puppo F, Indiveri F. Immunomodulatory effects of blood transfusions: the synergic role of soluble HLA class I free heavy-chain molecules detectable in blood components. Transfusion 48: 1591-1597 (2008).

• Ghoneim MA, Refaie AF. Is matching for human leukocyte antigen-DR beneficial in pediatric kidney transplantation? Nat. Clin. Pract. Nephrol. 5: 70-71 (2009).

• Ghoreschi K, Rocken M. Immune deviation strategies in the therapy of psoriasis. Curr. Drug Targets Inflamm. Allergy 3: 193-198 (2004).

• Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, van Eden W, van der Zee R, Biedermann T, Prinz J, Mack M, Mrowietz U, Christophers E, Schlondorff D, Plewig G, Sander CA, Rocken M. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat. Med. 9: 40-46 (2003). *

• Giannopoulos K, Schmitt M, Kowal M, Wlasiuk P, Bojarska-Junak A, Chen J, Rolinski J, Dmoszynska A. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol. Rep. 20: 677-682 (2008). *

• Gibelli NE, Tannuri U, Mello ES, Cancado ER, Santos MM, Ayoub AA, Maksoud-Filho JG, Velhote MC, Silva MM, Pinho-Apezzato ML, Maksoud JG. Successful treatment of de novo autoimmune hepatitis and cirrhosis after pediatric liver transplantation. Pediatr. Transplant. 10: 371-376 (2006).

• Gibelli NE, Tannuri U, Pinho-Apezzato ML, Tannuri AC, Maksoud-Filho JG, Andrade WC, Velhote MC, Santos MM, Ayoub AA, Marques da Silva M. Sirolimus in pediatric liver transplantation: a single-center experience. Transplant. Proc. 41: 901-903 (2009). *

• Gill KR, Pelaez-Luna M, Keaveny A, Woodward TA, Wallace MB, Chari ST, Smyrk TC, Takahashi N, Clain JE, Levy MJ, Pearson RK, Petersen BT, Topazian MD, Vege SS, Kendrick M, Farnell MB, Raimondo M. Branch duct intraductal papillary mucinous neoplasm of the pancreas in solid organ transplant recipients. Am. J. Gastroenterol. 104: 1256-1261 (2009). *

• Girlanda R, Rela M, Williams R, O'Grady JG, Heaton ND. Long-term outcome of immunosuppression withdrawal after liver transplantation. Transplant. Proc. 37: 1708-1709 (2005). *

• Girlanda R, Vilca-Melendez H, Srinivasan P, Muiesan P, O'Grady JG, Rela M, Heaton ND. Immunosuppression withdrawal after auxiliary liver transplantation for acute liver failure. Transplant. Proc. 37: 1720-1721 (2005). *

• Girnita A, Mazariegos GV, Castellaneta A, Reyes J, Bentlejewski C, Thomson AW, Zeevi A. Liver transplant recipients weaned off immunosuppression lack circulating donor-specific antibodies. Hum. Immunol. Dec 14 [Epub ahead of print] (2009).

• Gisbert JP, Jones EA, Pajares JM, Moreno-Otero R. Review article: is there an optimal therapeutic regimen for antimitochondrial antibody-negative primary biliary cirrhosis (autoimmune cholangitis)? Aliment. Pharmacol. Ther. 17: 17-27 (2003). *

• Godoy L. World Immune Regulation Meeting (WIRM) - III: Special focus on regulatory and effector mechanisms. Drug News Perspect. 22: 623-626 (2009).

• Goh MS, McCormack C, Dinh HV, Welsh B, Foley P, Prince HM. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients. Br. J. Dermatol. 156: 990-996 (2007). *

• Gohlke F, Lohse AW, Dienes HP, Lohr H, Marker-Hermann E, Gerken G, Meyer zum Buschenfelde KH. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J. Hepatol. 24: 699-705 (1996). *

• Gold R, Schneider-Gold C. Current and future standards in treatment of myasthenia gravis. Neurotherapeutics 5: 535-541 (2008).

• Goldani LZ, Zavascki AP, Maia AL. Fungal thyroiditis: an overview. Mycopathologia 161: 129-139 (2006). *

• Golshayan D, Jiang S, Tsang J, Garin MI, Mottet C, Lechler RI. In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance. Blood 109: 827-835 (2007). *

• Golusinski W, Kordylewska M, Krzysztof M, Wasko R, Sowinski J. Endoscopic decompresion of orbital cavity in the course of the Graves' ophthalmopathy. Otolaryngol. Pol. 62: 587-592 (2008).

• Gonzaga JE, Ananthakrishnan AN, Issa M, Beaulieu DB, Skaros S, Zadvornova Y, Johnson K, Otterson MF, Binion DG. Durability of infliximab in Crohn's disease: a single-center experience. Inflamm. Bowel Dis. 15: 1837-1843 (2009).

• Gonzalez A, Varo N, Alegre E, Diaz A, Melero I. Immunosuppression routed via the kynurenine pathway: a biochemical and pathophysiologic approach. Adv. Clin. Chem. 45: 155-197 (2008).

• Gonzalez-Rapado L, Abdo A, Hernandez H, Cepero M, Samada M, Ramos L, Ysla R, Gomez F, Delgado D, Melian K, Gonzalez C, Perez J, Bernardos A. Results of liver transplantation at the Cuban center for medical and surgical research. Transplant. Proc. 40: 2983-2984 (2008). *

• Good RA. Progress toward production of immunologic tolerance with no or minimal toxic immunosuppression for prevention of immunodeficiency and autoimmune diseases. World J. Surg. 24: 797-810 (2000). *

• Gordon RD, Shaw BW Jr, Iwatsuki S, Esquivel CO, Starzl TE. Indications for liver transplantation in the cyclosporine era. Surg. Clin. North Am. 66: 541-556 (1986).

• Gore JI, Surawicz C. Severe acute diarrhea. Gastroenterol. Clin. North Am. 32: 1249-1267 (2003).

• Goronzy JJ, Weyand CM. T-cell co-stimulatory pathways in autoimmunity. Arthritis Res. Ther. 10 Suppl. 1: S3 (2008). *

• Goss JA, Shackleton CR, Farmer DG, Arnaout WS, Seu P, Markowitz JS, Martin P, Stribling RJ, Goldstein LI, Busuttil RW. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann. Surg. 225: 472-481 (1997). *

• Goto A, Mukai M, Notoya A, Kohno M. Rheumatoid arthritis complicated with myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis: a case report. Mod. Rheumatol. 15: 118-122 (2005).

• Gouw AS, Haagsma EB, Manns M, Klompmaker IJ, Slooff MJ, Gerber MA. Is there recurrence of primary biliary cirrhosis after liver transplantation? A clinicopathologic study in long-term survivors. J. Hepatol. 20: 500-507 (1994).

• Gow PJ, Chapman RW. Liver transplantation for primary sclerosing cholangitis. Liver 20: 97-103 (2000). *

• Grafft CA, Cornell LD, Gloor JM, Cosio FG, Gandhi MJ, Dean PG, Stegall MD, Amer H. Antibody-mediated rejection following transplantation from an HLA-identical sibling. Nephrol. Dial. Transplant. 25: 307-310 (2010).

• Granito A, Muratori L, Pappas G, Muratori P, Ferri S, Cassani F, Lenzi M, Bianchi FB. Clinical features of type 1 autoimmune hepatitis in elderly Italian patients. Aliment. Pharmacol. Ther. 21: 1273-1277 (2005). *

• Grannas G, Neipp M, Hoeper MM, Gottlieb J, Luck R, Becker T, Simon A, Strassburg CP, Manns MP, Welte T, Haverich A, Klempnauer J, Nashan B, Strueber M. Indications for and outcomes after combined lung and liver transplantation: a single-center experience on 13 consecutive cases. Transplantation 85: 524-531 (2008).

• Graziadei IW, Obermoser GE, Sepp NT, Erhart KH, Vogel W. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus 12: 409-412 (2003). *

• Greenberg R, Greenwald B, Roth JS, Ioffe O, Cross R. Squamous dysplasia of the rectum in a patient with ulcerative colitis treated with 6-mercaptopurine. Dig. Dis. Sci. 53: 760-764 (2008). *

• Greene MT, Whitington PF. Outcomes in pediatric autoimmune hepatitis. Curr. Gastroenterol. Rep. 11: 248-251 (2009).

• Greenfield EA, Nguyen KA, Kuchroo VK. CD28/B7 costimulation: a review. Crit. Rev. Immunol. 18: 389-418 (1998).

• Greenfield JR, Tuthill A, Soos MA, Semple RK, Halsall DJ, Chaudhry A, O'Rahilly S. Severe insulin resistance due to anti-insulin antibodies: response to plasma exchange and immunosuppressive therapy. Diabet. Med. 26: 79-82 (2009). *

• Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, Mieli-Vergani G. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 33: 544-553 (2001). *

• Greupink R, Bakker HI, Reker-Smit C, van Loenen-Weemaes AM, Kok RJ, Meijer DK, Beljaars L, Poelstra K. Studies on the targeted delivery of the antifibrogenic compound mycophenolic acid to the hepatic stellate cell. J. Hepatol. 43: 884-892 (2005). *

• Grima P, Chiavaroli R, Calabrese P, Tundo P, Grima P. Severe hepatitis with autoimmune features following a HHV-6: a case report. Cases J. 1: 110 (2008). *

• Grimble RF. Immunonutrition. Curr. Opin. Gastroenterol. 21: 216-222 (2005).

• Grimble RF. Nutritional modulation of immune function. Proc. Nutr. Soc. 60: 389-397 (2001). *

• Gross S, Geldmacher A, Sharav T, Losch F, Walden P. Immunosuppressive mechanisms in cancer: consequences for the development of therapeutic vaccines. Vaccine 27: 3398-3400 (2009). *

• Grosskreutz C, Gudzowaty O, Shi P, Rodriguez-Laiz G, Malone A, Isola L. Partial HLA matching and RH incompatibility resulting in graft versus host reaction and Evans syndrome after liver transplantation. Am. J. Hematol. 83: 599-601 (2008). *

• Guarneri F, Asmundo A, Sapienza D, Gazzola A, Cannavo SP. Polymorphism of glutathione S-transferases M1 and T1: susceptibility to solar keratoses in an Italian population. Clin. Exp. Dermatol. Oct 23 [Epub ahead of print] (2009). *

• Guibal F, Baran R, Duhard E, Feuilhade de Chauvin M. Epidemiology and management of onychomycosis in private dermatological practice in France. Ann. Dermatol. Venereol. 135: 561-566 (2008).

• Guo L, Li XK, Enosawa S, Funeshima N, Suzuki S, Kimura H, Sugawara Y, Tezuka K, Makuuchi M. Significant enhancement by anti-ICOS antibody of suboptimal tacrolimus immunosuppression in rat liver transplantation. Liver Transpl. 10: 743-747 (2004). *

• Guy JE, Qian P, Lowell JA, Peters MG. Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant. Liver Transpl. 11: 1252-1257 (2005). *

• Haagsma EB. Clinical relevance of recurrence of primary biliary cirrhosis after liver transplantation. Eur. J. Gastroenterol. Hepatol. 11: 639-642 (1999).

• Haagsma EB, Van Den Berg AP, Kleibeuker JH, Slooff MJ, Dijkstra G. Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens. Aliment. Pharmacol. Ther. 18: 33-44 (2003). *

• Haarmann-Stemmann T, Bothe H, Abel J. Growth factors, cytokines and their receptors as downstream targets of arylhydrocarbon receptor (AhR) signaling pathways. Biochem. Pharmacol. 77: 508-520 (2009). *

• Hagenah GC, Wundisch T, Eckstein E, Zimmermann S, Holst F, Grimm W, Neubauer A, Lohoff M. Sepsis-like disease in an immunocompromised patient with a travel history to Mallorca. Internist (Berl.) 48: 727-730 (2007).

• Halff G, Speeg KV, Washburn K, Esterl R, Abrahamian G, Mejia A, Nichols L, Neigut D, Dodd G, Cigarroa F. Liver transplantation at the University of Texas Health Science Center/University Hospital in San Antonio. Clin. Transpl. 2003: 247-253 (2003).

• Halim MA, Said T, Nair P, Schmidt I, Hassan A, Johny KV, Al-Muzairai I, Samhan M, Nampoory MR, Al-Mousawi M. De novo Crohn's disease in a renal transplant recipient. Transplant. Proc. 39: 1278-1279 (2007). *

• Hamar P, Wang M, Godo M, Kokeny G, Rosivall L, Ouyang N, Heemann U. Lupus nephritis reoccurs following transplantation in the lupus prone mouse. Lupus Nov 27 [Epub ahead of print] (2009).

• Hamlin PJ, Shah MN, Scott N, Wyatt JI, Howdle PD. Systemic cytomegalovirus infection complicating ulcerative colitis: a case report and review of the literature. Postgrad. Med. J. 80: 233-235 (2004). *

• Hanauer SB. Assessing the risk of lymphomas in inflammatory bowel disease. Rev. Gastroenterol. Disord. 3: 50-51 (2003). *

• Hanauer SB. Factoring in growth factors for treatment of inflammatory bowel disease. Curr. Gastroenterol. Rep. 5: 485 (2003).

• Harada K, Isse K, Kamihira T, Shimoda S, Nakanuma Y. Th1 cytokine-induced downregulation of PPARgamma in human biliary cells relates to cholangitis in primary biliary cirrhosis. Hepatology 41: 1329-1338 (2005). *

• Haraguchi S, Good RA, Day-Good NK. A potent immunosuppressive retroviral peptide: cytokine patterns and signaling pathways. Immunol. Res. 41: 46-55 (2008). *

• Harboe E, Goransson L, Wildhagen K, Omdal R. Mycophenolate mofetil: a new therapeutic agent for chronic autoimmune diseases. Tidsskr. Nor. Laegeforen. 125: 1650-1652 (2005).

• Harle P, Straub RH, Fleck M. Perioperative management of immunosuppression in rheumatic diseases - what to do? Rheumatol. Int. Dec 24 [Epub ahead of print] (2009). *

• Harloff S, Hartwig D, Kasper K, Wedel T, Muller M, Geerling G. Epitheliotrophic capacity of serum eye drops from healthy donors versus serum from immunosuppressed patients with rheumatoid arthritis. Klin. Monatsbl. Augenheilkd. 225: 200-206 (2008).

• Harms B, Bremner AR, Mulligan J, Fairhurst J, Griffiths DM, Salmon T, Beattie RM. Crohn's disease post-cardiac transplantation presenting with severe growth failure and delayed onset of puberty. Pediatr. Allergy Immunol. 15: 186-189 (2004). *

• Harpaz N, Schiano T, Ruf AE, Shukla D, Tao Y, Fishbein TM, Sauter BV, Gondolesi GE. Early and frequent histological recurrence of Crohn's disease in small intestinal allografts. Transplantation 80: 1667-1670 (2005).

• Hartung HP, Kieseier BC, Hemmer B. Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis. J. Neurol. 252 Suppl. 5: v30-v37 (2005).

• Hashimoto E, Taniai M, Yatsuji S, Tokushige K, Shiratori K, Yamamoto M, Fuchinoue S. Long-term clinical outcome of living-donor liver transplantation for primary biliary cirrhosis. Hepatol. Res. 37 Suppl. 3: S455-S461 (2007). *

• Hasserjian RP, Chen S, Perkins SL, de Leval L, Kinney MC, Barry TS, Said J, Lim MS, Finn WG, Medeiros LJ, Harris NL, O'Malley DP. Immunomodulator agent-related lymphoproliferative disorders. Mod. Pathol. 22: 1532-1540 (2009).

• Havrdova E. Aggressive multiple sclerosis - is there a role for stem cell transplantation? J. Neurol. 252 Suppl. 3: iii34-iii37 (2005). *

• Hayashi M, Keeffe EB, Krams SM, Martinez OM, Ojogho ON, So SK, Garcia G, Imperial JC, Esquivel CO. Allograft rejection after liver transplantation for autoimmune liver diseases. Liver Transpl. Surg. 4: 208-214 (1998).

• Hayashi T, Gray CS, Chan M, Tawatao RI, Ronacher L, McGargill MA, Datta SK, Carson DA, Corr M. Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7. Proc. Natl. Acad. Sci. U.S.A. 106: 2764-2769 (2009). *

• He XS, Zhang S, Zhu XF, Ji Y, Zeng JX, Ma Y, Wang DP, Ju WQ, Wu LW, Li Z, Huang JF. Combined total hepatectomy, orthotopic liver transplantation and pancreatoduodenectomy for irresectable hilar bile duct carcinoma. Zhonghua Wai Ke Za Zhi 44: 302-305 (2006).

• He Yi LM, Liu ZG, Luo YW, Wang M, Zhang J, Sun EW. Effect of FK506 on cytokine secretion in whole blood. Nan Fang Yi Ke Da Xue Xue Bao 30: 249-251 (2010).

• Heckmann JM, Uwimpuhwe H, Ballo R, Kaur M, Bajic VB, Prince S. A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis. Genes Immun. Aug 13 [Epub ahead of print] (2009). *

• Hegarty AM, Barrett AW, Scully C. Pyostomatitis vegetans. Clin. Exp. Dermatol. 29: 1-7 (2004). *

• Heidelbaugh JJ, Sherbondy M. Cirrhosis and chronic liver failure: part II. Complications and treatment. Am. Fam. Physician 74: 767-776 (2006). *

• Heilman RL, Chakkera HA, Reddy KS, Colby TV, Moss AA, Williams JW, Mazur MJ, Petrides S, Mulligan DC. Clinical factors associated with graft fibrosis in kidney-transplant recipients on steroid-avoidance immunosuppression. Clin. Transplant. 22: 309-315 (2008). *

• Hemmer B, Frohman E, Hartung HP, Stuve O. Central nervous system infections - a potential complication of systemic immunotherapy. Curr. Opin. Neurol. 19: 271-276 (2006).

• Hendrickson RJ, Karrer FM, Wachs ME, Slater K, Bak TE, Kam I. Pediatric liver transplantation. Curr. Opin. Pediatr. 16: 309-313 (2004).

• Heneghan MA, Al-Chalabi T, McFarlane IG. Cost-effectiveness of pharmacotherapy for autoimmune hepatitis. Expert Opin. Pharmacother. 7: 145-156 (2006).

• Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 35: 7-13 (2002). *

• Hennes EM, Zeniya M, Czaja AJ, Pares A, Dalekos GN, Krawitt EL, Bittencourt PL, Porta G, Boberg KM, Hofer H, Bianchi FB, Shibata M, Schramm C, Eisenmann de Torres B, Galle PR, McFarlane I, Dienes HP, Lohse AW; International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48: 169-176 (2008). *

• Herfarth H, Isaacs K. Early combined immunosuppression in Crohn's disease. Lancet 371: 1995-1996 (2008). *

• Hering BJ, Kandaswamy R, Ansite JD, Eckman PM, Nakano M, Sawada T, Matsumoto I, Ihm SH, Zhang HJ, Parkey J, Hunter DW, Sutherland DE. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 293: 830-835 (2005). *

• Herr AL, Latulippe JF, Carignan S, Mitchell A, Belanger R, Roy J. Is severe intestinal chronic graft-versus-host disease an indication for surgery? A report of two cases. Transplantation 77: 1617-1620 (2004).

• Herrero JI, Espana A, Quiroga J, Sangro B, Pardo F, Alvarez-Cienfuegos J, Prieto J. Nonmelanoma skin cancer after liver transplantation. Study of risk factors. Liver Transpl. 11: 1100-1106 (2005). *

• Herrero JI, Lorenzo M, Quiroga J, Sangro B, Pardo F, Rotellar F, Alvarez-Cienfuegos J, Prieto J. De novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl. 11: 89-97 (2005). *

• Herrero JI, Quiroga J, Sangro B, Pardo F, Rotellar F, Alvarez-Cienfuegos J, Prieto J. Herpes zoster after liver transplantation: incidence, risk factors, and complications. Liver Transpl. 10: 1140-1143 (2004). *

• Herrlinger KR, Deibert P, Schwab M, Kreisel W, Fischer C, Fellermann K, Stange EF. Remission maintenance by tioguanine in chronic active Crohn's disease. Aliment. Pharmacol. Ther. 17: 1459-1464 (2003). *

• Hindupur S, Yeung M, Shroff P, Fritz J, Kirmani N. Vanishing bile duct syndrome in a patient with advanced AIDS. HIV Med. 8: 70-72 (2007). *

• Hirose R, Vincenti F. Immunosuppression: today, tomorrow, and withdrawal. Semin. Liver Dis. 26: 201-210 (2006).

• Hirschfield GM, Al-Harthi N, Heathcote EJ. Review: current status of therapy in autoimmune liver disease. Ther. Adv. Gastroenterol. 2: 11-28 (2009). *

• Hivroz C. Everything you ever wanted to know about ZAP-70. Med. Sci. (Paris) 21: 150-155 (2005).

• Ho GT, Seddon AJ, Therapondos G, Satsangi J, Hayes PC. The clinical course of ulcerative colitis after orthotopic liver transplantation for primary sclerosing cholangitis: further appraisal of immunosuppression post transplantation. Eur. J. Gastroenterol. Hepatol. 17: 1379-1385 (2005).

• Ho GT, Smith L, Aitken S, Lee HM, Ting T, Fennell J, Lees CW, Palmer KR, Penman ID, Shand AG, Arnott ID, Satsangi J. The use of adalimumab in the management of refractory Crohn's disease. Aliment. Pharmacol. Ther. 27: 308-315 (2008). *

• Hoentjen F, van Bodegraven AA. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J. Gastroenterol. 15: 2067-2073 (2009). *

• Hoge M, Amar S. Role of interleukin-1 in bacterial atherogenesis. Timely Top. Med. Cardiovasc. Dis. 11: E5 (2007).

• Hoge M, Amar S. Role of interleukin-1 in bacterial atherogenesis. Drugs Today (Barc.) 42: 683-688 (2006).

• Holtmann MH, Gerts AL, Weinman A, Galle PR, Neurath MF. Treatment of Crohn's disease with leflunomide as second-line immunosuppression: a phase 1 open-label trial on efficacy, tolerability and safety. Dig. Dis. Sci. 53: 1025-1032 (2008). *

• Holzknecht C, Rohl C. Effects of methylprednisolone and glatiramer acetate on nitric oxide formation of cytokine-stimulated cells from the rat oligodendroglial cell line OLN-93. Neuroimmunomodulation 17: 23-30 (2009).

• Hommes DW, Sterringa G, van Deventer SJH, TytgatGNJ, Weel J. The pathogenicity of cytomegalovirus in inflammatory bowel disease: a systematic review and evidence-based recommendations for future research. Inflamm. Bowel Dis. 10: 245-250 (2004). *

• Hong DK, Wong CJ, Gutierrez K. Severe cryptosporidiosis in a seven-year-old renal transplant recipient: case report and review of the literature. Pediatr. Transplant. 11: 94-100 (2007). *

• Horibe EK, Sacks J, Unadkat J, Raimondi G, Wang Z, Ikeguchi R, Marsteller D, Ferreira LM, Thomson AW, Lee WP, Feili-Hariri M. Rapamycin-conditioned, alloantigen-pulsed dendritic cells promote indefinite survival of vascularized skin allografts in association with T regulatory cell expansion. Transpl. Immunol. 18: 307-318 (2008).

• Horiuchi T, Gondo H, Miyagawa H, Otsuka J, Inaba S, Nagafuji K, Takase K, Tsukamoto H, Koyama T, Mitoma H, Tamimoto Y, Miyagi Y, Tahira T, Hayashi K, Hashimura C, Okamura S, Harada M. Association of MBL gene polymorphisms with major bacterial infection in patients treated with high-dose chemotherapy and autologous PBSCT. Genes Immun. 6: 162-166 (2005). *

• Horslen SP. Optimal management of the post-intestinal transplant patient. Gastroenterology 130: S163-S169 (2006). *

• Horslen SP, McCowan TC, Goertzen TC, Warkentin PI, Cai HB, Strom SC, Fox IJ. Isolated hepatocyte transplantation in an infant with a severe urea cycle disorder. Pediatrics 111: 1262-1267 (2003). *

• Howarth LJ, Wiskin AE, Griffiths DM, Afzal NA, Beattie RM. Outcome of childhood ulcerative colitis at 2 years. Acta Paediatr. 96: 1790-1793 (2007). *

• Hoyer BF, Mumtaz IM, Yoshida T, Hiepe F, Radbruch A. How to cope with pathogenic long-lived plasma cells in autoimmune diseases. Ann. Rheum. Dis. 67 Suppl. 3: iii87-iii89 (2008).

• Hsu JF, Chuang WJ, Shiesh SC, Lin YS, Liu CC, Wang CC, Fu TF, Tsai JH, Tsai WL, Huang YJ, Hsieh YH, Wu JJ, Lin MT, Huang W. Streptococcal pyrogenic exotoxin B cleaves human S-adenosylhomocysteine hydrolase and induces hypermethioninemia. J. Infect. Dis. 198: 367-374 (2008). *

• Huang B, Lei Z, Zhang GM, Li D, Song C, Li B, Liu Y, Yuan Y, Unkeless J, Xiong H, Feng ZH. SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood 112: 1269-1279 (2008). *

• Huang X, Moore DJ, Ketchum RJ, Nunemaker CS, Kovatchev B, McCall AL, Brayman KL. Resolving the conundrum of islet transplantation by linking metabolic dysregulation, inflammation, and immune regulation. Endocr. Rev. 29: 603-630 (2008). *

• Hubscher S. What does the long-term liver allograft look like for the pediatric recipient? Liver Transpl. 15: S19-S24 (2009).

• Humar A, Crotteau S, Gruessner A, Kandaswamy R, Gruessner R, Payne W, Lake J. Steroid minimization in liver transplant recipients: impact on hepatitis C recurrence and post-transplant diabetes. Clin. Transplant. 21: 526-531 (2007). *

• Hushmendy S, Jayakumar L, Hahn AB, Bhoiwala D, Bhoiwala DL, Crawford DR. Select phytochemicals suppress human T-lymphocytes and mouse splenocytes suggesting their use in autoimmunity and transplantation. Nutr. Res. 29: 568-578 (2009). *

• Iellem A, Colantonio L, D'Ambrosio D. Skin-versus gut-skewed homing receptor expression and intrinsic CCR4 expression on human peripheral blood CD4+CD25+ suppressor T cells. Eur. J. Immunol. 33: 1488-1496 (2003). *

• Ijichi H, Shimada M, Suehiro T, Soejima Y, Maehara Y, Nakamuta M, Nawata H. Living donor liver transplantation for a patient with renal failure. Fukuoka Igaku Zasshi 93: 266-271 (2002).

• Ikarashi Y, Kawai K, Watanabe H, Matsumoto Y, Omata S, Fujiwara M. Immunosuppressive activity of macrophages in mice undergoing graft-versus-host reaction due to major histocompatibility complex class I plus II difference. Immunology 79: 95-102 (1993). *

• Ikegami T, Sanchez EQ, Uemura T, Narasimhan G, Masannat O, Chinnakotla S, McKenna GJ, Randall HB, Levy MF, Goldstein RM, Klintmalm GB. Liver transplantation for cystic fibrosis in adults. Surg. Today 38: 26-29 (2008).

• Imafuku S, Yoshimura D, Moroi Y, Urabe K, Furue M. Systemic varicella zoster virus reinfection in a case of angioimmunoblastic T-cell lymphoma. J. Dermatol. 34: 387-389 (2007).

• Indoh T, Yokota SI, Okabayashi T, Yokosawa N, Fujii N. Suppression of NF-kappaB and AP-1 activation in monocytic cells persistently infected with measles virus. Virology 361: 294-303 (2006). *

• Infante B, Stallone G, Schena A, Maiorano A, Gesualdo L, Schena FP, Grandaliano G. Pro and anti-neoplastic effects of immunosuppressive drug in renal transplantation. G. Ital. Nefrol. 23: 389-395 (2006).

• Iqbal A, Huraib S, Tanimu D. Successful late conversion to mycophenolate mofetil and prednisone immunosuppression therapy in a renal transplant recipient. Saudi J. Kidney Dis. Transpl. 11: 197-200 (2000).

• Isenberg D, Rahman A. Systemic lupus erythematosus - 2005 annus mirabilis? Nat. Clin. Pract. Rheumatol. 2: 145-152 (2006). *

• Ishibashi H, Shimoda S, Nakamura M, Gershwin ME. Chapter 34. Autoimmune diseases in transplanted livers. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 451-457 (2007). *

• Ishimaru N, Kishimoto H, Hayashi Y, Sprent J. Regulation of naive T cell function by the NF-kappaB2 pathway. Nat. Immunol. 7: 763-772 (2006). *

• Ito T, Hanabuchi S, Wang YH, Park WR, Arima K, Bover L, Qin FX, Gilliet M, Liu YJ. Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity 28: 870-880 (2008). *

• Ito T, Shimada K, Gang M, Uchikoshi F, Tori M, Komoda H, Fumimoto Y, Ohmori K, Kawamoto K, Tanemura M, Nozawa M. Pancreas transplantation using type I and type II spontaneously diabetic rats - our experimental experience. Microsurgery 27: 305-311 (2007).

• Jackisch T, Freitag M, Ludwig K. Gas gangrene with ulcerative colitis under immunosuppressive therapy: report of a case. Zentralbl. Chir. 131: 84-87 (2006).

• Jackson LN, Zhou Y, Qiu S, Wang Q, Mark Evers B. Alternative medicine products as a novel treatment strategy for inflammatory bowel disease. Am. J. Chin. Med. 36: 953-965 (2008).

• Jacob DA, Neumann UP, Bahra M, Klupp J, Puhl G, Neuhaus R, Langrehr JM. Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients. Clin. Transplant. 20: 211-220 (2006).

• Jacob DA, Neumann UP, Bahra M, Langrehr JM, Neuhaus P. Liver transplantation for primary biliary cirrhosis: influence of primary immunosuppression on survival. Transplant. Proc. 37: 1691-1692 (2005). *

• Jaeckel E, von Boehmer H, Manns MP. Antigen-specific FoxP3-transduced T-cells can control established type 1 diabetes. Diabetes 54: 306-310 (2005). *

• Jager MD, Liu JY, Timrott KF, Popp FC, Stoeltzing O, Lang SA, Piso P, Geissler EK, Schlitt HJ, Dahlke MH. Sirolimus promotes tolerance for donor and recipient antigens after MHC class II disparate bone marrow transplantation in rats. Exp. Hematol. 35: 164-170 (2007). *

• Jain A, Kashyap R, Marsh W, Rohal S, Khanna A, Fung JJ. Reasons for long-term use of steroid in primary adult liver transplantation under tacrolimus. Transplantation 71: 1102-1106 (2001). *

• Jain A, Mazariegos G, Pokharna R, Parizhskaya M, Kashyap R, Kosmach-Park B, Smith A, Fung JJ, Reyes J. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis. Transplantation 75: 1020-1025 (2003).

• Jain A, Vekatramanan R, Eghtesad B, Gadomski M, Mohanka R, Marcos A, Fung J. Long-term outcome of adding mycophenolate mofetil to tacrolimus for nephrotoxicity following liver transplantation. Transplantation 80: 859-864 (2005).

• Jampol LM, Fishman GA. Immunosuppression for autoimmune retinopathy. Arch. Ophthalmol. 127: 573-575 (2009). *

• Jang TJ. Prevalence of Foxp3 positive T regulatory cells is increased during progression of cutaneous squamous tumors. Yonsei Med. J. 49: 942-948 (2008). *

• Jangpatarapongsa K, Chootong P, Sattabongkot J, Chotivanich K, Sirichaisinthop J, Tungpradabkul S, Hisaeda H, Troye-Blomberg M, Cui L, Udomsangpetch R. Plasmodium vivax parasites alter the balance of myeloid and plasmacytoid dendritic cells and the induction of regulatory T cells. Eur. J. Immunol. 38: 2697-2705 (2008). *

• Janosek J, Hilscherova K, Blaha L, Holoubek I. Environmental xenobiotics and nuclear receptors - interactions, effects and in vitro assessment. Toxicol. In Vitro 20: 18-37 (2006).

• Janson PC, Marits P, Thorn M, Ohlsson R, Winqvist O. CpG methylation of the IFNG gene as a mechanism to induce immunosuppression in tumor-infiltrating lymphocytes. J. Immunol. 181: 2878-2886 (2008). *

• Janssen SP, Phernambucq M, Martinez-Martinez P, De Baets MH, Losen M. Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil. J. Neuroimmunol. 201-202: 111-120 (2008).

• Jarvis LB, Goodall JC, Gaston JS. Human leukocyte antigen class I-restricted immunosuppression by human CD8(+) regulatory T cells requires CTLA-4-mediated interaction with dendritic cells. Hum. Immunol. 69: 687-695 (2008).

• Jasperson LK, Bucher C, Panoskaltsis-Mortari A, Mellor AL, Munn DH, Blazar BR. Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. Blood 114: 5062-5070 (2009). *

• Jayne D, Tyndall A. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 13: 359-365 (2004).

• Jazrawi SF, Zaman A, Muhammad Z, Rabkin JM, Corless CL, Olyaei A, Biggs A, Ham J, Chou S, Rosen HR. Tumor necrosis factor-alpha promoter polymorphisms and the risk of rejection after liver transplantation: a case control analysis of 210 donor-recipient pairs. Liver Transpl. 9: 377-382 (2003). *

• Jewell DP, Satsangi J, Lobo A, Probert C, Forbes A, Ghosh S, Shaffer J, Frenz M, Drummond H, Troy G, Turner S, Younge L, Evans L, Moosa M, Rodgers-Gray B, Buchan S. Infliximab use in Crohn's disease: impact on health care resources in the UK. Eur. J. Gastroenterol. Hepatol. 17: 1047-1052 (2005).

• Jiang S, Lombardi G. New trends in immunosuppression and immunotherapy. Int. Immunopharmacol. 6: 1874-1878 (2006).

• Jiang Y, Lv LZ, Cai QC, Zhang K, Hu HZ, Zhang SG, Yang F, Wei WM, Zhang XJ, Chen YB, Pan F. Liver transplant for 70 patients with end-stage liver diseases. Hepatobiliary Pancreat. Dis. Int. 6: 24-28 (2007). *

• Jonas S, Neuhaus R, Junge G, Klupp J, Theruvat T, Langrehr JM, Settmacher U, Neuhaus P. Primary immunosuppression with tacrolimus after liver transplantation: 12-years follow-up. Int. Immunopharmacol. 5: 125-128 (2005).

• Jones BJ, McTaggart SJ. Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp. Hematol. 36: 733-741 (2008).

• Jones EA, ten Kate FJ, ter Borg F, Houben M, Reesink HW, Chamuleau RA. Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis. Eur. J. Gastroenterol. Hepatol. 11: 1165-1169 (1999).

• Joos L, Tamm M. Breakdown of pulmonary host defense in the immunocompromised host: cancer chemotherapy. Proc. Am. Thorac. Soc. 2: 445-448 (2005). *

• Joplin R. Infectious etiology of primary biliary cirrhosis? Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 19-20. October 15-16 (2003). *

• Jordan JT, Sun W, Hussain SF, Deangulo G, Prabhu SS, Heimberger AB. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol. Immunother. 57: 123-131 (2008). *

• Jorga A, Johnston A. Novel therapies in transplantation. Expert Opin. Investig. Drugs 14: 295-304 (2005).

• Juang CM, Hung CF, Yeh JY, Horng HC, Twu NF, Cheng MH, Wen KC, Yuan CC, Chao KC, Wu TC, Yen MS. Regulatory T cells: potential target in anticancer immunotherapy. Taiwan J. Obstet. Gynecol. 46: 215-221 (2007).

• Juedes AE, Von Herrath MG. Regulatory T-cells in type 1 diabetes. Diabetes Metab. Res. Rev. 20: 446-451 (2004).

• Jungling B, Kindermann I, Moser C, Puschel W, Ecker KW, Schafers HJ, Bohm M, Zeuzem S, Giese T, Stallmach A. Development of ulcerative colitis after heart transplantation during immunosuppressive therapy. Z. Gastroenterol. 43: 195-199 (2005).

• Kaaja RJ, Greer IA. Manifestations of chronic disease during pregnancy. JAMA 294: 2751-2757 (2005). *

• Kadry Z, Mullhaupt B, Renner EL, Bauerfeind P, Schanz U, Pestalozzi BC, Studer G, Zinkernagel R, Clavien PA. Living donor liver transplantation and tolerance: a potential strategy in cholangiocarcinoma. Transplantation 76: 1003-1006 (2003).

• Kahan BD. Forty years of publication of transplantation proceedings-the second decade: the cyclosporine revolution. Transplant. Proc. 41: 1423-1437 (2009). *

• Kahan BD. Individuality: the barrier to optimal immunosuppression. Nat. Rev. Immunol. 3: 831-838 (2003). *

• Kahan BD. Sirolimus-based immunosuppression: present state of the art. J. Nephrol. 17 Suppl. 8: S32-S39 (2004).

• Kamm MA. Review article: maintenance of remission in ulcerative colitis. Aliment. Pharmacol. Ther. 16 Suppl. 4: 21-24 (2002). *

• Kamm MA. Manipulation of enteric flora in clinical practice. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 36. May 7-8 (2004). *

• Kamm MA, Ng SC. Perianal fistulizing Crohn's disease: a call to action. Clin. Gastroenterol. Hepatol. 6: 7-10 (2008).

• Kane S. Abnormal Pap smears in inflammatory bowel disease. Inflamm. Bowel Dis. 14: 1158-1160 (2008). *

• Kane S, Khatibi B, Reddy D. Higher incidence of abnormal pap smears in women with inflammatory bowel disease. Am. J. Gastroenterol. 103: 631-636 (2008). *

• Kang HK, Ecklund D, Liu M, Datta SK. Apigenin, a nonmutagenic dietary flavonoid suppresses lupus by inhibiting autoantigen presentation for expansion of autoreactive Th1 and Th17 cells. Arthritis Res. Ther. 11: R59 (2009). *

• Kang MJ, Namgung KY, Kim MS, Ko BS, Han CS, Ahn HT, Shin HM. A case of Kaposi's sarcoma associated with ulcerative colitis. Korean J. Gastroenterol. 43: 316-319 (2004).

• Kaper T, Looger LL, Takanaga H, Platten M, Steinman L, Frommer WB. Nanosensor detection of an immunoregulatory tryptophan influx/kynurenine efflux cycle. PLoS Biol. 5: e257 (2007). *

• Karatolios K, Pankuweit S, Maisch B. Diagnosis and treatment of myocarditis: the role of endomyocardial biopsy. Curr. Treat. Options Cardiovasc. Med. 9: 473-481 (2007).

• Karoui S, Boubaker J, Filali A. Inflammatory bowel diseases and lymphoma. Tunis. Med. 82: 185-189 (2004).

• Kashif M, Qureshi A, Adil SN, Khurshid M. Successful use of rituximab in Evans syndrome and refractory immune thrombocytopenic purpura. J. Pak. Med. Assoc. 60: 64-65 (2010).

• Kato T, Selvaggi G, Panagiotis T, Hernandez E, McLaughlin G, Moon J, Nishida S, Levi D, Thompson J, Halliday N, Ruiz P, Tzakis A. Pediatric liver transplant with Campath 1H induction - preliminary report. Transplant. Proc. 38: 3609-3611 (2006). *

• Kato T, Yazawa K, Madono K, Saito J, Hosomi M, Itoh K. Acute graft-versus-host-disease in kidney transplantation: case report and review of literature. Transplant. Proc. 41: 3949-3952 (2009). *

• Kaushik SP, Kaye G, Clarke AC. Autoimmune hepatobiliary disease in trisomy 21. J. Clin. Gastroenterol. 30: 330-332 (2000).

• Kawai T, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, Saidman SL, Shaffer J, Preffer FI, Ding R, Sharma V, Fishman JA, Dey B, Ko DS, Hertl M, Goes NB, Wong W, Williams WW Jr, Colvin RB, Sykes M, Sachs DH. HLA-mismatched renal transplantation without maintenance immunosuppression. N. Engl. J. Med. 358: 353-361 (2008). *

• Kelly D. Indications and results of liver transplantation for autoimmune liver disease in children. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 92-94 (2004). *

• Kelly DA. Current issues in pediatric transplantation. Pediatr. Transplant. 10: 712-720 (2006). *

• Kelly DM, Demetris AJ, Fung JJ, Marcos A, Zhu Y, Subbotin V, Yin L, Totsuka E, Ishii T, Lee MC, Gutierrez J, Costa G, Venkataraman R, Madariaga JR. Porcine partial liver transplantation: a novel model of the "small-for-size" liver graft. Liver Transpl. 10: 253-263 (2004). *

• Kempen JH, Gangaputra S, Daniel E, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Foster CS, Jabs DA, Helzlsouer KJ. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am. J. Ophthalmol. 146: 802-812.e1 (2008). *

• Kerkar N, Dugan C, Rumbo C, Morotti RA, Gondolesi G, Shneider BL, Emre S. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am. J.Transplant. 5: 1085-1089 (2005). *

• Khalaf H, Mourad W, El-Sheikh Y, Abdo A, Helmy A, Medhat Y, Al-Sofayan M, Al-Sagheir M, Al-Sebayel M. Liver transplantation for autoimmune hepatitis: a single-center experience. Transplant. Proc. 39: 1166-1170 (2007). *

• Khan FN, Prasad V, Klein MD. Cytomegalovirus enteritis mimicking Crohn's disease in a lupus nephritis patient: a case report. World J. Gastroenterol. 15: 4327-4330 (2009). *

• Khettry U, Anand N, Faul PN, Lewis WD, Pomfret EA, Pomposelli J, Jenkins RL, Gordon FD. Liver transplantation for primary biliary cirrhosis: a long-term pathologic study. Liver Transpl. 9: 87-96 (2003). *

• Khettry U, Keaveny A, Goldar-Najafi A, Lewis WD, Pomfret EA, Pomposelli JJ, Jenkins RL, Gordon FD. Liver transplantation for primary sclerosing cholangitis: a long-term clinicopathologic study. Hum. Pathol. 34: 1127-1136 (2003). *

• Kiely PD. The broadening use of leflunomide in clinical practice. Hosp. Med. 65: 735-739 (2004).

• Kil JS, Lee JH, Han AR, Kang JY, Won HJ, Jung HY, Lim HM, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC. Long-term treatment outcomes for autoimmune hepatitis in Korea. J. Korean Med. Sci. 25: 54-60 (2010). *

• Kilpatrick DC. Mannan-binding lectin and its role in innate immunity. Transfus. Med. 12: 335-352 (2002). *

• Kim HM, Kang JS, Park SK, Lee K, Kim JY, Kim YJ, Hong JT, Kim Y, Han SB. Antidiabetic activity of angelan isolated from Angelica gigas Nakai. Arch. Pharm. Res. 31: 1489-1496 (2008).

• Kim JY, Park JN, Lee JG, Lee YA, Kim YH, Hong SJ, Yang HI, Lee SH. The use of etanercept in a patient with disseminated tuberculosis. Rheumatol. Int. 29: 1377-1380 (2009). *

• Kim KC, Lee IH, Choi JH, Oh MR, Ahn MJ, Kim SY. Autologous stem cell transplantation in the treatment of refractory rheumatoid arthritis. J. Korean Med. Sci. 17: 129-132 (2002). *

• Kim R, Emi M, Tanabe K. Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology 119: 254-264 (2006). *

• Kinney T, Rawlins M, Kozarek R, France R, Patterson D. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions. Am. J. Gastroenterol. 98: 608-612 (2003). *

• Kishore J, Ghoshal U, Ghoshal UC, Krishnani N, Kumar S, Singh M, Ayyagari A. Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. J. Med. Microbiol. 53: 1155-1160 (2004). *

• Kiss J, Urban S V, Dudics V, Vas V, Uher F. Mesenchymal stem cells and the immune system - immunosuppression without drugs. Orv. Hetil. 149: 339-346 (2008).

• Kitaichi N, Namba K, Taylor AW. Inducible immune regulation following autoimmune disease in the immune-privileged eye. J. Leukoc. Biol. 77: 496-502 (2005). *

• Klode J, Korber A, Dissemond J. Psoriasis vulgaris as a trigger for a superficial multilocular pyoderma gangrenosum? Hautarzt. 60: 569-572 (2009).

• Knechtle SJ, D'Alessandro AM, Harms BA, Pirsch JD, Belzer FO, Kalayoglu M. Relationships between sclerosing cholangitis, inflammatory bowel disease, and cancer in patients undergoing liver transplantation. Surgery 118: 615-619 (1995).

• Kneteman NM, Oberholzer J, Al Saghier M, Meeberg GA, Blitz M, Ma MM, Wong WW, Gutfreund K, Mason AL, Jewell LD, Shapiro AM, Bain VG, Bigam DL. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl. 10: 1301-1311 (2004). *

• Kniepeiss D, Iberer F, Schaffellner S, Jakoby E, Duller D, Tscheliessnigg Kh. Dyslipidemia during sirolimus therapy in patients after liver transplantation. Clin. Transplant. 18: 642-646 (2004). *

• Kniepeiss D, Iberer F, Schaffellner S, Jakoby E, Duller D, Tscheliessnigg KH. Nonnephrotoxic immunosuppression in patients after liver transplantation. Int. Immunopharmacol. 5: 133-136 (2005).

• Knight JG, Menkes DB, Highton J, Adams DD. Rationale for a trial of immunosuppressive therapy in acute schizophrenia. Mol. Psychiatry 12: 424-431 (2007).

• Knoop M, Bechstein WO, Schrem H, Lobeck H, Hopf U, Neuhaus P. Clinical significance of recurrent primary biliary cirrhosis after liver transplantation. Transpl. Int. 9 Suppl. 1: S115-S119 (1996).

• Ko HH, Greanya E, Lee TK, Steinbrecher UP, Erb SR, Yoshida EM. Mycophenolate mofetil in liver transplant patients with calcineurin-inhibitor-induced renal impairment. Ann. Hepatol. 7: 376-380 (2008).

• Kobayashi M, Ishida E, Yasuda H, Yamamoto O, Tokura Y. Tinea profunda cysticum caused by Trichophyton rubrum. J. Am. Acad. Dermatol. 54: S11-S13 (2006).

• Kobayashi N. Bioartificial pancreas for the treatment of diabetes. Cell Transplant. 17: 11-17 (2008).

• Koch RO, Graziadei IW, Schulz F, Nachbaur K, Konigsrainer A, Margreiter R, Vogel W. Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction. Transpl. Int. 17: 518-524 (2004).

• Kohm AP, Turley DM, Miller SD. Targeting the TCR: T-cell receptor and peptide-specific tolerance-based strategies for restoring self-tolerance in CNS autoimmune disease. Int. Rev. Immunol. 24: 361-392 (2005).

• Kokolina E, Alexopoulos E, Dimitriadis C, Vainas A, Giamalis P, Papagianni A, Ekonomidou D, Memmos D. Immunosuppressive therapy and clinical evolution in forty-nine patients with antineutrophil cytoplasmic antibody-associated glomerulonephritis. Ann. N. Y. Acad. Sci. 1051: 597-605 (2005). *

• Komatsu H, Inui A, Sogo T, Fujisawa T, Egawa H, Tanaka K. Severe hypogammaglobulinemia associated with hepatic vein stenosis causes cytomegalovirus infection after living-related liver transplantation. Transpl. Infect. Dis. 7: 41-44 (2005). *

• Komolmit P, Davies MH. Tacrolimus in liver transplantation. Expert Opin. Investig. Drugs 8: 1239-1254 (1999).

• Korkina L, Pastore S. The role of redox regulation in the normal physiology and inflammatory diseases of skin. Front. Biosci. (Elite Ed.) 1: 123-141 (2009).

• Korman BD, Tyler KL, Korman NJ. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists. Arch. Dermatol. 145: 937-942 (2009). *

• Korten S, Badusche M, Buttner DW, Hoerauf A, Brattig N, Fleischer B. Natural death of adult Onchocerca volvulus and filaricidal effects of doxycycline induce local FOXP3+/CD4+ regulatory T cells and granzyme expression. Microbes Infect. 10: 313-324 (2008). *

• Kortylewski M, Kujawski M, Herrmann A, Yang C, Wang L, Liu Y, Salcedo R, Yu H. Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy. Cancer Res. 69: 2497-2505 (2009).

• Koshiba T, Ito A, Li Y, Wu Y, Takemura M, Sakaguchi S. Regulatory T cell based transplant tolerance - freedom from immunosuppression. Nippon Rinsho 65: 557-567 (2007).

• Kovarik P, Sauer I, Schaljo B. Molecular mechanisms of the anti-inflammatory functions of interferons. Immunobiology 212: 895-901 (2008).

• Kozak T, Becvar R, Havrdova E, Pitha J, Gregora E, Pytlik R, Maaloufova J, Kobylka P, Vodvarkova S. Hematopoietic stem cell transplantation in autoimmune diseases in rheumatology practice. Cas. Lek. Cesk. 139: 329-333 (2000).

• Kozak T, Rychlik I. Developments in hematopoietic stem-cell transplantation in the treatment of autoimmune diseases. Isr. Med. Assoc. J. 4: 268-271 (2002). *

• Kreijveld E, van der Meer A, Tijssen HJ, Hilbrands LB, Joosten I. KIR gene and KIR ligand analysis to predict graft rejection after renal transplantation. Transplantation 84: 1045-1051 (2007).

• Kremer JM. Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis. J. Clin. Rheumatol. 11: S55-S62 (2005).

• Kretschmer K, Apostolou I, Jaeckel E, Khazaie K, von Boehmer H. Making regulatory T cells with defined antigen specificity: role in autoimmunity and cancer. Immunol. Rev. 212: 163-169 (2006). *

• Kroep JR, Bolk JH, Weverling-Rijnsburger AW, van Hoek B. Three patients with autoimmune hepatitis: the importance of early diagnosis and remission. Ned. Tijdschr. Geneeskd. 149: 2437-2441 (2005).

• Kugelmas M, Spiegelman P, Osgood MJ, Young DA, Trotter JF, Steinberg T, Wachs ME, Bak T, Kam I, Everson GT. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 9: 727-732 (2003). *

• Kuijk LM, van Die I. Worms to the rescue: can worm glycans protect from autoimmune diseases? IUBMB Life. Jan 25 [Epub ahead of print] (2010). *

• Kulikowska A, Boslaugh SE, Huddleston CB, Gandhi SK, Gumbiner C, Canter CE. Infectious, malignant, and autoimmune complications in pediatric heart transplant recipients. J. Pediatr. 152: 671-677 (2008). *

• Kulkarni O, Eulberg D, Selve N, Zollner S, Allam R, Pawar RD, Pfeiffer S, Segerer S, Klussmann S, Anders HJ. Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice. J. Pharmacol. Exp. Ther. 328: 371-377 (2009). *

• Kulkarni S, Cronin DC 2nd. Ethics in liver transplantation. Semin. Liver Dis. 26: 234-238 (2006).

• Kuo TK, Hung SP, Chuang CH, Chen CT, Shih YR, Fang SC, Yang VW, Lee OK. Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology 134: 2111-2121.e1-e3 (2008). *

• Kvell K, Cooper EL, Engelmann P, Bovari J, Nemeth P. Blurring borders: innate immunity with adaptive features. Clin. Dev. Immunol. 2007: 83671 (2007). *

• Kwon JH, Farrell RJ. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents. Crit. Rev. Oncol. Hematol. 56: 169-178 (2005).

• Kwun J, Knechtle SJ, Hu H. Determination of the functional status of alloreactive T cells by interferon-gamma kinetics. Transplantation 81: 590-598 (2006).

• Kyvelidou C, Chatzi K, Semitekolou M, Papathanassiou X, Vassiliadis S, Athanassakis I. Characterization of CD25-positive T cells during syngeneic pregnancy: production of stimulatory class II MHC molecules. Scand. J. Immunol. 70: 584-595 (2009). *

• La Mantia L, Milanese C, Mascoli N, D'Amico R, Weinstock-Guttman B. Cyclophosphamide for multiple sclerosis. Cochrane Database Syst. Rev. 1: CD002819 (2007). *

• Labat ML. Retroviruses, immunosuppression and osteopetrosis. Biomed. Pharmacother. 40: 85-90 (1986).

• Laing ME, Kay E, Conlon P, Murphy GM. Genetic factors associated with skin cancer in renal transplant patients. Photodermatol. Photoimmunol. Photomed. 23: 62-67 (2007).

• Lake JR, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Wiesner RH. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am. J. Transplant. 5: 549-557 (2005). *

• Lang B, Vincent A. Autoimmune disorders of the neuromuscular junction. Curr. Opin. Pharmacol. 9: 336-340 (2009).

• Lanzarotto F, Carpani M, Chaudhary R, Ghosh S. Novel treatment options for inflammatory bowel disease: targeting alpha4 Integrin. Drugs 66: 1179-1189 (2006).

• Larbi A, Fulop T, Pawelec G. Immune receptor signaling, aging and autoimmunity. Adv. Exp. Med. Biol. 640: 312-324 (2008). *

• Larsen CP, Knechtle SJ, Adams A, Pearson T, Kirk AD. A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. Am. J. Transplant. 6: 876-883 (2006). *

• Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobertm E, Anderson D, Cowan S, Price K, Naemura J, Emswiler J, Greene J, Turk LA, Bajorath J, Townsend R, Hagerty D, Linsley PS, Peach RJ. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am. J. Transplant. 5: 443-453 (2005). *

• Lashner BA. Clinical advances in ulcerative colitis. American College of Gastroenterology 68th Annual Scientific Meeting and Postgraduate Course, October 10 - 15, 2003, Baltimore, Maryland (2003).

• Laughlin E, Burke G, Pugliese A, Falk B, Nepom G. Recurrence of autoreactive antigen-specific CD4+ T cells in autoimmune diabetes after pancreas transplantation. Clin. Immunol. 128: 23-30 (2008). *

• Lavagna A, Bergallo M, Daperno M, Sostegni R, Ravarino N, Crocella L, Ramella A, Rocca R, Torchio B, Cavallo R, Pera A. The hazardous burden of Herpesviridae in inflammatory bowel disease: the case of refractory severe ulcerative colitis. Dig. Liver Dis. 38: 887-893 (2006).

• Lawson BR, Manenkova Y, Ahamed J, Chen X, Zou JP, Baccala R, Theofilopoulos AN, Yuan C. Inhibition of transmethylation down-regulates CD4 T cell activation and curtails development of autoimmunity in a model system. J. Immunol. 178: 5366-5374 (2007). *

• Le Guern V, Guillevin L. Therapeutic apheresis for myositises. Transfus. Apher. Sci. 36: 169-172 (2007).

• Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 44: 1542-1545 (2005). *

• Lebwohl M, Kathryn M. New roles for systemic retinoids. J. Drugs Dermatol. 5: 406-409 (2006).

• Lee EJ, Heo YM, Choi JH, Song HO, Ryu JS, Ahn MH. Suppressed production of pro-inflammatory cytokines by LPS-activated macrophages after treatment with Toxoplasma gondii lysate. Korean J. Parasitol. 46: 145-151 (2008).

• Lee JH, Park HY, Choe YH, Lee SK, Lee SI. The development of eosinophilic colitis after liver transplantation in children. Pediatr. Transplant. 11: 518-523 (2007). *

• Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, Wise RP, Brown SL, Udall JN Jr, Braun MM. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 46: 2565-2570 (2002). *

• Lee JK, Song HJ, Yu JR. Prevalence of diarrhea caused by Cryptosporidium parvum in non-HIV patients in Jeollanam-do, Korea. Korean J. Parasitol. 43: 111-114 (2005).

• Lee SH, Hao E, Savinov AY, Geron I, Strongin AY, Itkin-Ansari P. Human beta-cell precursors mature into functional insulin-producing cells in an immunoisolation device: implications for diabetes cell therapies. Transplantation 87: 983-991 (2009).

• Lee SJ, Chinen J, Kavanaugh A. Immunomodulator therapy: monoclonal antibodies, fusion proteins, cytokines, and immunoglobulins. J. Allergy Clin. Immunol. Dec 24 [Epub ahead of print] (2009). *

• Lee SW, Lee SY, Kim KN, Jung JK, Chung WT. Adalimumab treatment for life threatening pulmonary artery aneurysm in Behcet disease: a case report. Clin. Rheumatol. Oct 9 [Epub ahead of print] (2009).

• Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu. Rev. Immunol. 25: 243-265 (2007). *

• Lees CW, Satsangi J. Early combined immunosuppression in Crohn's disease. Lancet 371: 1995 (2008). *

• Lefaucheur C, Nochy D, Glotz D. Antibody-mediated acute rejection. Nephrol. Ther. 4 Suppl. 3: S188-S191 (2008).

• Lefkowitch JH. Hepatobiliary pathology. Curr. Opin. Gastroenterol. 23: 221-231 (2007).

• Leguern C. Tolerogenic property of MHC class I and class II molecules: lessons from a gene therapy approach. Front. Biosci. 12: 3133-3139 (2007).

• Lenert PS. Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus. Arthritis Res. Ther. 8: 203 (2006). *

• Leng Q, Bentwich Z, Borkow G. Increased TGF-beta, Cbl-b and CTLA-4 levels and immunosuppression in association with chronic immune activation. Int. Immunol. 18: 637-644 (2006). *

• Lerner SM. Kidney and pancreas transplantation in type 1 diabetes mellitus. Mt. Sinai J. Med. 75: 372-384 (2008). *

• Lerut J, Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. Am. J. Transplant. 6: 1774-1780 (2006). *

• Leung N, Textor SC. Acute renal failure after liver transplantation: the role of dopamine and fenoldopam. Liver Transpl. 10: 993-994 (2004). *

• Leuschner U. Novel approach to the treatment of primary biliary cirrhosis (PBC). Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 79-80 (2004). *

• Levitsky J, Hart J, Cohen SM, Te HS. The effect of immunosuppressive regimens on the recurrence of primary biliary cirrhosis after liver transplantation. Liver Transpl. 9: 733-736 (2003). *

• Levy C, Lindor KD. Treatment options for primary biliary cirrhosis and primary sclerosing cholangitis. Curr. Treat. Options Gastroenterol. 6: 93-103 (2003).

• Levy C, Lindor KD. Management of primary biliary cirrhosis. Curr. Treat. Options Gastroenterol. 6: 493-498 (2003).

• Li AH, Qiu GQ, Gu WY, Ling Y, Weng KZ, Tan Q, Cao XS. Expression of CD4(+) CD25(+) regulatory T cells in the patients with acute lymphocytic leukemia. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 23: 439-442 (2007).

• Li Pira G, Kapp M, Manca F, Einsele H. Pathogen specific T-lymphocytes for the reconstitution of the immunocompromised host. Curr. Opin. Immunol. 21: 549-556 (2009).

• Liao JJ, Huang MC, Goetzl EJ. Cutting edge: alternative signaling of Th17 cell development by sphingosine 1-phosphate. J. Immunol. 178: 5425-5428 (2007). *

• Liberman AC, Druker J, Refojo D, Holsboer F, Arzt E. Glucocorticoids inhibit GATA-3 phosphorylation and activity in T cells. FASEB J. 23: 1558-1571 (2009). *

• Liberman AC, Refojo D, Druker J, Toscano M, Rein T, Holsboer F, Arzt E. The activated glucocorticoid receptor inhibits the transcription factor T-bet by direct protein-protein interaction. FASEB J. 21: 1177-1188 (2007). *

• Lidar M, Langevitz P, Barzilai O, Ram M, Porat-Katz BS, Bizzaro N, Tonutti E, Maieron R, Chowers Y, Bar-Meir S, Shoenfeld Y. Infectious serologies and autoantibodies in inflammatory bowel disease. Ann. N. Y. Acad. Sci. 1173: 640-648 (2009). *

• Lim A, Manley K, Roberts M, Fraenkel M. Fish oil for kidney transplant recipients. Cochrane Database Syst. Rev. 2: CD005282 (2007). *

• Lim LL, Scarborough JD, Thorne JE, Graham E, Kempen JH, Mackensen F, Nguyen QD, Prabriputaloong T, Read RW, Suhler EB, Schwartz JM, Smith JR. Uveitis in patients with autoimmune hepatitis. Am. J. Ophthalmol. 147: 332-338.e1 (2009). *

• Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin. Infect. Dis. 35: 866-872 (2002). *

• Lin CH, Yu JC, Chen TW, Chan DC, Chen CJ, Hsieh CB. Sclerosing encapsulating peritonitis in a liver transplant patient: a case report. World J. Gastroenterol. 11: 5412-5413 (2005). *

• Lin MT, Yeh SL, Yeh CL, Lai YN, Chang KJ, Lee PH, Chen WJ. Parenteral n-3 fatty acids modulate inflammatory and immune response in rats undergoing total gastrectomy. Shock 25: 56-60 (2006). *

• Lindgren S, Glaumann H, Almer S, Bergquist A, Bjornsson E, Broome U, Danielsson A, Lebrun B, Prytz H, Olsson R. Transitions between variant forms of primary biliary cirrhosis during long-term follow-up. Eur. J. Intern. Med. 20: 398-402 (2009).

• Lindstrom J, Luo J, Kuryatov A. Myasthenia gravis and the tops and bottoms of AChRs: antigenic structure of the MIR and specific immunosuppression of EAMG using AChR cytoplasmic domains. Ann. N. Y. Acad. Sci. 1132: 29-41 (2008). *

• Linsley PS, Wallace PM, Johnson J, Gibson MG, Greene JL, Ledbetter JA, Singh C, Tepper MA. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257: 792-795 (1992). *

• Liossis SN, Tsokos GC. Monoclonal antibodies and fusion proteins in medicine. J. Allergy Clin. Immunol. 116: 721-729 (2005). *

• Lisukov IA, Sizikova SA, Kulagin AD, Kruchkova IV, Gilevich AV, Konenkova LP, Zonova EV, Chernykh ER, Leplina OY, Sentyakova TN, Demin AA, Kozlov VA. High-dose immunosuppression with autologous stem cell transplantation in severe refractory systemic lupus erythematosus. Lupus 13: 89-94 (2004).

• Liu CL, Fan ST, Lo CM, Chan SC, Ng IO, Lai CL, Wong J. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl. 10: 728-733 (2004). *

• Liu EH, Digon BJ 3rd, Hirshberg B, Chang R, Wood BJ, Neeman Z, Kam A, Wesley RA, Polly SM, Hofmann RM, Rother KI, Harlan DM. Pancreatic beta cell function persists in many patients with chronic type 1 diabetes, but is not dramatically improved by prolonged immunosuppression and euglycaemia from a beta cell allograft. Diabetologia 52: 1369-1380 (2009). *

• Liu L, Wu G, Yao JX, Ding Q, Huang SA. CD4+CD25high regulatory cells in peripheral blood of cancer patients. Neuro. Endocrinol. Lett. 29: 240-245 (2008).

• Liu Z, Yuan X, Luo Y, He Y, Jiang Y, Chen ZK, Sun E. Evaluating the effects of immunosuppressants on human immunity using cytokine profiles of whole blood. Cytokine 45: 141-147 (2009).

• Lockman J, Burns TM. Stiff-person syndrome. Curr. Treat. Options Neurol. 9: 234-240 (2007).

• Lohr HF, Schlaak JF, Lohse AW, Bocher WO, Arenz M, Gerken G, Meyer Zum Buschenfelde KH. Autoreactive CD4+ LKM-specific and anticlonotypic T-cell responses in LKM-1 antibody-positive autoimmune hepatitis. Hepatology 24: 1416-1421 (1996). *

• Lohse AW. Round table: classification of autoimmune liver diseases and diagnostic criteria. Overlap syndromes exist. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, p. 60 (2004). *

• Lohse AW. Is small duct PSC a separate disease? Falk Workshop "Primary Sclerosing Cholangitis: Complications and Consequences", Moscow (Russia), June 11, 2006, p. 9 (2006). *

• Lohse AW. Standard treatment of autoimmune hepatitis. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 65-66 (2004). *

• Lohse AW, Kogel M, Meyer zum Buschenfelde KH. Evidence for spontaneous immunosuppression in autoimmune hepatitis. Hepatology 22: 381-388 (1995).

• Long ET, Wood KJ. Regulatory T cells - a journey from rodents to the clinic. Front. Biosci. 12: 4042-4049 (2007).

• Longerich T, Schirmacher P. General aspects and pitfalls in liver transplant pathology. Clin. Transplant. 20 Suppl. 17: 60-68 (2006). *

• Longerich T, Schirmacher P, Dienes HP, Stein H, Loddenkemper C. Malignant lymphomas of the liver: new diagnostic algorithms. Pathologe 27: 263-272 (2006).

• Longhi MS, Hussain MJ, Mitry RR, Arora SK, Mieli-Vergani G, Vergani D, Ma Y. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J. Immunol. 176: 4484-4491 (2006). *

• Lopes CT, Gallo AP, Palma PV, Cury PM, Bueno V. Skin allograft survival and analysis of renal parameters after FTY720 + tacrolimus treatment in mice. Transplant. Proc. 40: 856-860 (2008).

• Lopez L, Arai K, Gimenez E, Jimenez M, Pascuzo C, Rodriguez-Bonfante C, Bonfante-Cabarcas R. C-reactive protein and interleukin-6 serum levels increase as Chagas disease progresses towards cardiac failure. Rev. Esp. Cardiol. 59: 50-56 (2006).

• Lopez-Hoyos M, Rodrigo E, Fernandez-Fresnedo G, Martinez-Taboada VM, Valero R, Arias M. Lack of effect of rapamycin in anti-CCP antibody production in a rheumatoid arthritis kidney allograft recipient. Clin. Exp. Rheumatol. 23: 529-531 (2005).

• Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 394: 897-901 (1998). *

• Lord JD, Hackman RC, Moklebust A, Thompson JA, Higano CS, Chielens D, Steinbach G, McDonald GB. Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3(+) T cells. Dig. Dis. Sci. Jun 9 [Epub ahead of print] (2009). *

• Loser K, Apelt J, Voskort M, Mohaupt M, Balkow S, Schwarz T, Grabbe S, Beissert S. IL-10 controls ultraviolet-induced carcinogenesis in mice. J. Immunol. 179: 365-371 (2007). *

• Lowenberg M, Stahn C, Hommes DW, Buttgereit F. Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. Steroids 73: 1025-1029 (2008).

• Lu J, Goh SJ, Tng PY, Deng YY, Ling EA, Moochhala S. Systemic inflammatory response following acute traumatic brain injury. Front. Biosci. 14: 3795-3813 (2009).

• Lu Y, Jacobson D, Bousvaros A. Immunizations in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 15: 1417-1423 (2009). *

• Lu Y, Jacobson DL, Ashworth LA, Grand RJ, Meyer AL, McNeal MM, Gregas MC, Burchett SK, Bousvaros A. Immune response to influenza vaccine in children with inflammatory bowel disease. Am. J. Gastroenterol. 104: 444-453 (2009).

• Lucas RM, Repacholi MH, McMichael AJ. Is the current public health message on UV exposure correct? Bull. World Health Organ. 84: 485-491 (2006).

• Lukes DJ, Herlenius G, Rizell M, Mjornstedt L, Bacman L, Olausson M, Friman S. Late mortality in 679 consecutive liver transplant recipients: the Gothenburg liver transplant experience. Transplant. Proc. 38: 2671-2672 (2006). *

• Luth S, Birklein F, Schramm C, Herkel J, Hennes E, Muller-Forell W, Galle PR, Lohse AW. Multiplex neuritis in a patient with autoimmune hepatitis: a case report. World J. Gastroenterol. 12: 5396-5398 (2006). *

• Luth S, Kanzler S, Frenzel C, Kasper HU, Dienes HP, Schramm C, Galle PR, Herkel J, Lohse AW. Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. J. Clin. Gastroenterol. 43: 75-80 (2009).

• Luxon BA. Autoimmune hepatitis: diagnosis, treatment, and prognosis. Curr. Gastroenterol. Rep. 8: 83-88 (2006).

• MacQuillan GC, Neuberger J. Liver transplantation for primary biliary cirrhosis. Clin. Liver Dis. 7: 941-956, ix (2003).

• Maddox JS, Soltani K. Risk of nonmelanoma skin cancer with azathioprine use. Inflamm. Bowel Dis. 14: 1425-1431 (2008). *

• Madsen K. Probiotics in critically ill patients. J. Clin. Gastroenterol. 42: S116-S118 (2008).

• Maggiore G, Riva S, Sciveres M. Autoimmune diseases of the liver and biliary tract and overlap syndromes in childhood. Minerva Gastroenterol. Dietol. 55: 53-70 (2009).

• Maggiore G, Sciveres M. Autoimmune hepatitis: a childhood disease. Current Pediatric Reviews 1: 73-90 (2005). *

• Magliocca JF, Held IK, Odorico JS. Undifferentiated murine embryonic stem cells cannot induce portal tolerance but may possess immune privilege secondary to reduced major histocompatibility complex antigen expression. Stem Cells Dev. 15: 707-717 (2006).

• Magro F, Portela F, Lago P, de Deus JR, Vieira A, Peixe P, Cremers I, Cotter J, Cravo M, Tavares L, Reis J, Goncalves R, Lopes H, Caldeira P, Ministro P, Carvalho L, Azevedo L, Da Costa-Pereira A, et al. Crohn's disease in a southern European country: Montreal classification and clinical activity. Inflamm. Bowel Dis. 15: 1343-1350 (2009).

• Maheshwari A, Mishra R, Thuluvath PJ. Post-liver-transplant anemia: etiology and management. Liver Transpl. 10: 165-173 (2004). *

• Maheshwari A, Yoo HY, Thuluvath PJ. Long-term outcome of liver transplantation in patients with PSC: a comparative analysis with PBC. Am. J. Gastroenterol. 99: 538-542 (2004). *

• Mahnke K, Johnson TS, Ring S, Enk AH. Tolerogenic dendritic cells and regulatory T cells: a two-way relationship. J. Dermatol. Sci. 46: 159-167 (2007).

• Mahnke K, Ring S, Johnson TS, Schallenberg S, Schonfeld K, Storn V, Bedke T, Enk AH. Induction of immunosuppressive functions of dendritic cells in vivo by CD4+CD25+ regulatory T cells: role of B7-H3 expression and antigen presentation. Eur. J. Immunol. 37: 2117-2126 (2007). *

• Majewska M, Zajac K, Srebro Z, Sura P, Ksiazek L, Zemelka M, Szczepanik M. Epicutaneous immunization with myelin basic protein protects from the experimental autoimmune encephalomyelitis. Pharmacol. Rep. 59: 74-79 (2007). *

• Majewski S, Jantschitsch C, Maeda A, Schwarz T, Schwarz A. IL-23 antagonizes UVR-induced immunosuppression through two mechanisms: reduction of UVR-induced DNA damage and inhibition of UVR-induced regulatory T cells. J. Invest. Dermatol. Sep 3 [Epub ahead of print] (2009). *

• Mak A, Chan BP, Yeh IB, Ho RC, Boey ML, Feng PH, Koh DR, Ong BK. Neuropsychiatric lupus and reversible posterior leucoencephalopathy syndrome: a challenging clinical dilemma. Rheumatology (Oxford) 47: 256-262 (2008). *

• Makaritsis KP, Gatselis NK, Ioannou M, Petinaki E, Dalekos GN. Polyclonal hypergammaglobulinemia and high smooth-muscle autoantibody titers with specificity against filamentous actin: consider visceral leishmaniasis, not just autoimmune hepatitis. Int. J. Infect. Dis. 13: e157-e160 (2009).

• Mallet F, Prudhomme S. Retroviral inheritance in man. J. Soc. Biol. 198: 399-412 (2004).

• Mancardi G, Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol. 7: 626-636 (2008).

• Manchanda PK, Kumar A, Sharma RK, Goel H, Mittal RD. Association of pro/anti-inflammatory cytokine gene variants in renal transplant patients with allograft outcome and cyclosporine immunosuppressant levels. Biologics 2: 875-884 (2008). *

• Mandak JS, Pollack B, Fishman NO, Furth EE, Kochman ML, Acker MA, Lichtenstein GR. Acalculous candidal cholecystitis: a previously unrecognized complication after cardiac transplantation. Am. J. Gastroenterol. 90: 1333-1337 (1995).

• Mandapathil M, Hilldorfer B, Szczepanski MJ, Czystowska M, Szajnik M, Ren J, Lang S, Jackson EK, Gorelik E, Whiteside TL. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells (TREG). J. Biol. Chem. Oct 26 [Epub ahead of print] (2009). *

• Manns MP. Viruses and autoimmune liver disease. Intervirology 35: 108-115 (1993).

• Manns MP, Obermayer-Straub P. Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease. Hepatology 26: 1054-1066 (1997). *

• Manousou P, Arvaniti V, Tsochatzis E, Isgro G, Jones K, Shirling G, Dhillon A, O'Beirne J, Patch D, Burroughs A. Primary biliary cirrhosis after liver transplantation: influence of immunosuppression and HLA locus disparity. Liver Transpl. Oct 28 [Epub ahead of print] (2009).

• Manz RA, Moser K, Burmester GR, Radbruch A, Hiepe F. Immunological memory stabilizing autoreactivity. Curr. Top. Microbiol. Immunol. 305: 241-257 (2006).

• Manzarbeitia CY, Ortiz JA, Jeon H, Rothstein KD, Martinez O, Araya VR, Munoz SJ, Reich DJ. Long-term outcome of controlled, non-heart-beating donor liver transplantation. Transplantation 78: 211-215 (2004).

• Marder W, McCune WJ. Advances in immunosuppressive drug therapy for use in autoimmune disease and systemic vasculitis. Semin. Respir. Crit. Care Med. 25: 581-594 (2004).

• Margolles-Clark E, Jacques-Silva MC, Ganesan L, Umland O, Kenyon NS, Ricordi C, Berggren PO, Buchwald P. Suramin inhibits the CD40-CD154 costimulatory interaction: a possible mechanism for immunosuppressive effects. Biochem. Pharmacol. 77: 1236-1245 (2009).

• Mariette X, Tubach F, Bagheri H, Bardet M, Berthelot JM, Gaudin P, Heresbach D, Martin A, Schaeverbeke T, Salmon D, Lemann M, Hermine O, Raphael M, Ravaud P. Lymphoma in patients treated with anti-TNF. Results of the 3-year prospective French RATIO registry. Ann. Rheum. Dis. Oct 14 [Epub ahead of print] (2009).

• Marmon S, Strober BE. Balancing immunity and immunosuppression: vaccinating patients receiving treatment with efalizumab. J. Invest. Dermatol. 128: 2567-2569 (2008). *

• Marsh EA, Hirst CL, Llewelyn JG, Cossburn MD, Reilly MM, Krishnan A, Doran M, Ryan AM, Coles AJ, Jones JL, Robertson NP. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. J. Neurol. Jan 6 [Epub ahead of print] (2010).

• Marsh JE, Andrews PA. HLA matching: still important despite modern immunosuppression. Transplantation 85: 312-313 (2008).

• Marshall SE, Welsh KI. The role of cytokine polymorphisms in rejection after solid organ transplantation. Genes Immun. 2: 297-303 (2001). *

• Martín De Carpi J, Varea V. Response to stopping azathioprine in Crohn's patients on combined treatment with infliximab. An. Pediatr. (Barc.) 70: 271-277 (2009).

• Martin SR, Atkison P, Anand R, Lindblad AS; The SPLIT Research Group. Studies of pediatric liver transplantation 2002: patient and graft survival and rejection in pediatric recipients of a first liver transplant in the United States and Canada. Pediatr. Transplant. 8: 273-283 (2004).

• Martínez-Hernandez E, Rosenfeld M, Pruitt A, Dalmau J. Neurological complications of transplantation. Neurologia 23: 373-386 (2008).

• Martinic MM, von Herrath MG. Novel strategies to eliminate persistent viral infections. Trends Immunol. 29: 116-124 (2008). *

• Martins L, Malheiro J, Henriques AC, Dias L, Dores J, Oliveira F, Seca R, Almeida R, Sarmento AM, Cabrita A, Teixeira M. Pancreas-kidney transplantation and the evolution of pancreatic autoantibodies. Transplant. Proc. 41: 913-915 (2009). *

• Marubashi S, Dono K, Amano K, Hama N, Gotoh K, Takahashi H, Hashimoto K, Miyamoto A, Takeda Y, Nagano H, Umeshita K, Monden M. Steroid-free living-donor liver transplantation in adults. Transplantation 80: 704-706 (2005).

• Marzano AV, Tourlaki A, Merlo V, Spinelli D, Venegoni L, Crosti C. Herpes simplex virus infection and pemphigus. Int. J. Immunopathol. Pharmacol. 22: 781-786 (2009).

• Maschmeyer G, Haas A. Infectious complications related to nucleoside analogs and monoclonal antibodies. Dtsch. Med. Wochenschr. 131: 2414-2419 (2006).

• Mason A, Nair S. Primary biliary cirrhosis: new thoughts on pathophysiology and treatment. Curr. Gastroenterol. Rep. 4: 45-51 (2002).

• Matsumoto Y. New approach to immunotherapy against organ-specific autoimmune diseases with T cell receptor and chemokine receptor DNA vaccines. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5: 73-77 (2005).

• Matsumura Y, Kobayashi T, Ichiyama K, Yoshida R, Hashimoto M, Takimoto T, Tanaka K, Chinen T, Shichita T, Wyss-Coray T, Sato K, Yoshimura A. Selective expansion of Foxp3-positive regulatory T cells and immunosuppression by suppressors of cytokine signaling 3-deficient dendritic cells. J. Immunol. 179: 2170-2179 (2007). *

• Matsuoka K, Iwao Y, Mori T, Sakuraba A, Yajima T, Hisamatsu T, Okamoto S, Morohoshi Y, Izumiya M, Ichikawa H, Sato T, Inoue N, Ogata H, Hibi T. Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. Am. J. Gastroenterol. 102: 331-337 (2007). *

• Matsuura T, West GA, Levine AD, Fiocchi C. Selective resistance of mucosal T-cell activation to immunosuppression in Crohn's disease. Dig. Liver Dis. 32: 484-494 (2000).

• Mayer L. Review article: local and systemic regulation of mucosal immunity. Aliment. Pharmacol. Ther. 11 Suppl. 3: 81-85 (1997).

• Mazariegos GV, Salzedas AA, Zavatsky J, Sindhi R, Parizhskaya M, McGhee W, Jain A, Reyes J. Long term management of liver transplant rejection in children. BioDrugs 14: 31-48 (2000).

• Mazzone PJ, Jane Thomassen M, Kavuru MS. Pulmonary alveolar proteinosis: recent advances. Semin. Respir. Crit. Care Med. 23: 115-126 (2002).

• McCarron M, Reen DJ. Activated human neonatal CD8+ T cells are subject to immunomodulation by direct TLR2 or TLR5 stimulation. J. Immunol. 182: 55-62 (2009). *

• McCulloch MI, Burger H, Spearman CW, Cooke L, Goddard E, Gajjar P, Numanoglu A, Rode H, Kahn D, Millar AJ. Nephrotoxic effects of immunosuppressant therapy in pediatric liver transplant recipients. Transplant. Proc. 37: 1220-1223 (2005). *

• McDiarmid SV. Liver transplantation. The pediatric challenge. Clin. Liver Dis. 4: 879-927 (2000).

• McGrath H Jr. Ultraviolet A1 (340-400 nm) irradiation and systemic lupus erythematosus. J. Invest. Dermatol. Symp. Proc. 4: 79-84 (1999).

• McHugh RS. Autoimmune gastritis is a well-defined autoimmune disease model for the study of CD4+CD25+ T cell-mediated suppression. Curr. Top. Microbiol. Immunol. 293: 153-177 (2005).

• McIntyre N. Sheila: Professor Dame Sheila Sherlock (1918-2001). Hepatology 35: 507-509 (2002). *

• McKaig BC, Stack WA. Current pharmacotherapy for inflammatory bowel disease. Expert Opin. Pharmacother. 1: 3-14 (1999).

• McNamara NA. Molecular mechanisms of keratinizing ocular surface disease. Optom. Vis. Sci. Dec 14 [Epub ahead of print] (2009).

• Mehrabi A, Fonouni H, Wente M, Sadeghi M, Eisenbach C, Encke J, Schmied BM, Libicher M, Zeier M, Weitz J, Buchler MW, Schmidt J. Wound complications following kidney and liver transplantation. Clin. Transplant. 20 Suppl. 17: 97-110 (2006). *

• Mehta S, Fantry L. Gastrointestinal infections in the immunocompromised host. Curr. Opin. Gastroenterol. 21: 39-43 (2005).

• Meier J, Sturm A. Concomitant use of immunomodulators with anti-TNF in Crohn's disease: yes or no? Curr. Drug Targets Nov 17 [Epub ahead of print] (2009).

• Mellgren K, Fasth A, Saalman R, Olausson M, Abrahamsson J. Liver transplantation after stem cell transplantation with the same living donor in a monozygotic twin with acute myeloid leukemia. Ann. Hematol. 84: 755-757 (2005). *

• Mells G, Mann C, Hubscher S, Neuberger J. Late protocol liver biopsies in the liver allograft: a neglected investigation? Liver Transpl. 15: 931-938 (2009).

• Mells G, Neuberger J. Reducing the risks of cardiovascular disease in liver allograft recipients. Transplantation 83: 1141-1150 (2007).

• Melmed GY, Agarwal N, Frenck RW, Ippoliti AF, Ibanez P, Papadakis KA, Simpson P, Barolet-Garcia C, Ward J, Targan SR, Vasiliauskas EA. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am. J. Gastroenterol. 105: 148-154 (2010). *

• Menger MD, Vollmar B. Surgical trauma: hyperinflammation versus immunosuppression? Langenbecks Arch. Surg. 389: 475-484 (2004). *

• Mertz KD, Junt T, Schmid M, Pfaltz M, Kempf W. Inflammatory monocytes are a reservoir for Merkel cell polyomavirus. J. Invest. Dermatol. Dec 17 [Epub ahead of print] (2009). *

• Metz I, Lucchinetti CF, Openshaw H, Garcia-Merino A, Lassmann H, Freedman MS, Atkins HL, Azzarelli B, Kolar OJ, Bruck W. Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain 130: 1254-1262 (2007).

• Michetti P. Fistula treatment: the unresolved challenge. Dig. Dis. 27: 387-393 (2009).

• Mieli-Vergani G, Vergani D. Autoimmune paediatric liver disease. World J. Gastroenterol. 14: 3360-3367 (2008). *

• Mieli-Vergani G, Vergani D. Immunological liver diseases in children. Semin. Liver Dis. 18: 271-279 (1998).

• Mieli-Vergani G, Vergani D. Autoimmune liver disease in children. Ann. Acad. Med. Singapore 32: 239-243 (2003). *

• Mieli-Vergani G, Vergani D. Autoimmune liver disease - therapeutic aspects in children. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 89-91 (2004). *

• Mifsud NA, Purcell AW, Chen W, Holdsworth R, Tait BD, McCluskey J. Immunodominance hierarchies and gender bias in direct T(CD8)-cell alloreactivity. Am. J. Transplant. 8: 121-132 (2008).

• Mignogna MD, Fortuna G, Leuci S. Oral pemphigus. Minerva Stomatol. 58: 501-518 (2009).

• Miller GA, Yeh BM, Breiman RS, Roberts JP, Qayyum A, Coakley FV. Use of CT cholangiography to evaluate the biliary tract after liver transplantation: initial experience. Liver Transpl. 10: 1065-1070 (2004). *

• Mino De Kaspar H, Ta CN, Froehlich SJ, Schaller UC, Engelbert M, Klauss V, Kampik A. Prospective study of risk factors for conjunctival bacterial contamination in patients undergoing intraocular surgery. Eur. J. Ophthalmol. 19: 717-722 (2009).

• Mirocha S, Elagin RB, Salamat S, Jaume JC. T regulatory cells distinguish two types of primary hypophysitis. Clin. Exp. Immunol. 155: 403-411 (2009). *

• Misharin A, Hewison M, Chen CR, Lagishetty V, Aliesky HA, Mizutori Y, Rapoport B, McLachlan SM. Vitamin D deficiency modulates Graves' hyperthyroidism induced in BALB/c mice by thyrotropin receptor immunization. Endocrinology 150: 1051-1060 (2009). *

• Mitchell A, Adams LA, Macquillan G, Tibballs J, Vanden Driesen R, Delriviere L. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl. 14: 210-213 (2008). *

• Mithoefer AB, Supran S, Freeman RB. Risk factors associated with the development of skin cancer after liver transplantation. Liver Transpl. 8: 939-944 (2002). *

• Mix E, Goertsches R, Zettl UK. Immunology and neurology. J. Neurol. 254 Suppl. 2: II2-II7 (2007).

• Miyagawa-Hayashino A, Haga H, Egawa H, Hayashino Y, Sakurai T, Minamiguchi S, Tanaka K, Manabe T. Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation. Transplantation 78: 128-135 (2004).

• Miyake K. Endotoxin recognition molecules MD-2 and Toll-like receptor 4 as potential targets for therapeutic intervention of endotoxin shock. Curr. Drug Targets Inflamm. Allergy 3: 291-297 (2004).

• Mizukawa Y, Shiohara T. Virus-induced immune dysregulation as a triggering factor for the development of drug rashes and autoimmune diseases: with emphasis on EB virus, human herpesvirus 6 and hepatitis C virus. J. Dermatol. Sci. 22: 169-180 (2000).

• Mizushima T, Ito T, Kishi D, Kai Y, Tamagawa H, Nezu R, Kiyono H, Matsuda H. Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin- 10 gene-deficient mice with colitis. Inflamm. Bowel Dis. 10: 182-192 (2004). *

• Mochizuki M. Intraocular inflammation and homeostasis of the eye. Nippon Ganka Gakkai Zasshi 113: 344-377 (2009).

• Molina-Holgado E, Guaza C, Borrell J, Molina-Holgado F. Effects of cannabinoids on the immune system and central nervous system: therapeutic implications. BioDrugs 12: 317-326 (1999).

• Molleston JP, Alevy YG, SivaSai KS, Mohanakumar T, Howard TK. Evidence that pediatric liver transplant recipients may undergo late rejection episodes in spite of donor-specific microchimerism. Transplantation 61: 656-657 (1996).

• Montero JL, Pozo JC, Barrera P, Fraga E, Costan G, Dominguez JL, Muntane J, Rodriguez-Ariza A, Pleguezuelo M, Rufian S, Lopez-Cillero P, de la Mata M. Treatment of refractory cholestatic pruritus with molecular adsorbent recirculating system (MARS). Transplant. Proc. 38: 2511-2513 (2006). *

• Monti P, Scirpoli M, Maffi P, Ghidoli N, De Taddeo F, Bertuzzi F, Piemonti L, Falcone M, Secchi A, Bonifacio E. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J. Clin. Invest. 118: 1806-1814 (2008). *

• Moore Dalal K, Antonescu CR, Dematteo RP, Maki RG. EBV-associated smooth muscle neoplasms: solid tumors arising in the presence of immunosuppression and autoimmune diseases. Sarcoma 2008: 859407 (2008).

• Mor E, Yussim A, Chodoff L, Schwartz ME. New immunosuppressive agents for maintenance therapy in organ transplantation. BioDrugs 8: 469-488 (1997).

• Mor F, Cohen IR. Vaccines to prevent and treat autoimmune diseases. Int. Arch. Allergy Immunol. 108: 345-349 (1995).

• Moreno Casado P, Alvarez Kindelan A, Algar Algar FJ, Espinosa Jimenez D, Cano Garcia JR, Cerezo Madueno F, Baamonde Laborda C, Lopez Cillero P, Salvatierra Velazquez A. Combined lung and liver transplantation - University Hospital Reina Sofia experience: two case reports. Transplant. Proc. 40: 3126-3127 (2008). *

• Moreno R, Berenguer M. Post-liver transplantation medical complications. Ann. Hepatol. 5: 77-85 (2006). *

• Moreno-Otero R, Lisker-Melman M, Jones EA. Primary biliary cirrhosis. Med. Clin. North Am. 73: 911-929 (1989).

• Moscandrew M, Mahadevan U, Kane S. General health maintenance in IBD. Inflamm. Bowel Dis. 15: 1399-1409 (2009). *

• Moss P, Rickinson A. Cellular immunotherapy for viral infection after HSC transplantation. Nat. Rev. Immunol. 5: 9-20 (2005). *

• Mottershead M, Neuberger J. Transplantation in autoimmune liver diseases. World J. Gastroenterol. 14: 3388-3395 (2008). *

• Mowat AP. Orthotopic liver transplantation in liver-based metabolic disorders. Eur. J. Pediatr. 151 Suppl. 1: S32-S38 (1992).

• Mueller AR, Pascher A, Platz KP, Braun F, Fandrich F, Rayes N, Seehofer D, Radtke C, Neuhaus P, Kremer B. Immunosuppression following intestinal transplantation. Transplant. Proc. 36: 325-328 (2004). *

• Muiesan P, Vergani D, Mieli-Vergani G. Liver transplantation in children. J. Hepatol. 46: 340-348 (2007). *

• Muller S, Rihs S, Dayer Schneider JM, Paredes BE, Seibold I, Brunner T, Mueller C. Soluble TNF-alpha but not transmembrane TNF-alpha sensitizes T cells for enhanced activation-induced cell death. Eur. J. Immunol. 39: 3171-3180 (2009). *

• Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 117: 1147-1154 (2007). *

• Munoz AS, Rioveros AA, Cabanayan-Casasola CB, Danguilan RA, Ona ET. Rituximab in highly sensitized kidney transplant recipients. Transplant. Proc. 40: 2218-2221 (2008). *

• Muratori L, Cassani F, Pappas G, Guidi M, Mele L, Lorenza V, Lenzi M, Bianchi FB, Muratori P. The hepatitic/cholestatic "overlap" syndrome: an Italian experience. Autoimmunity 35: 565-568 (2002).

• Muratori P, Granito A, Quarneti C, Ferri S, Menichella R, Cassani F, Pappas G, Bianchi FB, Lenzi M, Muratori L. Autoimmune hepatitis in Italy: the Bologna experience. J. Hepatol. 50: 1210-1218 (2009).

• Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 111: 352-356 (2004). *

• Murphy CC, Greiner K, Plskova J, Duncan L, Frost NA, Forrester JV, Dick AD. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch. Ophthalmol. 123: 634-641 (2005). *

• Muthu K, He LK, Melstrom K, Szilagyi A, Gamelli RL, Shankar R. Perturbed bone marrow monocyte development following burn injury and sepsis promote hyporesponsive monocytes. J. Burn Care Res. 29: 12-21 (2008).

• Naderi AS, Farsian FN, Lee WM. Cholangiocarcinoma after lung transplantation in a patient with cystic fibrosis. Eur. J. Gastroenterol. Hepatol. 20: 1115-1117 (2008).

• Nagai H, Matsumaru K, Shiozawa K, Momiyama K, Wakui N, Shinohara M, Watanabe M, Ishii K, Nonaka H, Hasegawa A, Teramoto T, Yamamuro W, Sumino Y, Miki K. Disappearance of HCV after cessation of immunosuppression in a patient with ulcerative colitis and renal transplantation. J. Gastroenterol. 40: 848-853 (2005). *

• Nagarkatti M, Rieder SA, Vakharia D, Nagarkatti PS. Evaluation of apoptosis in immunotoxicity testing. Methods Mol. Biol. 598: 241-257 (2010). *

• Nagata H, Nishitai R, Shirota C, Zhang JL, Koch CA, Cai J, Awwad M, Schuurman HJ, Christians U, Abe M, Baranowska-Kortylewicz J, Platt JL, Fox IJ. Prolonged survival of porcine hepatocytes in cynomolgus monkeys. Gastroenterology 132: 321-329 (2007). *

• Nagler A, Ilan Y, Amiel A, Eid A, Tur-Kaspa R. Systemic chimerism in sex-mismatched liver transplant recipients detected by fluorescence in situ hybridization. Transplantation 57: 1458-1461 (1994).

• Najafian N, Sayegh MH. CTLA4-Ig: a novel immunosuppressive agent. Expert Opin. Investig. Drugs 9: 2147-2157 (2000).

• Nandakumar G, Stein SL, Michelassi F. Anastomoses of the lower gastrointestinal tract. Nat. Rev. Gastroenterol. Hepatol. 6: 709-716 (2009).

• Nangaku M, Couser WG. Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin. Exp. Nephrol. 9: 183-191 (2005).

• Narayana N, Gifford R, Giannini P, Casey J. Oral histoplasmosis: an unusual presentation. Head Neck 31: 274-277 (2009).

• Nasef A, Mathieu N, Chapel A, Frick J, Francois S, Mazurier C, Boutarfa A, Bouchet S, Gorin NC, Thierry D, Fouillard L. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 84: 231-237 (2007).

• Nash RA, Dansey R, Storek J, Georges GE, Bowen JD, Holmberg LA, Kraft GH, Mayes MD, McDonagh KT, Chen CS, Dipersio J, Lemaistre CF, Pavletic S, Sullivan KM, Sunderhaus J, Furst DE, McSweeney PA. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol. Blood Marrow Transplant. 9: 583-591 (2003).

• Nemati E, Taheri S, Pourfarziani V, Einollahi B. Human leukocyte antigen (HLA) B-27 and older age are associated with augmented cyclosporine blood bioavailability in renal allograft recipients: an attempt toward individualization of immunosuppression. Ann. Transplant. 13: 32-36 (2008). *

• Netea MG, Van der Meer JW, Kullberg BJ. Role of the dual interaction of fungal pathogens with pattern recognition receptors in the activation and modulation of host defence. Clin. Microbiol. Infect. 12: 404-409 (2006). *

• Neuberger J. Chapter 32. Acute and chronic rejection of the liver allograft. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 423-431 (2007). *

• Neuberger J. Liver transplantation for autoimmune liver diseases. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 82-83 (2004). *

• Neuberger J. Recurrence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis. Liver Transpl. Surg. 1: 109-115 (1995).

• Neuberger J. Incidence, timing, and risk factors for acute and chronic rejection. Liver Transpl. Surg. 5: S30-S36 (1999).

• Neuberger J. Liver transplantation for cholestatic liver disease. Curr. Treat. Options Gastroenterol. 6: 113-121 (2003).

• Neuberger J. Transplantation for autoimmune hepatitis. Semin. Liver Dis. 22: 379-386 (2002).

• Neuberger J. Liver transplantation for primary biliary cirrhosis. Autoimmun. Rev. 2: 1-7 (2003). *

• Neuberger J. Recurrence of autoimmune liver diseases after liver transplantation. Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 47-48. September 12 - 13 (2003). *

• Neuberger J. Liver transplantation for primary biliary cirrhosis: indications and risk of recurrence. J. Hepatol. 39: 142-148 (2003). *

• Neuberger J. Recurrent primary biliary cirrhosis. Best Pract. Res. Clin. Gastroenterol. 14: 669-680 (2000). *

• Neuberger J, Gunson B, Hubscher S, Nightingale P. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl. 10: 488-491 (2004). *

• Neuberger J, Jothimani D. Long-term immunosuppression for prevention of nonviral disease recurrence. Transplant. Proc. 37: 1671-1674 (2005). *

• Neuberger J, Wallace L, Joplin R, Hubscher S. Hepatic distribution of E2 component of pyruvate dehydrogenase complex after transplantation. Hepatology 22: 798-801 (1995).

• Neuhaus P. Organ shortage. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 112-113. October 17 - 19 (2003). *

• Neumann UP, Guckelberger O, Langrehr JM, Lang M, Schmitz V, Theruvath T, Schonemann C, Menzel S, Klupp J, Neuhaus P. Impact of human leukocyte antigen matching in liver transplantation. Transplantation 75: 132-137 (2003).

• Nicholson LB, Raveney BJ, Munder M. Monocyte dependent regulation of autoimmune inflammation. Curr. Mol. Med. 9: 23-29 (2009).

• Nickerson P. Post-transplant monitoring of renal allografts: are we there yet? Curr. Opin. Immunol. 21: 563-568 (2009).

• Niemczyk M, Zegarska J, Pawlowska M, Wyzgal J, Ciszek M, Paczek L. Different profile of gene expression of cytokines in peripheral blood mononuclear cells of transplant recipients treated with m-TOR inhibitor and calcineurin inhibitor. Transpl. Immunol. 20: 139-142 (2009).

• Nishihori T, Strazzabosco M, Saif MW. Incidence and management of colorectal cancer in liver transplant recipients. Clin. Colorectal Cancer 7: 260-266 (2008).

• No authors listed. In this issue. Eur. J. Immunol. 39: 919-920 (2009).

• No authors listed. Ustekinumab: new drug. Suspicion of carcinogenicity: too great a risk for psoriasis patients. Prescrire. Int. 18: 202-204 (2009).

• Nomura K, Fujimoto Y, Yamashita M, Morimoto Y, Ohshiro M, Sato K, Oyake T, Kowata S, Konishi H, Yoshikawa T, Ishida Y, Taniwaki M. Absence of pseudomembranes in Clostridium difficile-associated diarrhea in patients using immunosuppression agents. Scand. J. Gastroenterol. 44: 74-78 (2009). *

• Norval M. The mechanisms and consequences of ultraviolet-induced immunosuppression. Prog. Biophys. Mol. Biol. 92: 108-118 (2006). *

• Norval M, Cullen AP, de Gruijl FR, Longstreth J, Takizawa Y, Lucas RM, Noonan FP, van der Leun JC. The effects on human health from stratospheric ozone depletion and its interactions with climate change. Photochem. Photobiol. Sci. 6: 232-251 (2007). *

• Nos P, Garrigues V, Bastida G, Maroto N, Ponce M, Ponce J. Outcome of patients with nonstenotic, nonfistulizing Crohn's disease. Dig. Dis. Sci. 49: 1771-1776 (2004). *

• Nosari A, Marbello L, De Carlis LG, De Gasperi A, Muti G, Mancini V, Morra E. Bone marrow hypoplasia complicating tacrolimus (FK506) therapy. Int. J. Hematol. 79: 130-132 (2004).

• Nowack R, Grab I, Flores-Suarez LF, Schnulle P, Yard B, van der Woude FJ. ANCA titres, even of IgG subclasses, and soluble CD14 fail to predict relapses in patients with ANCA-associated vasculitis. Nephrol. Dial. Transplant. 16: 1631-1637 (2001). *

• O'Carroll RE, Couston M, Cossar J, Masterton G, Hayes PC. Psychological outcome and quality of life following liver transplantation: a prospective, national, single-center study. Liver Transpl. 9: 712-720 (2003). *

• O'Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, McGregor JM, Walker SL, Hanaoka F, Karran P. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 309: 1871-1874 (2005). *

• O'Neill BP, Vernino S, Dogan A, Giannini C. EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil. Neuro-oncol. 9: 364-369 (2007).

• Obermayer-Straub P, Manns MP. Hepatitis C and D, retroviruses and autoimmune manifestations. J. Autoimmun. 16: 275-285 (2001). *

• Obermayer-Straub P, Strassburg CP, Manns MP. Autoimmune hepatitis. J. Hepatol. 32: S181-S197 (2000).

• Ochs HD, Gambineri E, Torgerson TR. IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity. Immunol. Res. 38: 112-121 (2007). *

• Oger J. Immunosuppression: promises and failures. J. Neurol. Sci. 259: 74-78 (2007). *

• Oh-I K, Keino H, Goto H, Yamakawa N, Takeuchi M, Usui M, Iwasaki T. Up-regulation of neurotrophic factor-related gene expression in retina with experimental autoimmune uveoretinitis by intravitreal injection of tacrolimus (FK506). Br. J. Ophthalmol. 91: 1537-1540 (2007). *

• Okita R, Yamaguchi Y, Emi A, Matsuura K, Toge T. Enhancement of lymphokine-activated killer cell induction using anti-CD25 and anti-CTLA-4 monoclonal antibodies. Oncol. Rep. 17: 1429-1435 (2007). *

• Oksenberg JR. Selective targeting of the immune response in autoimmune demyelination. West. J. Med. 161: 255-259 (1994). *

• Oldakowska-Jedynak U, Nowak M, Mucha K, Foroncewicz B, Nyckowski P, Zieniewicz K, Ziarkiewicz-Wroblewska B, Patkowski W, Gornicka B, Paczkowska A, Michalowicz B, Pilecki T, Pawlak J, Krawczyk M, Paczek L. Recurrence of primary sclerosing cholangitis in patients after liver transplantation. Transplant. Proc. 38: 240-243 (2006). *

• Openshaw H, Atkins HL, Chen JT, de Bittencourt PR, Griffiths LM, Kerr DA, Khoury SA, Muraro PA, Nash RA, Saccardi R. Multiple sclerosis conference synopsis and discussion: cellular therapy for treatment of autoimmune diseases. Mult. Scler. 12: 824-825 (2006). *

• Openshaw H, Nash RA, McSweeney PA. High-dose immunosuppression and hematopoietic stem cell transplantation in autoimmune disease: clinical review. Biol. Blood Marrow Transplant. 8: 233-248 (2002).

• Opilla M. Epidemiology of bloodstream infection associated with parenteral nutrition. Am. J. Infect. Control 36: S173.e5-e8 (2008). *

• Opitz CA, Litzenburger UM, Lutz C, Lanz TV, Tritschler I, Koppel A, Tolosa E, Hoberg M, Anderl J, Aicher WK, Weller M, Wick W, Platten M. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells 27: 909-919 (2009).

• Orlando G, Soker S, Wood K. Operational tolerance after liver transplantation. J. Hepatol. 50: 1247-1257 (2009).

• Ornatowski W, Poschet JF, Perkett E, Taylor-Cousar JL, Deretic V. Elevated furin levels in human cystic fibrosis cells result in hypersusceptibility to exotoxin A-induced cytotoxicity. J. Clin. Invest. 117: 3489-3497 (2007). *

• Ortonne JP, Prinz JC. Alefacept: a novel and selective biologic agent for the treatment of chronic plaque psoriasis. Eur. J. Dermatol. 14: 41-45 (2004).

• Ostroukhova M, Qi Z, Oriss TB, Dixon-McCarthy B, Ray P, Ray A. Treg-mediated immunosuppression involves activation of the Notch-HES1 axis by membrane-bound TGF-beta. J. Clin. Invest. 116: 996-1004 (2006). *

• Oya H, Sato Y, Yamamoto S, Kobayashi T, Watanabe T, Kokai H, Hatakeyama K. De novo autoimmune hepatitis after living donor liver transplantation in a 25-day-old newborn baby: a case report. Transplant. Proc. 41: 433-434 (2009). *

• Ozaslan E. Which level of immunosuppression is harmful for occult hepatitis B virus infection? Liver Int. 29: 1126-1127 (2009). *

• Pache I, Rogler G, Felley C. TNF-alpha blockers in inflammatory bowel diseases: practical consensus recommendations and a user's guide. Swiss Med. Wkly. 139: 278-287 (2009). *

• Padbury RT, Gunson BK, Dousset B, Hubscher SG, Mayer AD, Buckels JA, Neuberger JM, Elias E, McMaster P. Long-term immunosuppression after liver transplantation: are steroids necessary? Transpl. Int. 5 Suppl. 1: S470-S472 (1992).

• Page KM, Mendizabal AM, Prasad VK, Martin PL, Parikh S, Wood S, Sempowski GD, Szabolcs P, Kurtzberg J. Posttransplant autoimmune hemolytic anemia and other autoimmune cytopenias are increased in very young infants undergoing unrelated donor umbilical cord blood transplantation. Biol. Blood Marrow Transplant. 14: 1108-1117 (2008).

• Paik SW, Tan HP, Klein AS, Boitnott JK, Thuluvath PJ. Outcome of orthotopic liver transplantation in patients with hepatitis C. Dig. Dis. Sci. 47: 450-455 (2002). *

• Palace J. Inflammation versus neurodegeneration: consequences for treatment. J. Neurol. Sci. 259: 46-49 (2007). *

• Pan C, Jain A, Fung JJ. Analysis of causes of late mortality in liver transplant recipients. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 16: 547-551 (2004).

• Papadimitriou JC, Cangro CB, Lustberg A, Khaled A, Nogueira J, Wiland A, Ramos E, Klassen DK, Drachenberg CB. Histologic features of mycophenolate mofetil-related colitis: a graft-versus-host disease-like pattern. Int. J. Surg. Pathol. 11: 295-302 (2003).

• Papatheodoridis GV, Hamilton M, Mistry PK, Davidson B, Rolles K, Burroughs AK. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 43: 639-644 (1998). *

• Parajuli P, Mathupala S, Mittal S, Sloan AE. Dendritic cell-based active specific immunotherapy for malignant glioma. Expert Opin. Biol. Ther. 7: 439-448 (2007).

• Pardi DS, Loftus EV Jr, Camilleri M. Treatment of inflammatory bowel disease in the elderly: an update. Drugs Aging 19: 355-363 (2002).

• Parekkadan B, Tilles AW, Yarmush ML. Bone marrow-derived mesenchymal stem cells ameliorate autoimmune enteropathy independent of regulatory T cells. Stem Cells 26: 1913-1919 (2008). *

• Park FD, Lee JK, Madduri GD, Ghosh P. Generalized megaviscera of lupus: refractory intestinal pseudo-obstruction, ureterohydronephrosis and megacholedochus. World J. Gastroenterol. 15: 3555-3559 (2009). *

• Parrish JA. Immunosuppression, skin cancer, and ultraviolet a radiation. N. Engl. J. Med. 353: 2712-2713 (2005). *

• Pascher A, Klupp J, Kohler S, Langrehr JM, Neuhaus P. Transplantation of an eight-organ multivisceral graft in a patient with frozen abdomen after complicated Crohn's disease. World J. Gastroenterol. 12: 4431-4434 (2006). *

• Patenaude J, D'Elia M, Hamelin C, Bernier J. Selective effect of burn injury on splenic CD11c(+) dendritic cells and CD8alpha (+)CD4 (-)CD11c (+) dendritic cell subsets. Cell. Mol. Life Sci. Jan 20 [Epub ahead of print] (2010). *

• Paterson AM, Yates SF, Nolan KF, Waldmann H. The new immunosuppression: intervention at the dendritic cell-T-cell interface. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5: 397-411 (2005).

• Paul CF, Gourraud PA. Cancer risk evaluation in psoriasis: in search of the holy grail? J. Invest. Dermatol. 129: 2547-2549 (2009). *

• Pavletic SZ, Illei GG. The role of immune ablation and stem cell transplantation in severe SLE. Best Pract. Res. Clin. Rheumatol. 19: 839-858 (2005).

• Pedrosa MC, Rohrer RM, Kaplan MM. Alternate-day prednisone in the maintenance immunosuppressive therapy after orthotopic liver transplantation. Clin. Transplant. 9: 322-325 (1995).

• Pelletier SJ, Vanderwall K, Debroy MA, Englesbe MJ, Sung RS, Magee JC, Fontana RJ, Punch JD. Preliminary analysis of early outcomes of a prospective, randomized trial of complete steroid avoidance in liver transplantation. Transplant. Proc. 37: 1214-1216 (2005). *

• Pepin J, Valiquette L, Gagnon S, Routhier S, Brazeau I. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am. J. Gastroenterol. 102: 2781-2788 (2007). *

• Pereiro M Jr, Pereiro Ferreiros MM, De Hoog GS, Toribio J. Cutaneous infection caused by Alternaria in patients receiving tacrolimus. Med. Mycol. 42: 277-282 (2004).

• Perera MT, Mirza DF, Elias E. Liver transplantation: issues for the next 20 years. J. Gastroenterol. Hepatol. 24 Suppl. 3: S124-S131 (2009). *

• Perez-Rojas JM, Bobadilla NA. Novel action of aldosterone in CsA nephrotoxicity. Rev. Invest. Clin. 57: 147-155 (2005).

• Perini P, Calabrese M, Rinaldi L, Gallo P. The safety profile of cyclophosphamide in multiple sclerosis therapy. Expert Opin. Drug Saf. 6: 183-190 (2007).

• Perini P, Calabrese M, Rinaldi L, Gallo P. Cyclophosphamide-based combination therapies for autoimmunity. Neurol. Sci. 29 Suppl. 2: S233-S234 (2008).

• Perkins JD. The influence of CTLA-4 gene polymorphisms on liver transplant outcomes. Liver Transpl. 12: 1552-1556 (2006). *

• Perry I, Neuberger J. Immunosuppression: towards a logical approach in liver transplantation. Clin. Exp. Immunol. 139: 2-10 (2005). *

• Petit E, Langouet S, Akhdar H, Nicolas-Nicolaz C, Guillouzo A, Morel F. Differential toxic effects of azathioprine, 6-mercaptopurine and 6-thioguanine on human hepatocytes. Toxicol. In Vitro 22: 632-642 (2008).

• Petitpas D, Ould-Zein S, Korach JM. What are the indications for plasma exchanges in autoimmune diseases?: the registry of the Societe Francaise d'Hemapherese. Transfus. Apher. Sci. 36: 173-177 (2007).

• Petricevic B, Wessner B, Sachet M, Vrbanec D, Spittler A, Bergmann M. CL097, a TLR7/8 ligand inhibits TLR-4-dependent activation of IRAK-M and Bcl-3 expression. Shock 32: 484-490 (2009).

• Petrowsky H, Schuster H, Irani S, Schafer M, Jochum W, Schmid C, Boehler A, Clavien PA. Pancreatic cancer in cystic fibrosis after bilateral lung transplantation. Pancreas 33: 430-432 (2006).

• Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, Colombel JF. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet 372: 67-81 (2008). *

• Pfarr KM, Debrah AY, Specht S, Hoerauf A. Filariasis and lymphoedema. Parasite Immunol. 31: 664-672 (2009). *

• Pham CQ, Efros CB, Berardi RR. Cyclosporine for severe ulcerative colitis. Ann. Pharmacother. 40: 96-101 (2006).

• Phan C, Sanders D, Siddiqi Z. Mycophenolate mofetil in myasthenia gravis: the unanswered question. Expert Opin. Pharmacother. 9: 2545-2551 (2008).

• Phatak UP, Seo-Mayer P, Jain D, Selbst M, Husain S, Pashankar DS. Mycophenolate mofetil-induced colitis in children. J. Clin. Gastroenterol. 43: 967-969 (2009).

• Phelan D, Mohanakumar T, Ramachandran S, Jendrisak MD. Living donor renal transplantation in the presence of donor specific human leukocyte antigen antibody detected by solid phase assay. Hum. Immunol. 70: 584-588 (2009).

• Phillips B, Nylander K, Harnaha J, Machen J, Lakomy R, Styche A, Gillis K, Brown L, Gallo M, Knox J, Hogeland K, Trucco M, Giannoukakis N. A microsphere-based vaccine prevents and reverses new-onset autoimmune diabetes. Diabetes 57: 1544-1555 (2008). *

• Piccinni C, Sacripanti C, Poluzzi E, Motola D, Magro L, Moretti U, Conforti A, Montanaro N. Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents. Eur. J. Clin. Pharmacol. Oct 17 [Epub ahead of print] (2009). *

• Pirenne J, Van Gelder F, Kharkevitch T, Nevens F, Verslype C, Peetermans WE, Kitade H, Vanhees L, Devos Y, Hauser M, Hamoir E, Noizat-Pirenne F, Pirotte B. Tolerance of liver transplant patients to strenuous physical activity in high-altitude. Am. J. Transplant. 4: 554-560 (2004).

• Piton G, Dupont-Gossart AC, Weber A, Herbein G, Viennet G, Mantion G, Carbonnel F. Severe systemic cytomegalovirus infections in patients with steroid-refractory ulcerative colitis treated by an oral microemulsion form of cyclosporine: report of two cases. Gastroenterol. Clin. Biol. 32: 460-464 (2008).

• Pofelski J, Heluwaert F, Roblin X, Morand P, Gratacap B, Germain E, Brion JP, Salon C, Bonaz B. Cytomegalovirus and inflammatory bowel disease. Gastroenterol. Clin. Biol. 31: 292-296 (2007).

• Pohl C, Shishkova J, Schneider-Schaulies S. Viruses and dendritic cells: enemy mine. Cell. Microbiol. 9: 279-289 (2007). *

• Poirier N, Azimzadeh AM, Zhang T, Dilek N, Mary C, Nguyen B, Tillou X, Wu G, Reneaudin K, Hervouet J, Martinet B, Coulon F, Allain-Launay E, Karam G, Soulillou JP, Pierson III RN, Blancho G, Vanhove B. Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci. Transl. Med. 2: 17ra10 (2010).

• Politt D, Heintz B, Floege J, Mertens PR. Tacrolimus-(FK 506) based immunosuppression in severe systemic lupus erythematosus. Clin. Nephrol. 62: 49-53 (2004).

• Pollard LC. Inhibiting costimulatory activation of T cells: a viable treatment option for rheumatoid arthritis? Drugs 67: 1-9 (2007).

• Ponticelli C. Cyclosporine: from renal transplantation to autoimmune diseases. Ann. N. Y. Acad. Sci. 1051: 551-558 (2005). *

• Porta C, Caporali R, Montecucco C. Autoimmunity in thrombotic thrombocytopenic purpura. Semin. Thromb. Hemost. 31: 633-640 (2005).

• Portmann BC. Recurrence of primary biliary cirrhosis after transplantation. The pathologist's view. Eur. J. Gastroenterol. Hepatol. 11: 633-637 (1999).

• Pourfarziani V, Einollahi B, Taheri S, Nemati E, Nafar M, Kalantar E. Associations of human leukocyte antigen (HLA) haplotypes with risk of developing lymphoproliferative disorders after renal transplantation. Ann. Transplant. 12: 16-22 (2007).

• Powell LW. Overview: liver disease and transplantation. J. Gastroenterol. Hepatol. 24 Suppl. 3: S97-S104 (2009). *

• Prall RT, Lindor KD, Wiesner RH, LaRusso NF. Current therapies and clinical controversies in the management of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 2: 99-103 (2000).

• Prantera C, Scribano ML. Antibiotics and probiotics in inflammatory bowel disease: why, when, and how. Curr. Opin. Gastroenterol. 25: 329-333 (2009).

• Pratschke J, Steinmuller T, Bechstein WO, Neuhaus R, Tullius SG, Jonas S, Schumacher G, Luck W, Becker M, Neuhaus P. Orthotopic liver transplantation for hepatic associated metabolic disorders. Clin. Transplant. 12: 228-232 (1998).

• Preiningerova J. Oral laquinimod therapy in relapsing multiple sclerosis. Expert Opin. Investig. Drugs 18: 985-989 (2009).

• Prescott K, Costner M, Cohen S, Kazi S. Tumor necrosis factor-alpha inhibitor associated ulcerative colitis. Am. J. Med. Sci. 333: 137-139 (2007).

• Price BA, Cumberland NS, Clark CL, Pockley AG, Lear PA, Wood RF. The effect of rejection and graft-versus-host disease on small intestinal microflora and bacterial translocation after rat small bowel transplantation. Transplantation 56: 1072-1076 (1993).

• Priest VL, Begg EJ, Gardiner SJ, Frampton CM, Gearry RB, Barclay ML, Clark DW, Hansen P. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics 24: 767-781 (2006).

• Prince M, Christensen E, Gluud C. Glucocorticosteroids for primary biliary cirrhosis. Cochrane Database Syst. Rev. 2: CD003778 (2005). *

• Prud'homme GJ. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab. Invest. 87: 1077-1091 (2007). *

• Puente D, Pombo G, Forastiero R. Current management of antiphospholipid syndrome-related thrombosis. Expert Rev. Cardiovasc. Ther. 7: 1551-1558 (2009).

• Pulverer G, Beuth J, Roszkowski W, Burrichter H, Roszkowski K, Yassin A, Ko HL, Jeljaszewicz J. Bacteria of human physiological microflora liberate immunomodulating peptides. Zentralbl. Bakteriol. 272: 467-476 (1990).

• Pulverer G, Ko HL, Roszkowski W, Beuth J, Yassin A, Jeljaszewicz J. Digestive tract microflora liberates low molecular weight peptides with immunotriggering activity. Zentralbl. Bakteriol. 272: 318-327 (1990).

• Qiu DK, Li XM, Wei J, Ye LJ, Peng YS, Ma X. Clinical features of 107 autoimmune hepatitis patients and 30 of them with AIH-primary biliary cirrhosis overlap syndrome. Zhonghua Gan Zang Bing Za Zhi 16: 367-371 (2008).

• Quaglia M, Stratta P. Idiopathic membranous nephropathy: management strategies. Drugs 69: 1303-1317 (2009).

• Quiniou C, Kooli E, Joyal JS, Sapieha P, Sennlaub F, Lahaie I, Shao Z, Hou X, Hardy P, Lubell W, Chemtob S. Interleukin-1 and ischemic brain injury in the newborn: development of a small molecule inhibitor of IL-1 receptor. Semin. Perinatol. 32: 325-333 (2008).

• Radford-Smith GL, Edwards JE, Purdie DM, Pandeya N, Watson M, Martin NG, Green A, Newman B, Florin TH. Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn's disease. Gut 51: 808-813 (2002). *

• Rahier JF, Yazdanpanah Y, Viget N, Travis S, Colombel JF. Systematic review: influenza A (H1N1) virus in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 31: 5-10 (2010). *

• Rahman S, Gudetta B, Fink J, Granath A, Ashenafi S, Aseffa A, Derbew M, Svensson M, Andersson J, Brighenti SG. Compartmentalization of immune responses in human tuberculosis: few CD8+ effector T cells but elevated levels of FoxP3+ regulatory T cells in the granulomatous lesions. Am. J. Pathol. 174: 2211-2224 (2009). *

• Raimondi G, Sumpter TL, Matta BM, Pillai M, Corbitt N, Vodovotz Y, Wang Z, Thomson AW. Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipients. J. Immunol. 184: 624-636 (2010).

• Raja NS, Singh NN. Antimicrobial susceptibility pattern of clinical isolates of Pseudomonas aeruginosa in a tertiary care hospital. J. Microbiol. Immunol. Infect. 40: 45-49 (2007). *

• Rall GF. Measles virus 1998-2002: progress and controversy. Annu. Rev. Microbiol. 57: 343-367 (2003). *

• Ramirez S, Perez-Del-Pulgar S, Forns X. Virology and pathogenesis of hepatitis C virus recurrence. Liver Transpl. 14 Suppl. 2: S27-S35 (2008).

• Ramji A, Owen DA, Erb SR, Scudamore CH, Yoshida EM. Post-liver transplant Crohn's disease: graft tolerance but not self-tolerance? Dig. Dis. Sci. 47: 522-527 (2002). *

• Ransohoff RM. "Thinking without thinking" about natalizumab and PML. J. Neurol. Sci. 259: 50-52 (2007).

• Razonable RR. Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J. Gastroenterol. 14: 4849-4860 (2008). *

• Reding R, Bourdeaux C, Gras J, Evrard V, Buts JP, Carlier M, Ciccarelli O, Clapuyt P, de Clety SC, De Kock M, Hermans D, Janssen M, Moulin D, et al. The paediatric liver transplantation program at the Universite catholique de Louvain. Acta Gastroenterol. Belg. 67: 176-178 (2004).

• Reding R, Davies HF. Revisiting liver transplant immunology: from the concept of immune engagement to the dualistic pathway paradigm. Liver Transpl. 10: 1081-1086 (2004). *

• Reding R, Gras J, Sokal E, Otte JB, Davies HF. Steroid-free liver transplantation in children. Lancet 362: 2068-2070 (2003). *

• Redmond M, Quinn J, Murphy P, Patchett S, Leader M. Plasmablastic lymphoma presenting as a paravertebral mass in a patient with Crohn's disease after immunosuppressive therapy. J. Clin. Pathol. 60: 80-81 (2007). *

• Reiff A. A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation. Hematology 10: 79-93 (2005).

• Reily MM, Pantoja C, Hu X, Chinenov Y, Rogatsky I. The GRIP1:IRF3 interaction as a target for glucocorticoid receptor-mediated immunosuppression. EMBO J. 25: 108-117 (2006). *

• Rennebohm RM, Egan RA, Susac JO. Treatment of Susac's syndrome. Curr. Treat. Options Neurol. 10: 67-74 (2008).

• Reynoso JF, Gruessner CE, Sutherland DE, Gruessner RW. Short- and long-term outcome for living pancreas donors. J. Hepatobiliary Pancreat. Surg. Aug 4 [Epub ahead of print] (2009). *

• Ribeiro FM, Szyper-Kravitz M, Klumb EM, Lannes G, Ribeiro FR, Albuquerque EM, Shoenfeld Y. Can lupus flares be associated with tuberculosis infection? Clin. Rev. Allergy Immunol. Jun 24 [Epub ahead of print] (2009). *

• Rieckmann P. Concepts of induction and escalation therapy in multiple sclerosis. J. Neurol. Sci. 277 Suppl. 1: S42-S45 (2009).

• Rieder SA, Chauhan A, Singh U, Nagarkatti M, Nagarkatti P. Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology May 18 [Epub ahead of print] (2009).

• Rifle G, Mousson C, Hillon P, Marceau M, Chalopin JM, Tanter Y. Primary biliary cirrhosis: therapeutic trial using plasma exchange and immunosuppression. Preliminary results. Ann. Med. Interne (Paris) 139 Suppl. 1: 32-34 (1988).

• Rihova Z, Honsova E, Merta M, Jancova E, Rysava R, Reiterova J, Zabka J, Tesar V. Secondary membranous nephropathy - one center experience. Ren. Fail. 27: 397-402 (2005).

• Riis P. Extension of indications of immunosuppression in inflammatory bowel disease. J. Autoimmun. 5 Suppl. A: 289-291 (1992).

• Riley TR, Schoen RE, Lee RG, Rakela J. A case series of transplant recipients who despite immunosuppression developed inflammatory bowel disease. Am. J. Gastroenterol. 92: 279-282 (1997).

• Ringe B, Moritz M, Zeldin G, Soriano H. What is the best immunosuppression in living donor liver transplantation? Transplant. Proc. 37: 2169-2171 (2005). *

• Riscili BP, Wood KL. Noninvasive pulmonary Aspergillus infections. Clin. Chest Med. 30: 315-335, vii (2009).

• Robak E, Sysa-Jedrzejowska A, Wozniacka A. Progress and perspectives in the treatment of systemic lupus erythematosus. Przegl. Lek. 62: 894-899 (2005).

• Roberts T, Beyers N, Aguirre A, Walzl G. Immunosuppression during active tuberculosis is characterized by decreased interferon-gamma production and CD25 expression with elevated forkhead box P3, transforming growth factor-beta, and interleukin-4 mRNA levels. J. Infect. Dis. 195: 870-878 (2007). *

• Rodosskaia NK, Chernousova GM. Immune system and thiols: some peculiarities of thiol exchange. Comp. Immunol. Microbiol. Infect. Dis. 33: 65-71 (2010).

• Rodríguez VE, Freuler CB, Ezcurra C, Durlach RA. Acute cholecystitis and biliary tract infections due to Candida. Rev. Iberoam. Micol. 24: 152-154 (2007).

• Rogler G. Indications for use of infliximab. Falk Symposium 154: INFLAMMATORY BOWEL DISEASE - DIAGNOSTIC AND THERAPEUTIC STRATEGIES, Moscow (Russia), June 9 - 10, 2006, pp. 54-55 (2006). *

• Rogler G. Benefits and risks of immunosuppression in inflammatory bowel disease. Dtsch. Med. Wochenschr. 133: 1917-1921 (2008).

• Romero R, Abramowsky CR, Pillen T, Smallwood GA, Heffron TG. Peripheral eosinophilia and eosinophilic gastroenteritis after pediatric liver transplantation. Pediatr. Transplant. 7: 484-488 (2003).

• Romero-Vargas ME, Flores-Cortes M, Valera Z, Gomez-Bravo MA, Barrera-Pulido L, Pareja-Ciuro F, Serrano Diez-Canedo J, Garcia I, Bernardos A. Cancers of new appearance in liver transplant recipients: incidence and evolution. Transplant. Proc. 38: 2508-2510 (2006). *

• Rook GAW. Microecology, hygiene and mucosal immunology. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 33. May 7-8 (2004). *

• Rose NR. Myocarditis: infection versus autoimmunity. J. Clin. Immunol. 29: 730-737 (2009). *

• Rosen HR. Transplantation immunology: what the clinician needs to know for immunotherapy. Gastroenterology 134: 1789-1801 (2008). *

• Roskell DE, Hyde GM, Campbell AP, Jewell DP, Gray W. HIV associated cytomegalovirus colitis as a mimic of inflammatory bowel disease. Gut 37: 148-150 (1995). *

• Rostaing L, Guilbeau-Frugier C, Fort M, Mekhlati L, Kamar N. Treatment of symptomatic transplant glomerulopathy with rituximab. Transpl. Int. 22: 906-913 (2009).

• Rouphael NG, Talati NJ, Vaughan C, Cunningham K, Moreira R, Gould C. Infections associated with haemophagocytic syndrome. Lancet Infect. Dis. 7: 814-822 (2007).

• Rovin BH. The chemokine network in systemic lupus erythematous nephritis. Front. Biosci. 13: 904-922 (2008).

• Rozkova D, Horvath R, Bartunkova J, Spisek R. Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptors. Clin. Immunol. 120: 260-271 (2006). *

• Rubio-Tapia A, Abdulkarim AS, Wiesner RH, Moore SB, Krause PK, Murray JA. Celiac disease autoantibodies in severe autoimmune liver disease and the effect of liver transplantation. Liver Int. 28: 467-476 (2008). *

• Ruemmele FM, Brousse N, Goulet O. Autoimmune enteropathy: molecular concepts. Curr. Opin. Gastroenterol. 20: 587-591 (2004).

• Ruemmele FM, Moes N, Patey-Mariaud de Serre N, Rieux-Laucat F, Goulet O. Clinical and molecular aspects of autoimmune enteropathy and immune dysregulation, polyendocrinopathy autoimmune enteropathy X-linked syndrome. Curr. Opin. Gastroenterol. 24: 742-748 (2008).

• Rumbo C, Shneider BL, Emre SH. Utility of azathioprine metabolite measurements in post-transplant recurrent autoimmune and immune-mediated hepatitis. Pediatr. Transplant. 8: 571-575 (2004). *

• Rutgeerts P. Current dilemmas in the management of inflammatory bowel disease. Eur. J. Surg. Suppl. 587: 58-61 (2002).

• Rutgeerts P. Treatment of perianal fistulizing Crohn's disease. Aliment. Pharmacol. Ther. 20 Suppl. 4: 106-110 (2004). *

• Rutgeerts P. Medical therapy of inflammatory bowel disease. Digestion 59: 453-469 (1998).

• Rutgeerts P. A critical assessment of new therapies in inflammatory bowel disease. J. Gastroenterol. Hepatol. 17: S176-S185 (2002). *

• Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 126: 1593-1610 (2004). *

• Rutgeerts P, Van Assche G, Vermeire S. Review article: infliximab therapy for inflammatory bowel disease - seven years on. Aliment. Pharmacol. Ther. 23: 451-463 (2006). *

• Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 56: 453-455 (2007). *

• Rutgeerts PJ. An historical overview of the treatment of Crohn's disease: why do we need biological therapies? Rev. Gastroenterol. Disord. 4 Suppl. 3: S3-S9 (2004). *

• Ryan JG, Dorman AM, O'Connell PG. AA amyloidosis in psoriatic arthritis. Ir. J. Med. Sci. 175: 81-82 (2006).

• Ryckman FC, Alonso MH, Bucuvalas JC, Balistreri WF. Long-term survival after liver transplantation. J. Pediatr. Surg. 34: 845-849 (1999).

• Saccardi R, Di Gioia M, Bosi A. Haematopoietic stem cell transplantation for autoimmune disorders. Curr. Opin. Hematol. 15: 594-600 (2008).

• Sadallah S, Eken C, Schifferli JA. Erythrocyte-derived ectosomes have immunosuppressive properties. J. Leukoc. Biol. 84: 1316-1325 (2008). *

• Sadeghi M, Daniel V, Schnitzler P, Lahdou I, Naujokat C, Zeier M, Opelz G. Urinary proinflammatory cytokine response in renal transplant recipients with polyomavirus BK viruria. Transplantation 88: 1109-1116 (2009).

• Saeed SA, Integlia MJ, Pleskow RG, Calenda KA, Rohrer RJ, Dayal Y, Grand RJ. Tacrolimus-associated eosinophilic gastroenterocolitis in pediatric liver transplant recipients: role of potential food allergies in pathogenesis. Pediatr. Transplant. 10: 730-735 (2006). *

• Saggar S, Zeichner JA, Brown TT, Phelps RG, Cohen SR. Kaposi's sarcoma resolves after sirolimus therapy in a patient with pemphigus vulgaris. Arch. Dermatol. 144: 654-657 (2008). *

• Saha M, Powell AM, Bhogal B, Black MM, Groves RW. Pulsed intravenous cyclophosphamide and methylprednisolone therapy in refractory pemphigus. Br. J. Dermatol. Nov 18 [Epub ahead of print] (2009). *

• Sahrbacher U, Naumann L, Reischl U, Schoolmerich J, Gluck T. Reduced TH-1 cytokine release in an adult patient with chronic relapsing Mycobacterium malmoense infection. Infection 35: 282-286 (2007). *

• Said A, Einstein M, Lucey MR. Liver transplantation: an update 2007. Curr. Opin. Gastroenterol. 23: 292-298 (2007).

• Said A, Lucey MR. Liver transplantation: an update. Curr. Opin. Gastroenterol. 22: 272-278 (2006).

• Salvana EM, Salata RA. Infectious complications associated with monoclonal antibodies and related small molecules. Clin. Microbiol. Rev. 22: 274-290 (2009). *

• Salzmann J, Lightman S. The potential of newer immunomodulating drugs in the treatment of uveitis: a review. BioDrugs 13: 397-408 (2000).

• Sampathkumar S, Younger C, Cramer H, Chalasani N, Skierczynski PA. Langerhans' cell histiocytosis involving the pituitary, thyroid, lung, and liver. Endocr. Pract. 8: 217-221 (2002).

• Sanchez EQ, Levy MF, Goldstein RM, Fasola CG, Tillery GW, Netto GJ, Watkins DL, Weinstein JS, Murray NG, Byers D, Christensen LL, Klintmalm GB. The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation. Transplantation 76: 1583-1588 (2003).

• Sander LE, Koch A, Gartung C, Winograd R, Donner A, Wellmann A, Trautwein C, Geier A. Lessons from a patient with an unusual hepatic overlap syndrome. Nat. Clin. Pract. Gastroenterol. Hepatol. 4: 635-640 (2007). *

• Saner FH, Gensicke J, Damink SW, Pavlakovic G, Treckmann J, Dammann M, Kaiser GM, Sotiropoulos GC, Radtke A, Koeppen S, Beckebaum S, Cicinnati V, Nadalin S, Malago M, Paul A, Broelsch CE. Neurologic complications in adult living donor liver transplant patients: an underestimated factor? J. Neurol. Sep 1 [Epub ahead of print] (2009).

• Sani MU. Myocardial disease in human immunodeficiency virus (HIV) infection: a review. Wien. Klin. Wochenschr. 120: 77-87 (2008).

• Sanko-Resmer J, Paczek L, Wyzgal J, Ziolkowski J, Ciszek M, Alsharabi A, Grzelak I, Paluszkiewicz R, Patkowski W, Krawczyk M. Biliary liver cirrhosis secondary to cystic fibrosis: a rare indication for liver transplantation. Transplant. Proc. 38: 212-214 (2006). *

• Sapir T, Shternhall K, Meivar-Levy I, Blumenfeld T, Cohen H, Skutelsky E, Eventov-Friedman S, Barshack I, Goldberg I, Pri-Chen S, Ben-Dor L, Polak-Charcon S, Karasik A, Shimon I, Mor E, Ferber S. Cell-replacement therapy for diabetes: generating functional insulin-producing tissue from adult human liver cells. Proc. Natl. Acad. Sci. U.S.A. 102: 7964-7969 (2005). *

• Sarwal MM. Chipping into the human genome: novel insights for transplantation. Immunol. Rev. 210: 138-155 (2006). *

• Sathasivam S. Steroids and immunosuppressant drugs in myasthenia gravis. Nat. Clin. Pract. Neurol. 4: 317-327 (2008).

• Sato Y, Yamamoto S, Oya H, Nakatsuka H, Kobayashi T, Watanabe T, Hara Y, Kokai H, Hatakeyama K. Adult ABO-incompatible liver transplantation by intraportal transfusion of donor-specific antigen: a case report. Transplant. Proc. 40: 2811-2814 (2008). *

• Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 270: 283-286 (1995). *

• Scheuplein F, Rissiek B, Driver JP, Chen YG, Koch-Nolte F, Serreze DV. A recombinant heavy chain antibody approach blocks ART2 mediated deletion of an iNKT cell population that upon activation inhibits autoimmune diabetes. J. Autoimmun. Sep 29 [Epub ahead of print] (2009).

• Schiemann U, Ferhat A, Gotzberger M, Kaiser C, Stief J, Landgraf R, Dieterle C. Prevalence of cholecystolithiasis and its management among kidney/pancreas-transplanted type 1 (insulin-dependent) diabetic patients. Eur. J. Med. Res. 13: 127-130 (2008).

• Schippling S, Heesen C, Zander A, Martin R. Stem cell transplantation in multiple sclerosis. J. Neurol. 255 Suppl. 6: 43-47 (2008).

• Schippling S, Martin R. Stem cell therapy in multiple sclerosis: a clinical update. Z. Rheumatol. 68: 214-219 (2009).

• Schmidt C, Giese T, Hermann E, Zeuzem S, Meuer SC, Stallmach A. Predictive value of mucosal TNF-alpha transcripts in steroid-refractory Crohn's disease patients receiving intensive immunosuppressive therapy. Inflamm. Bowel Dis. 13: 65-70 (2007). *

• Schmitz A, Sankaranarayanan A, Azam P, Schmidt-Lassen K, Homerick D, Hansel W, Wulff H. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol. Pharmacol. 68: 1254-1270 (2005). *

• Schmitz V, Dombrowski F, Prieto J, Qian C, Diehl L, Knolle P, Sauerbruch T, Caselmann WH, Spengler U, Leifeld L. Induction of murine liver damage by overexpression of CD40 ligand provides an experimental model to study fulminant hepatic failure. Hepatology 44: 430-439 (2006). *

• Schneider M. Exploring new territory: considering the future. Lupus 16: 221-226 (2007).

• Schneider-Gold C, Hartung HP, Gold R. Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases. Muscle Nerve 34: 284-291 (2006).

• Schneider-Gold C, Kotting J, Epplen JT, Gold R, Gerding WM. Unusual Charcot-Marie-Tooth phenotype due to a mutation within the intracellular domain of myelin protein zero. Muscle Nerve Oct 30 [Epub ahead of print] (2009).

• Scholmerich J. Management of extraintestinal disease in IBD. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 38-39 (2005). *

• Scholmerich J. Systemic and topical steroids in inflammatory bowel disease. Aliment. Pharmacol. Ther. 20 Suppl. 4: 66-74 (2004). *

• Schreibman I, Regev A. Recurrent primary biliary cirrhosis after liver transplantation - the disease and its management. MedGenMed. 8: 30 (2006). *

• Schroder O, Blumenstein I, Stein J. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study. Eur. J. Gastroenterol. Hepatol. 18: 11-16 (2006).

• Schrumpf E, Boberg KM. Standard treatment of PSC and overlap AIH/PSC. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, p. 71 (2004). *

• Schrumpf E, Jorgensen KK, Boberg KM. Primary sclerosing cholangitis, inflammatory bowel disease and treatment options. Falk Workshop "Primary Sclerosing Cholangitis: Complications and Consequences", Moscow (Russia), June 11, 2006, p. 15-16 (2006). *

• Schultz H, Heintz H, van Zandbergen G, Ullrich S, Reinhold-Keller E, Gross WL. ANCA against the bactericidal/permeability increasing protein (BPI-ANCA) can compromise the antibiotic function of BPI in a Wegener's granulomatosis patient. Clin. Exp. Rheumatol. 21: 763-766 (2003).

• Schumann J, Prockl J, Kiemer AK, Vollmar AM, Bang R, Tiegs G. Silibinin protects mice from T cell-dependent liver injury. J. Hepatol. 39: 333-340 (2003). *

• Schwartz LK, Kim MK, Coleman M, Lichtiger S, Chadburn A, Scherl E. Case report: lymphoma arising in an ileal pouch anal anastomosis after immunomodulatory therapy for inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 4: 1030-1034 (2006).

• Schwartz M, Konstadoulakis M, Roayaie S. Recurrence of hepatocellular carcinoma after liver transplantation: is immunosuppression a factor? Liver Transpl. 11: 494-496 (2005). *

• Schwarz T. Regulatory T cells induced by ultraviolet radiation. Int. Arch. Allergy Immunol. 137: 187-193 (2005).

• Schweikert A, Kremer M, Ringel F, Liebig T, Duyster J, Stuve O, Hemmer B, Berthele A. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann. Neurol. 66: 403-406 (2009).

• Scully C, Mignogna M. Oral mucosal disease: pemphigus. Br. J. Oral Maxillofac. Surg. 46: 272-277 (2008).

• Sediva A, Lischke R, Simonek J, Tkaczyk J, Vavrova V, Bartosova J, Pohunek P, Bartunkova J, Pafko P. Lung transplantation for cystic fibrosis: immune system and autoimmunity. Med. Sci. Monit. 7: 1219-1223 (2001). *

• Seegers D, Bouma G, Pena AS. Review article: a critical approach to new forms of treatment of Crohn's disease and ulcerative colitis. Aliment. Pharmacol. Ther. 16 Suppl. 4: 53-58 (2002). *

• Selby W. Pathogenesis and therapeutic aspects of Crohn's disease. Vet. Microbiol. 77: 505-511 (2000). *

• Selden C, Hodgson H. Cellular therapies for liver replacement. Transpl. Immunol. 12: 273-288 (2004).

• Selvaggi G, Weppler D, Nishida S, Moon J, Levi D, Kato T, Tzakis AG. Ten-year experience in porto-caval hemitransposition for liver transplantation in the presence of portal vein thrombosis. Am. J. Transplant. 7: 454-460 (2007). *

• Selvaggi G, Weppler D, Tzakis A. Liver and gastrointestinal transplantation at the University of Miami. Clin. Transpl. 2003: 255-266 (2003).

• Sener G, Sehirli AO, Gedik N, Dulger GA. Rosiglitazone, a PPAR-gamma ligand, protects against burn-induced oxidative injury of remote organs. Burns 33: 587-593 (2007).

• Seo S, Toutounjian R, Conrad A, Blatt L, Tong MJ. Favorable outcomes of autoimmune hepatitis in a community clinic setting. J. Gastroenterol. Hepatol. 23: 1410-1414 (2008). *

• Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab therapy in acute ulcerative colitis. Gut 59: 49-54 (2010).

• Settbas Y, Alper M, Akcan Y, Gurbuz Y, Oksuz S. Massive gastrointestinal tuberculosis in a young patient without immunosuppression. World J. Gastroenterol. 9: 2382-2384 (2003). *

• Sgouroudis E, Piccirillo CA. Control of type 1 diabetes by CD4+Foxp3+ regulatory T cells: lessons from mouse models and implications for human disease. Diabetes Metab. Res. Rev. 25: 208-218 (2009).

• Shadmehr MB, Arab M, Pejhan S, Daneshvar A, Javaherzadeh N, Abbasi A, Ahmadi ZH, Radpay B, Dabir S, Parsa T, Mohammadi F, Mansoori SD, Tabarsi P, Amiri MV, Marjani M, Kashani BS, Najafizadeh K, Shafaghi S, Ghorbani F, Masjedi MR, Velayati AA. Eight years of lung transplantation: experience of the national research institute of tuberculosis and lung diseases. Transplant. Proc. 41: 2887-2889 (2009).

• Shaikh SR, Edidin M. Polyunsaturated fatty acids and membrane organization: elucidating mechanisms to balance immunotherapy and susceptibility to infection. Chem. Phys. Lipids 153: 24-33 (2008). *

• Shaked A, Colonna JO, Goldstein L, Busuttil RW. The interrelation between sclerosing cholangitis and ulcerative colitis in patients undergoing liver transplantation. Ann. Surg. 215: 598-603 (1992). *

• Shamekh R, El-Badri NS, Saporta S, Pascual C, Sanberg PR, Cameron DF. Sertoli cells induce systemic donor-specific tolerance in xenogenic transplantation model. Cell Transplant. 15: 45-53 (2006).

• Shapiro R, Young JB, Milford EL, Trotter JF, Bustami RT, Leichtman AB. Immunosuppression: evolution in practice and trends, 1993-2003. Am. J. Transplant. 5: 874-886 (2005).

• Sharma S, Chopra K, Kulkarni SK, Agrewala JN. Resveratrol and curcumin suppress immune response through CD28/CTLA-4 and CD80 co-stimulatory pathway. Clin. Exp. Immunol. 147: 155-163 (2007). *

• Shehata IH, Elghandour TM. A possible pathogenic role of CD4+CD25+ T-regulatory cells in psoriasis. Egypt. J. Immunol. 14: 21-31 (2007).

• Sheil AG. The new age of liver transplantation. Aust. N.Z. J. Surg. 66: 698-706 (1996).

• Shen C, Dillissen E, Kasran A, Lin Y, Clydesdale G, Sienaert I, Jonghe SD, Gao LJ, Geboes K, Boon L, Rutgeerts P, Ceuppens JL. Anti-inflammatory activity of a pteridine derivative (4AZA2096) alleviates TNBS-induced colitis in mice. J. Interferon Cytokine Res. 26: 575-582 (2006).

• Shergill AK, Terdiman JP. The early use of immunosuppression reduces morbidity in patients with moderately severe or severe Crohn's disease. Gastroenterology 135: 1417-1420 (2008). *

• Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol. Int. 55: 1-8 (2006). *

• Shipkova M, Armstrong VW, Oellerich M, Wieland E. Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. Expert Opin. Drug Metab. Toxicol. 1: 505-526 (2005).

• Shofner JD, Vasquez JG, Berger CL, Edelson RL. Improved generation of anti-tumor immunity by antigen dose limitation. J. Immune Based Ther. Vaccines 5: 2 (2007).

• Shrestha S, Wang C, Aissani B, Wilson CM, Tang J, Kaslow RA. Interleukin-10 gene (IL10) polymorphisms and human papillomavirus clearance among immunosuppressed adolescents. Cancer Epidemiol. Biomarkers Prev. 16: 1626-1632 (2007). *

• Shulman HM, McDonald GB. Chapter 31. Hepatic complications of hematopoietic cell transplantation. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 409-421 (2007). *

• Silva MA, Jambulingam PS, Mirza DF. Colorectal cancer after orthotopic liver transplantation. Crit. Rev. Oncol. Hematol. 56: 147-153 (2005).

• Simic P, Gasparovic V, Skegro M, Stern-Padovan R. Cholelithiasis and thrombosis of the central retinal vein in a renal transplant recipient treated with cyclosporin. Clin. Drug Investig. 26: 361-365 (2006).

• Singh K, Chaturvedi R, Asim M, Barry DP, Lewis ND, Vitek MP, Wilson KT. The apolipoprotein E-mimetic peptide COG112 inhibits the inflammatory response to Citrobacter rodentium in colonic epithelial cells by preventing NF-kappa B activation. J. Biol. Chem. 283: 16752-16761 (2008). *

• Singh N, Gayowski T, Wagener MM, Marino IR. Bloodstream infections in liver transplant recipients receiving tacrolimus. Clin. Transplant. 11: 275-281 (1997).

• Singh N, Husain S, De Vera M, Gayowski T, Cacciarelli TV. Cryptococcus neoformans infection in patients with cirrhosis, including liver transplant candidates. Medicine (Baltimore) 83: 188-192 (2004).

• Singh N, Perfect JR. Immune reconstitution syndrome and exacerbation of infections after pregnancy. Clin. Infect. Dis. 45: 1192-1199 (2007).

• Singh N, Pirsch J, Samaniego M. Antibody-mediated rejection: treatment alternatives and outcomes. Transplant. Rev. (Orlando) 23: 34-46 (2009).

• Singh P, Taylor SF, Murali R, Gomes LJ, Kanthan GL, Maloof AJ. Disseminated mucormycosis and orbital ischaemia in combination immunosuppression with a tumour necrosis factor alpha inhibitor. Clin. Experiment. Ophthalmol. 35: 275-280 (2007).

• Sinistro A, Almerighi C, Ciaprini C, Natoli S, Sussarello E, Di Fino S, Calo-Carducci F, Rocchi G, Bergamini A. Downregulation of CD40L response in monocytes from septic patients. Clin. Vaccine Immunol. 15: 1851-1858 (2008). *

• Skagen C, Lucey M, Said A. Liver transplantation: an update 2009. Curr. Opin. Gastroenterol. 25: 202-208 (2009).

• Sleijffers A, Garssen J, Vos JG, Loveren H. Ultraviolet light and resistance to infectious diseases. J. Immunotoxicol. 1: 3-14 (2004).

• Smrzova J, Ulrichova J, Dite P, Lata J. Transplantation of hepatocytes - present status and future perspectives. Vnitr. Lek. 47: 790-796 (2001).

• Soares MF, Macedo MS. Modulation of anaphylaxis by helminth-derived products in animal models. Curr. Allergy Asthma Rep. 7: 56-61 (2007).

• Soerensen H, Schneidewind-Mueller JM, Lange D, Kashiwagi N, Franz M, Yokoyama T, Ramlow W. Pilot clinical study of Adacolumn cytapheresis in patients with systemic lupus erythematosus. Rheumatol. Int. 26: 409-415 (2006). *

• Sokol RJ, Johnson KE, Karrer FM, Narkewicz MR, Smith D, Kam I. Improvement of cyclosporin absorption in children after liver transplantation by means of water-soluble vitamin E. Lancet 338: 212-214 (1991).

• Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J. Pharmacol. Exp. Ther. 330: 864-875 (2009). *

• Solomons NW. Giardiasis: nutritional implications. Rev. Infect. Dis. 4: 859-869 (1982).

• Spada M, Petz W, Bertani A, Riva S, Sonzogni A, Giovannelli M, Torri E, Torre G, Colledan M, Gridelli B. Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. Am. J. Transplant. 6: 1913-1921 (2006). *

• Spada M, Riva S, Maggiore G, Cintorino D, Gridelli B. Pediatric liver transplantation. World J. Gastroenterol. 15: 648-674 (2009). *

• Spelsberg H, Reichelt JA. Amniotic membrane transplantation in proven ulcerative herpetic keratitis: successful anti-inflammatory treatment in time. Klin. Monatsbl. Augenheilkd. 225: 75-79 (2008).

• Sprangers B, Waer M, Billiau AD. Xenotransplantation: where are we in 2008? Kidney Int. 74: 14-21 (2008). *

• Staeva T. Current and past prevention and intervention trials in type 1 diabetes. Novartis Found. Symp. 292: 99-109 (2008).

• Stahel PF, Smith WR, Moore EE. Role of biological modifiers regulating the immune response after trauma. Injury 38: 1409-1422 (2007).

• Stalder MP, Rovo A, Halter J, Heim D, Silzle T, Passweg J, Rischewski J, Stern M, Arber C, Buser A, Meyer-Monard S, Tichelli A, Gratwohl A. Aplastic anemia and concomitant autoimmune diseases. Ann. Hematol. 88: 659-665 (2009). *

• Stange EF. Immunosuppressors in inflammatory bowel disease. Falk Symposium 154: INFLAMMATORY BOWEL DISEASE - DIAGNOSTIC AND THERAPEUTIC STRATEGIES, Moscow (Russia), June 9 - 10, 2006, p. 53 (2006). *

• Staples JA, Ponsonby AL, Lim LL, McMichael AJ. Ecologic analysis of some immune-related disorders, including type 1 diabetes, in Australia: latitude, regional ultraviolet radiation, and disease prevalence. Environ. Health Perspect. 111: 518-523 (2003). *

• Starck M, Abedinpour F, Dendorfer U, Wagner-Czekalla J, Pachmann M, Mann JF, Nerl C. Acquired thrombotic thrombocytopenic purpura as the presenting symptom of systemic lupus erythematosus. Successful treatment with plasma exchange and immunosuppression - report of two cases. Eur. J. Haematol. 75: 436-440 (2005).

• Staropoli JF, Van Cott EM, Makar RS. Membrane autoantibodies in systemic lupus erythematosus: a case of autoimmune hemolytic anemia, antiphospholipid antibodies, and transient acquired activated protein C resistance. Transfusion 48: 2435-2441 (2008).

• Starzl TE. The future of transplantation. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 114. October 17 - 19 (2003). *

• Starzl TE, Murase N, Demetris A, Trucco M, Fung J. The mystique of hepatic tolerogenicity. Semin. Liver Dis. 20: 497-510 (2000).

• Stas P, D'Hoore A, Van Assche G, Geboes K, Steenkiste E, Penninckx F, Rutgeerts P, Vermeire S. Miliary tuberculosis following infliximab therapy for Crohn disease: a case report and review of the literature. Acta Gastroenterol. Belg. 69: 217-220 (2006).

• Stasiak-Barmuta A, Luczynski W, Ilendo E, Krawczuk-Rybak M, Szymanski M. Regulatory T cells in children with acute lymphoblastic leukaemia. Med. Wieku. Rozwoj. XIII: 53-58 (2009).

• Stegall MD, Everson G, Schroter G, Bilir B, Karrer F, Kam I. Metabolic complications after liver transplantation. Diabetes, hypercholesterolemia, hypertension, and obesity. Transplantation 60: 1057-1060 (1995).

• Stegall MD, Platt JL. Tolerance for immunosuppression in organ transplantation. Liver Transpl. 10: 573-575 (2004). *

• Steuer A, McCrea DJ, Colaco CB. Primary Sjogren's syndrome, ulcerative colitis and selective IgA deficiency. Postgrad. Med. J. 72: 499-500 (1996). *

• Stevens RB, Wakefield CB, Alonso D, Skorupa JY, Rigley TH, Penn DM, Wrenshall LE. Hashimoto's encephalopathy after intensive lymphocyte depletion with rabbit anti-thymocyte globulin in a renal transplant patient. Am. J. Transplant. 8: 245-249 (2008).

• Steward-Tharp SM, Song YJ, Siegel RM, O'Shea JJ. New insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppression. Ann. N. Y. Acad. Sci. 1183: 123-148 (2010). *

• Stewart CA, Trinchieri G. Reinforcing suppression using regulators: a new link between STAT3, IL-23, and Tregs in tumor immunosuppression. Cancer Cell 15: 81-83 (2009). *

• Stewart D, Chao A, Kodner I, Birnbaum E, Fleshman J, Dietz D. Subtotal colectomy for toxic and fulminant colitis in the era of immunosuppressive therapy. Colorectal Dis. 11: 184-190 (2009). *

• Stiehm ER. Disease versus disease: how one disease may ameliorate another. Pediatrics 117: 184-191 (2006). *

• Stokely ME, Garg P, Bhat MA, Koulen P. Transient 5-(4-phenylbutoxy)psoralen (PAP-1) treatment dissociates developing pathologies in autoimmune optic neuritis into two distinct pathology profiles. J. Neurosci. Res. 86: 2111-2124 (2008).

• Strassburg CP. Autoimmune liver diseases and their overlap syndromes. Schweiz. Rundsch. Med. Prax. 95: 1363-1381 (2006).

• Strassburg CP. Autoimmune liver diseases. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 66-70 (2005). *

• Strassburg CP, Manns MP. Treatment of autoimmune hepatitis. Semin. Liver Dis. 29: 273-285 (2009). *

• Strobel S, Hoyer PF, Mache CJ, Sulyok E, Liu WS, Richter H, Oppermann M, Zipfel PF, Jozsi M. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome. Nephrol. Dial. Transplant. 25: 136-144 (2010).

• Studenik P. The position of liver transplantation in the clinical practice. Vnitr. Lek. 50 Suppl. 1: S110-S114 (2004).

• Stuve O. Knowns and unknowns in the future of multiple sclerosis treatment. J. Neurol. Sci. 287 Suppl. 1: S30-S36 (2009).

• Su Y, Huang X, Raskovalova T, Zacharia L, Lokshin A, Jackson E, Gorelik E. Cooperation of adenosine and prostaglandin E(2) (PGE (2)) in amplification of cAMP-PKA signaling and immunosuppression. Cancer Immunol. Immunother. 57: 1611-1623 (2008).

• Subauste CS. CD154 and type-1 cytokine response: from hyper-IgM syndrome to human immunodeficiency virus infection. J. Infect. Dis. 185 Suppl. 1: S83-S89 (2002). *

• Subklewe M, Sebelin-Wulf K, Beier C, Lietz A, Mathas S, Dorken B, Pezzutto A. Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib. Hum. Immunol. 68: 147-155 (2007).

• Sugamura K, Ishii N, Weinberg AD. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat. Rev. Immunol. 4: 420-431 (2004). *

• Sugerman PB, Savage NW, Walsh LJ, Zhao ZZ, Zhou XJ, Khan A, Seymour GJ, Bigby M. The pathogenesis of oral lichen planus. Crit. Rev. Oral Biol. Med. 13: 350-365 (2002). *

• Sugimoto K, Murata M, Onizuka M, Inamoto Y, Terakura S, Kuwatsuka Y, Oba T, Miyamura K, Kodera Y, Naoe T. Decreased risk of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with the 5,10-methylenetetrahydrofolate reductase 677TT genotype. Int. J. Hematol. 87: 451-458 (2008).

• Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S, Xu T, Le A, Shi S. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 27: 1421-1432 (2009).

• Sundrud MS, Koralov SB, Feuerer M, Calado DP, Kozhaya AE, Rhule-Smith A, Lefebvre RE, Unutmaz D, Mazitschek R, Waldner H, Whitman M, Keller T, Rao A. Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Science 324: 1334-1338 (2009). *

• Sunesen KG, Norgaard M, Thorlacius-Ussing O, Laurberg S. Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978-2005. Int. J. Cancer Dec 3 [Epub ahead of print] (2009). *

• Svahn J, Capasso M, Lanciotti M, Marrone A, Haupt R, Bacigalupo A, Pongiglione C, Boschetto L, Longoni D, Pillon M, Pistorio A, Di Michele P, Iori AP, Calvillo M, Locasciulli A, Menna G, Riccardi R, Ramenghi U, Dufour C, Iolascon A. The polymorphisms -318C>T in the promoter and 49A>G in exon 1 of CTLA4 and the risk of aplastic anemia in a Caucasian population. Bone Marrow Transplant. 35 Suppl. 1: S89-S92 (2005).

• Svahn J, Fioredda F, Calvillo M, Molinari AC, Micalizzi C, Banov L, Schmidt M, Caprino D, Marinelli D, Gallisai D, Dufour C. Rituximab-based immunosuppression for autoimmune haemolytic anaemia in infants. Br. J. Haematol. 145: 96-100 (2009). *

• Svrcek M, Tiret E, Bennis M, Guyot P, Flejou JF. KSHV/HHV8-associated intestinal Kaposi's sarcoma in patient with ulcerative colitis receiving immunosuppressive drugs: report of a case. Dis. Colon Rectum 52: 154-158 (2009).

• Szegedi G. Immunomodulation therapy for autoimmune diseases. New hope for autoimmune patients. Orv. Hetil. 146: 635-643 (2005).

• Tadokoro CE, Vallochi AL, Rios LS, Martins GA, Schlesinger D, Mosca T, Kuchroo VK, Rizzo LV, Abrahamsohn IA. Experimental autoimmune encephalomyelitis can be prevented and cured by infection with Trypanosoma cruzi. J. Autoimmun. 23: 103-115 (2004).

• Tagle A M DR. Hepatobiliary infections in AIDS. Rev. Gastroenterol. Peru 17: 107-114 (1997).

• Tagoe C, Shah A, Yee H, Belmont HM. Aplastic anemia in systemic lupus erythematosus: a distinct presentation of acquired aplastic anemia? J. Clin. Rheumatol. 7: 377-383 (2001).

• Tajik N, Kazemi T, Delbandi A, Ghods A, Salek Moghaddam A. The predictive value of HLA-DR matching and cytokine gene polymorphisms in renal allograft acute rejection: a living-unrelated donor (LURD) study. Iran. J. Immunol. 3: 150-156 (2006).

• Takada Y, Tanaka K. Living related liver transplantation. Transplant. Proc. 36: S271-S273 (2004). *

• Takahashi H, Ohara M, Imai K. Collagen diseases with gastrointestinal manifestations. Nihon Rinsho Meneki Gakkai Kaishi 27: 145-155 (2004).

• Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, Watanabe S, Shiga Y, Kanaoka C, Fujimori J, Sato S, Itoyama Y. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 130: 1235-1243 (2007).

• Takatsuki M, Chen CL, Chen YS, Wang CC, Lin CC, Yang CH, Yong CC, Liu YW. Impact of late conversion from C0 to C2 monitoring of microemulsified cyclosporine in pediatric living donor liver transplant recipients. Clin. Transplant. 18: 694-699 (2004). *

• Takeshima E, Tomimori K, Takamatsu R, Ishikawa C, Kinjo F, Hirayama T, Fujita J, Mori N. Helicobacter pylori VacA activates NF-kappaB in T cells via the classical but not alternative pathway. Helicobacter 14: 271-279 (2009). *

• Talal N, Flescher E, Dang H. Are endogenous retroviruses involved in human autoimmune disease? J. Autoimmun. 5 Suppl. A: 61-66 (1992).

• Taltavull TC. Impact of cyclosporine on the development of immunosuppressive therapy in liver transplantation. Transplant. Proc. 36: S291-S294 (2004). *

• Tamura S, Sugawara Y, Kishi Y, Akamatsu N, Kaneko J, Murai N, Makuuchi M. Conversion to cyclosporine provides valuable rescue therapy for living donor adult liver transplant patients intolerant to tacrolimus: a single-center experience at the University of Tokyo. Transplant. Proc. 36: 3242-3244 (2004). *

• Tan HP, Wahlstrom HE, Zamora JU, Hassanein T. Aureobasidium pneumonia in a post liver transplant recipient: a case report. Hepatogastroenterology 44: 1215-1218 (1997).

• Tan PH, Yates JB, Xue SA, Chan C, Jordan WJ, Harper JE, Watson MP, Dong R, Ritter MA, Lechler RI, Lombardi G, George AJ. Creation of tolerogenic human DC via intracellular CTLA4: a novel strategy with potential in clinical immunosuppression. Blood 106: 2936-2943 (2005). *

• Tanvetyanon T, Stiff P. Recurrent steroid-responsive pancreatitis associated with myelodysplastic syndrome and transformations. Leuk. Lymphoma 46: 151-154 (2005).

• Tapirdamaz O, Pravica V, Metselaar HJ, Hansen B, Moons LM, van Meurs JB, Hutchinson IV, Shaw J, Agarwal K, Adams DH, Day CP, Kwekkeboom J. Polymorphisms in the T-cell regulatory gene CTLA-4 influence the rate of acute rejection after liver transplantation. Gut 55: 863-868 (2006). *

• Taylor AW, Kitaichi N. The diminishment of experimental autoimmune encephalomyelitis (EAE) by neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH) therapy. Brain Behav. Immun. 22: 639-646 (2008).

• Taylor MD, Harris A, Nair MG, Maizels RM, Allen JE. F4/80+ alternatively activated macrophages control CD4+ T cell hyporesponsiveness at sites peripheral to filarial infection. J. Immunol. 176: 6918-6927 (2006). *

• Taylor PJ, Kubler PA, Lynch SV, Allen J, Butler M, Pillans PI. Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients. Ann. Pharmacother. 38: 205-208 (2004).

• Tchervenkov JI, Tzimas GN, Cantarovich M, Barkun JS, Metrakos P. The impact of thymoglobulin on renal function and calcineurin inhibitor initiation in recipients of orthotopic liver transplant: a retrospective analysis of 298 consecutive patients. Transplant. Proc. 36: 1747-1752 (2004). *

• Teachey DT, Jubelirer T, Baluarte HJ, Wade A, Manno CS. Treatment with sirolimus ameliorates tacrolimus-induced autoimmune cytopenias after solid organ transplant. Pediatr. Blood Cancer 53: 1114-1116 (2009).

• Tector AJ, Fridell JA, Mangus RS, Shah A, Milgrom M, Kwo P, Chalasani N, Yoo H, Rouch D, Liangpunsakul S, Herring S, Lumeng L. Promising early results with immunosuppression using rabbit anti-thymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients. Liver Transpl. 10: 404-407 (2004). *

• Teicher E, Abbara C, Duclos-Vallee JC, Antonini T, Bonhomme-Faivre L, Desbois D, Samuel D, Vittecoq D. Enfuvirtide: a safe and effective antiretroviral agent for human immunodeficiency virus-infected patients shortly after liver transplantation. Liver Transpl. 15: 1336-1342 (2009).

• Teitelbaum JE, Perez-Atayde AR, Cohen M, Bousvaros A, Jonas MM. Minocycline-related autoimmune hepatitis: case series and literature review. Arch. Pediatr. Adolesc. Med. 152: 1132-1136 (1998).

• Thanou-Stavraki A, James JA. Primary Sjogren's syndrome: current and prospective therapies. Semin. Arthritis Rheum. 37: 273-292 (2008). *

• Thapar N, Shah N, Ramsay AD, Lindley KJ, Milla PJ. Long-term outcome of intractable ulcerating enterocolitis of infancy. J. Pediatr. Gastroenterol. Nutr. 40: 582-588 (2005). *

• Therapondos G, Flapan AD, Plevris JN, Hayes PC. Cardiac morbidity and mortality related to orthotopic liver transplantation. Liver Transpl. 10: 1441-1453 (2004). *

• Thimme R, Opitz OG, Blum HE, Kreisel W. Cholestatic liver diseases. Ther. Umsch. 61: 521-527 (2004).

• Thomas CW, Myhre GM, Tschumper R, Sreekumar R, Jelinek D, McKean DJ, Lipsky JJ, Sandborn WJ, Egan LJ. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J. Pharmacol. Exp. Ther. 312: 537-545 (2005). *

• Thomas LD, Hongo I, Bloch KC, Tang YW, Dummer S. Human ehrlichiosis in transplant recipients. Am. J. Transplant. 7: 1641-1647 (2007). *

• Thudi KR, Kreikemeier JT, Phillips NJ, Salvalaggio PR, Kennedy DJ, Hayashi PH. Cat scratch disease causing hepatic masses after liver transplant. Liver Int. 27: 145-148 (2007). *

• Tiao G, Ryckman FC. Pediatric liver transplantation. Clin. Liver Dis. 10: 169-197 (2006).

• Tiegs G, Lohse AW. Immune tolerance: what is unique about the liver. J. Autoimmun. Aug 28 [Epub ahead of print] (2009).

• Tietge UJ, Selberg O, Kreter A, Bahr MJ, Pirlich M, Burchert W, Muller MJ, Manns MP, Boker KH. Alterations in glucose metabolism associated with liver cirrhosis persist in the clinically stable long-term course after liver transplantation. Liver Transpl. 10: 1030-1040 (2004). *

• Tilg H, Moschen AR, Kaser A. Suppression of interleukin-17 by type I interferons: a contributing factor in virus-induced immunosuppression? Eur. Cytokine Netw. 20: 1-6 (2009).

• Timmann C, Fuchs S, Thoma C, Lepping B, Brattig NW, Sievertsen J, Thye T, Muller-Myhsok B, Horstmann RD. Promoter haplotypes of the interleukin-10 gene influence proliferation of peripheral blood cells in response to helminth antigen. Genes Immun. 5: 256-260 (2004). *

• Tishon A, LaFace DM, Lewicki H, van Binnendijk RS, Osterhaus A, Oldstone MB. Transgenic mice expressing human HLA and CD8 molecules generate HLA-restricted measles virus cytotoxic T lymphocytes of the same specificity as humans with natural measles virus infection. Virology 275: 286-293 (2000). *

• Tox U, Theilmann L, Stiehl A. Immunosuppression caused by ursodeoxycholic acid. Z. Gastroenterol. 32: 470-471 (1994).

• Toyoki Y, Hakamada K, Narumi S, Totsuka E, Nara M, Ono H, Ishizawa Y, Sasaki M. Primary immunosuppression regimen of rapid steroid withdrawal after living related liver transplantation: a single-center experience. Transplant. Proc. 36: 2279-2281 (2004). *

• Tracey C, Hawley C, Griffin AD, Strutton G, Lynch S. Generalized, pruritic, ulcerating maculopapular rash necessitating cessation of sirolimus in a liver transplantation patient. Liver Transpl. 11: 987-989 (2005). *

• Trail KC, Stratta RJ, Larsen JL, Langnas AN, Donovan JP, Sorrell MF, Zetterman RK, Taylor RJ, Shaw BW Jr. Orthotopic hepatic transplantation in patients with type I diabetes mellitus. J. Am. Coll. Surg. 178: 337-342 (1994).

• Tran MQ, Gohh RY, Morrissey PE, Dworkin LD, Gautam A, Monaco AP, Yango AF Jr. Cryptosporidium infection in renal transplant patients. Clin. Nephrol. 63: 305-309 (2005).

• Tran TT. Liver transplantation: a clinical update. 54th Annual Meeting of the American Association for the Study of Liver Diseases (2003).

• Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 49: 725-728 (2001). *

• Traynor A, Burt RK. Haematopoietic stem cell transplantation for active systemic lupus erythematosus. Rheumatology (Oxford) 38: 767-772 (1999). *

• Traynor AE, Schroeder J, Rosa RM, Cheng D, Stefka J, Mujais S, Baker S, Burt RK. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. Lancet 356: 701-707 (2000). *

• Trebst C, VoB E, Skripuletz T, Stangel M. Specific immune intervention with monoclonal antibodies for the treatment of multiple sclerosis. Curr. Med. Chem. Jan 21 [Epub ahead of print] (2010).

• Tredger JM, Brown NW, Adams J, Gonde CE, Dhawan A, Rela M, Heaton N. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range. Liver Transpl. 10: 492-502 (2004). *

• Triulzi DJ. Transfusion support in liver transplantation. Curr. Hematol. Rep. 3: 444-449 (2004).

• Trotter J, Wallack A, Steinberg T. Low incidence of cytomegalovirus disease in liver transplant recipients receiving sirolimus primary immunosuppression with 3-day corticosteroid taper. Transpl. Infect. Dis. 5: 174-180 (2003). *

• Trotter JF, Wachs ME, Trouillot TE, Bak T, Kugelmas M, Kam I, Everson G. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus. Liver Transpl. 7: 401-408 (2001). *

• Trouillot TE, Shrestha R, Kam I, Wachs M, Everson GT. Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis. Liver Transpl. Surg. 5: 375-380 (1999).

• Trune DR, Kempton JB. Blocking the glucocorticoid receptor with RU-486 does not prevent glucocorticoid control of autoimmune mouse hearing loss. Audiol. Neurootol. 14: 423-431 (2009).

• Trunecka P. Immunological mechanisms of liver allograft rejection. Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 44-46. September 12 - 13 (2003). *

• Truong W, Hancock WW, Anderson CC, Merani S, Shapiro AM. Coinhibitory T-cell signaling in islet allograft rejection and tolerance. Cell Transplant. 15: 105-119 (2006).

• Truong W, Shapiro AM. The TIM family of cosignaling receptors: emerging targets for the regulation of autoimmune disease and transplantation tolerance. Cell. Transplant. 16: 977-986 (2008).

• Tryphonopoulos P, Tzakis AG, Weppler D, Garcia-Morales R, Kato T, Madariaga JR, Levi DM, Nishida S, Moon J, Selvaggi G, Regev A, Nery C, Bejarano P, Khaled A, Kleiner G, Esquenazi V, Miller J, Ruiz P, Ricordi C. The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation. Am. J. Transplant. 5: 608-613 (2005). *

• Tsikrikoni A, Rigopoulou EI, Zachou K, Liaskos C, Kyriakou D, Dalekos GN. Bone marrow findings in patients with autoimmune liver diseases. J. Gastroenterol. Hepatol. 23: e416-e421 (2008). *

• Tsunemi Y, Tada Y, Saeki H, Ihn H, Tamaki K. Multiple dermatofibromas in a patient with systemic lupus erythematosus and Sjogren's syndrome. Clin. Exp. Dermatol. 29: 483-485 (2004). *

• Tsunoda I, Fujinami RS. Neuropathogenesis of Theiler's murine encephalomyelitis virus infection, an animal model for multiple sclerosis. J. Neuroimmune Pharmacol. Nov 6 [Epub ahead of print] (2009).

• Tuchinda P, Boonchai W, Prukpaisarn P, Maungprasat C, Suthipinittharm P. Prevalence of onychomycosis in patients with autoimmune diseases. J. Med. Assoc. Thai. 89: 1249-1252 (2006).

• Turley DM, Miller SD. Prospects for antigen-specific tolerance based therapies for the treatment of multiple sclerosis. Results Probl. Cell Differ. Jan 8 [Epub ahead of print] (2009).

• Tutaj M, Szczepanik M. Mechanisms involved in the regulation of immune response in experimental autoimmune encephalomyelitis in mice. Postepy. Hig. Med. Dosw. (Online) 60: 571-583 (2006).

• Tutaj M, Szczepanik M. Epicutaneous (EC) immunization with myelin basic protein (MBP) induces TCRalphabeta(+) CD4(+) CD8(+) double positive suppressor cells that protect from experimental autoimmune encephalomyelitis (EAE). J. Autoimmun. 28: 208-215 (2007).

• Tuve S, Chen BM, Liu Y, Cheng TL, Toure P, Sow PS, Feng Q, Kiviat N, Strauss R, Ni S, Li ZY, Roffler SR, Lieber A. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res. 67: 5929-5939 (2007). *

• Tyndall A. Hematopoietic stem cell transplantation in rheumatic diseases other than systemic sclerosis and systemic lupus erythematosus. J. Rheumatol. Suppl. 48: 94-97 (1997).

• Tyndall A, Gratwohl A. Adult stem cell transplantation in autoimmune disease. Curr. Opin. Hematol. 16: 285-291 (2009).

• Tyndall A, Matucci-Cerinic M. Haematopoietic stem cell transplantation for the treatment of systemic sclerosis and other autoimmune disorders. Expert Opin. Biol. Ther. 3: 1041-1049 (2003).

• Tzakis AG, Tryphonopoulos P, Kato T, Nishida S, Levi DM, Madariaga JR, Gaynor JJ, De Faria W, Regev A, Esquenazi V, Weppler D, Ruiz P, Miller J. Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation 77: 1209-1214 (2004).

• Tzaribachev N, Well C, Schedel J, Horger M. Whole-body MRI: a helpful diagnostic tool for juvenile dermatomyositis case report and review of the literature. Rheumatol. Int. 29: 1511-1514 (2009). *

• Tzimas GN, Deschenes M, Barkun JS, Wong P, Tchervenkov JI, Hayati H, Alpert E, Metrakos P. Leukoreduction and acute rejection in liver transplantation: an interim analysis. Transplant. Proc. 36: 1760-1762 (2004). *

• Tzu J, Kerdel F. From conventional to cutting edge: the new era of biologics in treatment of psoriasis. Dermatol. Ther. 21: 131-141 (2008).

• Uccelli A, Zappia E, Benvenuto F, Frassoni F, Mancardi G. Stem cells in inflammatory demyelinating disorders: a dual role for immunosuppression and neuroprotection. Expert Opin. Biol. Ther. 6: 17-22 (2006).

• Ueki S, Yamashita K, Aoyagi T, Haga S, Suzuki T, Itoh T, Taniguchi M, Shimamura T, Furukawa H, Ozaki M, Umezawa K, Todo S. Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin. Transplantation 82: 1720-1727 (2006).

• Uemoto S, Tanaka K, Fujita S, Sano K, Shirahase I, Kato H, Yamamoto E, Inomata Y, Ozawa K. Infectious complications in living related liver transplantation. J. Pediatr. Surg. 29: 514-517 (1994).

• Uhlin M, Masucci M, Levitsky V. Is the activity of partially agonistic MHC:peptide ligands dependent on the quality of immunological help? Scand. J. Immunol. 64: 581-587 (2006). *

• Ulinski T, Perrin L, Morris M, Houang M, Cabrol S, Grapin C, Chabbert-Buffet N, Bensman A, Deschenes G, Giurgea I. APECED syndrome with renal failure: impact of post transplant immunosuppression on disease activity. J. Clin. Endocrinol. Metab. 91: 192-195 (2006). *

• Unger WW, Laban S, Kleijwegt FS, van der Slik AR, Roep BO. Induction of regulatory T cells by monocyte-derived dendritic cells modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur. J. Immunol. 39: 3147-3159 (2009). *

• Urbani L, Mazzoni A, Catalano G, De Simone P, Vanacore R, Pardi C, Bortoli M, Biancofiore G, Campani D, Perrone V, Mosca F, Scatena F, Filipponi F. The use of extracorporeal photopheresis for allograft rejection in liver transplant recipients. Transplant. Proc. 36: 3068-3070 (2004). *

• Usui M, Isaji S, Mizuno S, Sakurai H, Uemoto S. Experiences and problems pre-operative anti-CD20 monoclonal antibody infusion therapy with splenectomy and plasma exchange for ABO-incompatible living-donor liver transplantation. Clin. Transplant. 21: 24-31 (2007). *

• Usuki S, Taguchi K, Thompson SA, Chapman PB, Yu RK. Novel anti-idiotype antibody therapy for lipooligosaccharide-induced experimental autoimmune neuritis: Use relevant to Guillain-Barre syndrome. J. Neurosci. Res. Jan 13 [Epub ahead of print] (2010).

• Utterson EC, Shepherd RW, Sokol RJ, Bucuvalas J, Magee JC, McDiarmid SV, Anand R; The Split Research Group. Biliary atresia: clinical profiles, risk factors, and outcomes of 755 patients listed for liver transplantation. J. Pediatr. 147: 180-185 (2005). *

• Vaknin I, Blinder L, Wang L, Gazit R, Shapira E, Genina O, Pines M, Pikarsky E, Baniyash M. A common pathway mediated through Toll-like receptors leads to T and natural killer cell immunosuppression. Blood 111: 1437-1447 (2008). *

• Vallejo R, De Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review. Am. J. Ther. 11: 354-365 (2004).

• Van Assche G, Magdelaine-Beuzelin C, D'Haens G, Baert F, Noman M, Vermeire S, Ternant D, Watier H, Paintaud G, Rutgeerts P. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134: 1861-1868 (2008). *

• Van Assche G, Vermeire S, Rutgeerts P. Immunosuppression in inflammatory bowel disease: traditional, biological or both? Curr. Opin. Gastroenterol. 25: 323-328 (2009).

• Van Dam GM, Gips CH. Primary biliary cirrhosis in The Netherlands. An analysis of associated diseases, cardiovascular risk, and malignancies on the basis of mortality figures. Scand. J. Gastroenterol. 32: 77-83 (1997).

• van de Vrie W, de Man RA, van Buuren HR, Schouten WR, Tilanus HW, Metselaar HJ. Inflammatory bowel disease and liver transplantation for primary sclerosing cholangitis. Eur. J. Gastroenterol. Hepatol. 15: 657-663 (2003).

• van Deventer SJ. New biological therapies in inflammatory bowel disease. Best Pract. Res. Clin. Gastroenterol. 17: 119-130 (2003). *

• van Dieren JM, Kuipers EJ, Samsom JN, Nieuwenhuis EE, van der Woude CJ. Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD. Inflamm. Bowel Dis. 12: 311-327 (2006). *

• van Laar JM, Tyndall A. Adult stem cells in the treatment of autoimmune diseases. Rheumatology (Oxford) 45: 1187-1193 (2006). *

• Van Laar JM, Tyndall A. Intense immunosuppression and stem-cell transplantation for patients with severe rheumatic autoimmune disease: a review. Cancer Control 10: 57-65 (2003). *

• van Laar JM, Verburg RJ, Fibbe WE, Breedveld FC. Intensive immunosuppression and autologous stem cell transplantation for patients with severe rheumatoid arthritis: the Leiden experience. J. Rheumatol. Suppl. 64: 25-27 (2001).

• van Poll D, Parekkadan B, Cho CH, Berthiaume F, Nahmias Y, Tilles AW, Yarmush ML. Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology 47: 1634-1643 (2008). *

• Van Thiel DH, Finkel R, Friedlander L, Gavaler JS, Wright HI, Gordon R. The association of IgA deficiency but not IgG or IgM deficiency with a reduced patient and graft survival following liver transplantation. Transplantation 54: 269-273 (1992).

• Varani S, Frascaroli G, Landini MP, Soderberg-Naucler C. Human cytomegalovirus targets different subsets of antigen-presenting cells with pathological consequences for host immunity: implications for immunosuppression, chronic inflammation and autoimmunity. Rev. Med. Virol. 19: 131-145 (2009).

• Vasoo S, Hughes GR. Theory, targets and therapy in systemic lupus erythematosus. Lupus 14: 181-188 (2005).

• Vendrame F, Pileggi A, Laughlin E, Allende G, Martin-Pagola A, Molano RD, Diamantopoulos S, Standifer N, Geubtner K, Falk BA, Ichii H, Takahashi H, Snowhite I, Chen Z, Mendez A, Chen L, Sageshima J, Ruiz P, Ciancio G, Ricordi C, Reijonen H, et al. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes Jan 19 [Epub ahead of print] (2010).

• Venet F, Tissot S, Debard AL, Faudot C, Crampe C, Pachot A, Ayala A, Monneret G. Decreased monocyte human leukocyte antigen-DR expression after severe burn injury: correlation with severity and secondary septic shock. Crit. Care Med. 35: 1910-1917 (2007).

• Venick RS, McDiarmid SV, Farmer DG, Gornbein J, Martin MG, Vargas JH, Ament ME, Busuttil RW. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am. J. Transplant. 7: 955-963 (2007). *

• Vera A, Gunson BK, Ussatoff V, Nightingale P, Candinas D, Radley S, Mayer AD, Buckels JA, McMaster P, Neuberger J, Mirza DF. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation 75: 1983-1988 (2003).

• Verbeeck J, Van Assche G, Ryding J, Wollants E, Rans K, Vermeire S, Pourkarim M, Noman M, Dillner J, Van Ranst M, Rutgeerts P. JC viral loads in Crohn's disease patients treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy? Gut 57: 1393-1397 (2008).

• Verburg R, Flierman R, Sont J, Ponchel F, van Dreunen L, Levahrt N, Welling M, Toes R, Isaacs J, van Laar JM. The outcome of intensive immunosuppression and autologous stem cell transplantation in patients with severe rheumatoid arthritis is associated with the composition of synovial T cell infiltration. Ann. Rheum. Dis. 64: 1397-1405 (2005). *

• Verdonk RC, Haagsma EB, Jonker MR, Bok LI, Zandvoort JH, Kleibeuker JH, Faber KN, Dijkstra G. Effects of different immunosuppressive regimens on regulatory T-cells in noninflamed colon of liver transplant recipients. Inflamm. Bowel Dis. 13: 703-709 (2007). *

• Vergani D, Mieli-Vergani G. Chapter 20. Autoimmune hepatitis. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 263-275 (2007). *

• Vergani D, Mieli-Vergani G. Autoimmune hepatitis. Ann. Ital. Med. Int. 11: 119-124 (1996).

• Verma S, Torbenson M, Thuluvath PJ. The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology 46: 1828-1835 (2007). *

• Vermeire S, Noman M, van Assche G, Baert F, D'Haens G, Rutgeerts PJ. Effectiviness of concomitant immunosuppressive therapy to suppress formation of antibodies to infliximab in crohn's disease. Gut 56: 1226-1231 (2007). *

• Viazis N, Vlachogiannakos J, Georgiou O, Rodias M, Georgiadis D, Papastamopoulos V, Baraboutis IG, Karamanolis DG, Skoutelis A. Course of inflammatory bowel disease in patients infected with human immunodeficiency virus. Inflamm. Bowel Dis. 16: 507-511 (2010).

• Vierling JM. Chapter 30. Clinical use of immunosuppressive drugs to control the immune response. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 391-407 (2007). *

• Vierling JM. Is primary sclerosing cholangitis an autoimmune disease? Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 67-69. October 15-16 (2003). *

• Vierling JM. The liver as an immune organ. Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 19-22. September 12 - 13 (2003). *

• Vincent S, Slease RB, Rocca PV. Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics? Del. Med. J. 74: 469-473 (2002).

• Vincenti F. Costimulation blockade in autoimmunity and transplantation. J. Allergy Clin. Immunol. 121: 299-306 (2008). *

• Vincenti F. What’s in the pipeline? New immunosuppressive drugs in transplantation. Am. J. Transplant. 2: 898-903 (2002). *

• Vincenti FG, Luggen M. T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation. Annu. Rev. Med. 58: 347-358 (2007). *

• Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, Coutinho M, Malmegrim KC, Foss-Freitas MC, Simoes BP, Foss MC, Squiers E, Burt RK. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 297: 1568-1576 (2007). *

• von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat. Immunol. 6: 338-344 (2005). *

• Voss CY, Fry TJ, Coppes MJ, Blajchman MA. Extending the horizon for cell-based immunotherapy by understanding the mechanisms of action of photopheresis. Transfus. Med. Rev. 24: 22-32 (2010).

• Waaga-Gasser AM, Grimm MR, Lutz J, Lange V, Lenhard SM, Aviles B, Kist-van Holthe JE, Lebedeva T, Samsonov D, Meyer D, Hancock WW, Heemann U, Gasser M, Chandraker A. Regulatory allospecific T cell clones abrogate chronic allograft rejection. J. Am. Soc. Nephrol. 20: 820-830 (2009).

• Wagner M, Zeuzem S. Prophylaxis and therapy of reactivation of hepatitis B in immunosuppressed patients. Dtsch. Med. Wochenschr. 134: 255-258 (2009).

• Wahbeh G, Hupertz V, Hallowell S, Patel R, Chrisant MR. Idiopathic colitis following cardiac transplantation: three pediatric cases. Pediatr. Transplant. 7: 464-468 (2003).

• Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J. Clin. Invest. 101: 1163-1174 (1998). *

• Wakata N, Sugimoto H, Nomoto N, Konno S, Nakazora H, Nemoto H, Karihara T. Extrathymic tumors in patients with myasthenia gravis: a 35-year retrospective study. Neurologist 12: 53-55 (2006).

• Waldman M, Appel GB. Update on the treatment of lupus nephritis. Kidney Int. 70: 1403-1412 (2006). *

• Walker LS. Regulatory T cells overturned: the effectors fight back. Immunology 126: 466-474 (2009). *

• Wall WJ, Duff JH, Ghent CN, Stiller CR, Keown PA, Kutt JL. Liver transplantation: the initial experience of a Canadian centre. Can. J. Surg. 28: 286-289 (1985).

• Wallot MA, Mathot M, Janssen M, Holter T, Paul K, Buts JP, Reding R, Otte JB, Sokal EM. Long-term survival and late graft loss in pediatric liver transplant recipients - a 15-year single-center experience. Liver Transpl. 8: 615-622 (2002). *

• Walsh KP, Brady MT, Finlay CM, Boon L, Kingston HG. Infection with a helminth parasite attenuates autoimmunity through TGF-beta-mediated suppression of Th17 and Th1 responses. J. Immunol. 183: 1577-1586 (2009).

• Wang GY, Meng W, Ji B, Du XH, Zhao J. Expression of inducible nitric oxide synthase in transplanted rat liver and its inhibitory effect. Hepatobiliary Pancreat. Dis. Int. 4: 360-363 (2005). *

• Wang J, Lu ZH, Gabius HJ, Rohowsky-Kochan C, Ledeen RW, Wu G. Cross-linking of GM1 ganglioside by galectin-1 mediates regulatory T cell activity involving TRPC5 channel activation: possible role in suppressing experimental autoimmune encephalomyelitis. J. Immunol. 182: 4036-4045 (2009).

• Wang L, Jameson SC, Hogquist KA. Epidermal Langerhans cells are not required for UV-induced immunosuppression. J. Immunol. 183: 5548-5553 (2009).

• Wang LY, Zeng Y, Pan ZZ, Zhu ZH. Detection of intracellular and extracellular cytokines of CD(4+)CD(25+) regulatory T cells in gastric cancer patients. Ai Zheng 26: 270-273 (2007).

• Wang S, Mao C, Zhao Z, Gu Q, Jin M, Xiao Y, Jiang X, Zhao Y, Zhang Y, Ning G. Increased TTS abrogates IDO-mediated CD4(+) T cells suppression in patients with Graves' disease. Endocrine 36: 119-125 (2009).

• Wang Z, Duarte AG, Schnadig VJ. Fatal reactive hemophagocytosis related to disseminated histoplasmosis with endocarditis: an unusual case diagnosed at autopsy. South. Med. J. 100: 208-211 (2007).

• Warle MC, Metselaar HJ, Hop WC, Tilanus HW. Cytokine gene polymorphisms and acute liver graft rejection: a meta-analysis. Liver Transpl. 11: 19-26 (2005). *

• Washington K. Update on post-liver transplantation infections, malignancies, and surgical complications. Adv. Anat. Pathol. 12: 221-226 (2005).

• Weber C, Krueger A, Munk A, Bode C, Van Veldhoven PP, Graler MH. Discontinued postnatal thymocyte development in sphingosine 1-phosphate-lyase-deficient mice. J. Immunol. 183: 4292-4301 (2009).

• Webster KE, Walters S, Kohler RE, Mrkvan T, Boyman O, Surh CD, Grey ST, Sprent J. In vivo expansion of Treg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J. Exp. Med. 206: 751-760 (2009). *

• Wei HB, Wang JF, Chen GH. Effect of retinoic acid (RA) on the T-lymphocyte subsets and T-cell colony of patients with colorectal cancer. Ai Zheng 22: 202-205 (2003).

• Wei SH, Ho MC, Ni YH, Lin DT, Lee PH. Cytomegalovirus-associated immune thrombocytopenic purpura after liver transplantation. J. Formos. Med. Assoc. 106: 327-329 (2007).

• Weiner HL. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch. Neurol. 61: 1613-1615 (2004). *

• Weitzel LR, Mayles WJ, Sandoval PA, Wischmeyer PE. Effects of pharmaconutrients on cellular dysfunction and the microcirculation in critical illness. Curr. Opin. Anaesthesiol. 22: 177-183 (2009).

• Welsh CJ, Steelman AJ, Mi W, Young CR, Storts R, Welsh TH Jr, Meagher MW. Neuroimmune interactions in a model of multiple sclerosis. Ann. N. Y. Acad. Sci. 1153: 209-219 (2009). *

• Welt CK. Autoimmune oophoritis in the adolescent. Ann. N. Y. Acad. Sci. 1135: 118-122 (2008). *

• Wen H, Dou Y, Hogaboam CM, Kunkel SL. Epigenetic regulation of dendritic cell-derived interleukin-12 facilitates immunosuppression after a severe innate immune response. Blood 111: 1797-1804 (2008). *

• Wen H, Schaller MA, Dou Y, Hogaboam CM, Kunkel SL. Dendritic cells at the interface of innate and acquired immunity: the role for epigenetic changes. J. Leukoc. Biol. 83: 439-446 (2008). *

• Weng X, Zhong M, Liang Z, Lu S, Hao J, Chen X, Li J, Gong F, Wu X. Peptide-dependent inhibition of alloreactive T-cell response by soluble divalent HLA-A2/IgG molecule in vitro. Transplantation 84: 1298-1306 (2007).

• Wesley Alexander J, Goodman HR, Cardi M, Austin J, Goel S, Safdar S, Huang S, Munda R, Fidler JP, Buell JF, Hanaway M, Susskind B, Roy-Chaudhury P, Trofe J, Alloway R, Steve Woodle E. Simultaneous corticosteroid avoidance and calcineurin inhibitor minimization in renal transplantation. Transpl. Int. 19: 295-302 (2006). *

• West K. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr. Opin. Investig. Drugs 10: 491-504 (2009).

• Westall FC. Comments to: integrating theories of the etiology of Crohn's disease on the etiology of Crohn's disease: questioning the hypotheses. Med. Sci. Monit. 12: LE5-LE6 (2006). *

• Westendorf AM, Fleissner D, Deppenmeier S, Gruber AD, Bruder D, Hansen W, Liblau R, Buer J. Autoimmune-mediated intestinal inflammation - impact and regulation of antigen-specific CD8(+) T cells. Gastroenterology 131: 510-524 (2006). *

• Whartenby KA, Calabresi PA, McCadden E, Nguyen B, Kardian D, Wang T, Mosse C, Pardoll DM, Small D. Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. Proc. Natl. Acad. Sci. U.S.A. 102: 16741-16746 (2005). *

• Wiegard C, Lohse AW. Liver and rheumatism. Z. Rheumatol. 64: 26-31 (2005).

• Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 16: 183-200 (2002).

• Wiesner RH. Advances in diagnosis, prevention, and management of hepatic allograft rejection. Clin. Chem. 40: 2174-2185 (1994). *

• Wiesner RH, Rakela J, Ishitani MB, Mulligan DC, Spivey JR, Steers JL, Krom RA. Recent advances in liver transplantation. Mayo Clin. Proc. 78: 197-210 (2003). *

• Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford) 48: 716-720 (2009).

• Williams JM. Potential immunosuppressive therapeutics to target small vessel vasculitis of the kidney. Curr. Opin. Investig. Drugs 6: 1142-1148 (2005).

• Williams JW, Vera SR, Peters TG, Van Voorst S. Survival following hepatic transplantation in the cyclosporine era. Am. Surg. 52: 291-293 (1986).

• Wilson NS, Behrens GM, Lundie RJ, Smith CM, Waithman J, Young L, Forehan SP, Mount A, Steptoe RJ, Shortman KD, de Koning-Ward TF, Belz GT, Carbone FR, Crabb BS, Heath WR, Villadangos JA. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat. Immunol. 7: 165-172 (2006). *

• Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr. Treat. Options Neurol. 10: 55-66 (2008).

• Winston N, Vernino S. Autoimmune autonomic ganglionopathy. Front. Neurol. Neurosci. 26: 85-93 (2009).

• Wissing KM, Fomegne G, Broeders N, Ghisdal L, Hoang AD, Mikhalski D, Donckier V, Vereerstraeten P, Abramowicz D. HLA mismatches remain risk factors for acute kidney allograft rejection in patients receiving quadruple immunosuppression with anti-interleukin-2 receptor antibodies. Transplantation 85: 411-416 (2008).

• Witt MN, Braun GS, Ihrler S, Schmid H. Occurrence of HSV-1-induced pneumonitis in patients under standard immunosuppressive therapy for rheumatic, vasculitic, and connective tissue disease. BMC Pulm. Med. 9: 22 (2009). *

• Wittig B, Schwarzler C, Fohr N, Gunthert U, Zoller M. Curative treatment of an experimentally induced colitis by a CD44 variant V7-specific antibody. J. Immunol. 161: 1069-1073 (1998). *

• Wolf AM, Eller K, Zeiser R, Durr C, Gerlach UV, Sixt M, Markut L, Gastl G, Rosenkranz AR, Wolf D. The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo. J. Immunol. 183: 3751-3760 (2009).

• Wolfraim LA. Treating autoimmune diseases through restoration of antigen-specific immune tolerance. Arch. Immunol. Ther. Exp. (Warsz.) 54: 1-13 (2006).

• Wollina U. Clinical management of pyoderma gangrenosum. Am. J. Clin. Dermatol. 3: 149-158 (2002).

• Wong MT, Eu KW. Primary colorectal lymphomas. Colorectal Dis. 8: 586-591 (2006). *

• Wong NA, Herbst H, Herrmann K, Kirchner T, Krajewski AS, Moorghen M, Niedobitek F, Rooney N, Shepherd NA, Niedobitek G. Epstein-Barr virus infection in colorectal neoplasms associated with inflammatory bowel disease: detection of the virus in lymphomas but not in adenocarcinomas. J. Pathol. 201: 312-318 (2003). *

• Wong PY, Portmann B, O'Grady JG, Devlin JJ, Hegarty JE, Tan KC, Williams R. Recurrence of primary biliary cirrhosis after liver transplantation following FK506-based immunosuppression. J. Hepatol. 17: 284-287 (1993).

• Wong RT, Hon CC, Zeng F, Leung FC. Screening of differentially expressed transcripts in infectious bursal disease virus-induced apoptotic chicken embryonic fibroblasts by using cDNA microarrays. J. Gen. Virol. 88: 1785-1796 (2007). *

• World MJ, Stevens PE, Ashton MA, Rainford DJ. Mesalazine-associated interstitial nephritis. Nephrol. Dial. Transplant. 11: 614-621 (1996).

• Worns MA, Lohse AW, Neurath MF, Croxford A, Otto G, Kreft A, Galle PR, Kanzler S. Five cases of de novo inflammatory bowel disease after orthotopic liver transplantation. Am. J. Gastroenterol. 101: 1931-1937 (2006). *

• Wrzesinski SH, Wan YY, Flavell RA. Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin. Cancer Res. 13: 5262-5270 (2007). *

• Wu QL, Fu YF, Zhou WL, Wang JX, Feng YH, Liu J, Xu JY, He PL, Zhou R, Tang W, Wang GF, Zhou Y, Yang YF, Ding J, Li XY, Chen XR, Yuan C, Lawson BR, Zuo JP. Inhibition of S-adenosyl-L-homocysteine hydrolase induces immunosuppression. J. Pharmacol. Exp. Ther. 313: 705-711 (2005). *

• Wu SL, Pan CE, Yu L, Meng KW. Immunosuppression by combined use of cyclosporine and resveratrol in a rat liver transplantation model. Transplant. Proc. 37: 2354-2359 (2005). *

• Wu YM, Joseph B, Gupta S. Immunosuppression using the mTOR inhibition mechanism affects replacement of rat liver with transplanted cells. Hepatology 44: 410-419 (2006). *

• Wulff H, Pennington M. Targeting effector memory T-cells with Kv1.3 blockers. Curr. Opin. Drug Discov. Devel. 10: 438-445 (2007).

• Xia CQ, Campbell KA, Clare-Salzler MJ. Extracorporeal photopheresis-induced immune tolerance: a focus on modulation of antigen-presenting cells and induction of regulatory T cells by apoptotic cells. Curr. Opin. Organ Transplant. 14: 338-343 (2009).

• Xiao SY, Lu L, Wang HL. Fibrosing cholestatic hepatitis: clinicopathologic spectrum, diagnosis and pathogenesis. Int. J. Clin. Exp. Pathol. 1: 396-402 (2008). *

• Xu H, Mao Y, Dai Y, Wang Q, Zhang X. CD4CD25+ regulatory T cells in patients with advanced gastrointestinal cancer treated with chemotherapy. Onkologie 32: 246-252 (2009).

• Xu J, Lucas R, Wendel A. The potential of GM-CSF to improve resistance against infections in organ transplantation. Trends Pharmacol. Sci. 25: 254-258 (2004). *

• Xu L, Zhang F, Xu W, Xiong S. Specific antibodies induced by DNA vaccination with extracellular domain of CD25 gene protect against ConA-induced autoimmune hepatitis. Clin. Immunol. 132: 412-419 (2009). *

• Yagi T, Hattori H, Ohira M, Nakamichi K, Takayama-Ito M, Saijo M, Shimizu T, Ito D, Takahashi K, Suzuki N. Progressive multifocal leukoencephalopathy developed in incomplete Heerfordt syndrome, a rare manifestation of sarcoidosis, without steroid therapy responding to cidofovir. Clin. Neurol. Neurosurg. Nov 3 [Epub ahead of print] (2009).

• Yamagiwa S, Ichida T. Recurrence of primary biliary cirrhosis and primary sclerosing cholangitis after liver transplantation in Japan. Hepatol. Res. 37 Suppl. 3: S449-S454 (2007). *

• Yang JH, Wu SL. Multiple sclerosis preceding CNS lymphoma: a case report. Acta Neurol. Taiwan 16: 92-97 (2007).

• Yang Q, Xie Y, Alexson SE, Nelson BD, DePierre JW. Involvement of the peroxisome proliferator-activated receptor alpha in the immunomodulation caused by peroxisome proliferators in mice. Biochem. Pharmacol. 63: 1893-1900 (2002). *

• Yang Z, Zhang B, Li D, Lv M, Huang C, Shen GX, Huang B. Mast cells mobilize myeloid-derived suppressor cells and Treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model. PLoS One 5: e8922 (2010). *

• Yaniv I, Ash S, Farkas DL, Askenasy N, Stein J. Consideration of strategies for hematopoietic cell transplantation. J. Autoimmun. 33: 255-259 (2009).

• Yeung MY, Sayegh MH. Regulatory T cells in transplantation: what we know and what we do not know. Transplant. Proc. 41: S21-S26 (2009). *

• Yin X, Knecht DA, Lynes MA. Metallothionein mediates leukocyte chemotaxis. BMC Immunol. 6: 21 (2005). *

• Yong Z, Chang L, Mei YX, Yi L. Role and mechanisms of CD4(+)CD25(+) regulatory T cells in the induction and maintenance of transplantation tolerance. Transpl. Immunol. 17: 120-129 (2007).

• Yoon JH, Gores GJ. Diagnosis, staging, and treatment of cholangiocarcinoma. Curr. Treat. Options Gastroenterol. 6: 105-112 (2003).

• Yoshida EM, Devonshire VA, Prout AJ. Remission of multiple sclerosis post-liver transplantation. Can. J. Neurol. Sci. 31: 539-541 (2004).

• Yoshida EM, Singh RA, Vartanian RK, Owen DA, Erb SR, Scudamore CH. Late recurrent post-transplant primary biliary cirrhosis in British Columbia. Can. J. Gastroenterol. 11: 229-233 (1997). *

• Yoshida H. Immune regulation by IL-27 for therapeutic usage. Nihon Rinsho Meneki Gakkai Kaishi 32: 202-213 (2009).

• Yoshida H, Nakaya M, Miyazaki Y. Interleukin 27: a double-edged sword for offense and defense. J. Leukoc. Biol. 86: 1295-1303 (2009). *

• Yoshida H, Yoshiyuki M. Regulation of immune responses by interleukin-27. Immunol. Rev. 226: 234-247 (2008). *

• Yoshikawa M, Tsujii T, Matsumura K, Yamao J, Matsumura Y, Kubo R, Fukui H, Ishizaka S. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 16: 358-364 (1992).

• Young LJ, Wilson NS, Schnorrer P, Mount A, Lundie RJ, La Gruta NL, Crabb BS, Belz GT, Heath WR, Villadangos JA. Dendritic cell preactivation impairs MHC class II presentation of vaccines and endogenous viral antigens. Proc. Natl. Acad. Sci. U.S.A. 104: 17753-17758 (2007). *

• Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7: 41-51 (2007). *

• Yu J, Sauter S, Parlesak A. Suppression of TNF-alpha production by S-adenosylmethionine in human mononuclear leukocytes is not mediated by polyamines. Biol. Chem. 387: 1619-1627 (2006).

• Yu P, Xiong S, He Q, Chu Y, Lu C, Ramlogan CA, Steel JC. Induction of allogeneic mixed chimerism by immature dendritic cells and bone marrow transplantation leads to prolonged tolerance to major histocompatibility complex disparate allografts. Immunology 127: 500-511 (2009). *

• Zaba R, Grzybowski A, Prokop J, Zaba Z, Zaba C. Fournier's gangrene: historical survey, current status, and case description. Med. Sci. Monit. 15: CS34-CS39 (2009). *

• Zaccaria E, Rebora A, Rongioletti F. Multiple eruptive dermatofibromas and immunosuppression: report of two cases and review of the literature. Int. J. Dermatol. 47: 723-727 (2008). *

• Zaffaroni M, Ghezzi A, Comi G. Intensive immunosuppression in multiple sclerosis. Neurol. Sci. 27 Suppl. 1: s13-s17 (2006). *

• Zamir G, Gelman AE, Olthoff KM, Debonera F, Aldeguer X, Shaked A. Patterns of transgene expression and viral clearance from the transplanted liver following ex vivo adenovirus-mediated gene transfer. J. Hepatol. 41: 714-720 (2004). *

• Zandi P, Panis Y, Debray D, Bernard O, Houssin D. Pediatric liver transplantation for Langerhans' cell histiocytosis. Hepatology 21: 129-133 (1995).

• Zandman-Goddard G, Shoenfeld Y. Infections and SLE. Autoimmunity 38: 473-485 (2005).

• Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. Autoimmun. Rev. 1: 329-337 (2002).

• Zankel E, Rogler G, Andus T, Reng CM, Scholmerich J, Timmer A. Crohn's disease patient characteristics in a tertiary referral center: comparison with patients from a population-based cohort. Eur. J. Gastroenterol. Hepatol. 17: 395-401 (2005).

• Zeevi A, Lunz JG 3rd, Shapiro R, Randhawa P, Mazariegos G, Webber S, Girnita A. The emerging role of donor-specific anti-human leukocyte antigen antibody determination for clinical management after solid organ transplantation. Hum. Immunol. 70: 645-650 (2009).

• Zeitler H, Ulrich-Merzenich G, Goldmann G, Vidovic N, Brackmann HH, Oldenburg J. The relevance of the bleeding severity in the treatment of acquired haemophilia - an update of a single-centre experience with 67 patients. Haemophilia Nov 14 [Epub ahead of print] (2008).

• Zhang H, Stern JN, Strominger JL. T cell receptors in an IL-10-secreting amino acid copolymer-specific regulatory T cell line that mediates bystander immunosuppression. Proc. Natl. Acad. Sci. U.S.A. 106: 3336-3341 (2009). *

• Zhang Y, Yao YM, Yu Y, Wu Y, Sheng ZY. Influence of high mobility group box-1 protein on the correlation between regulatory T cells and CD4+ CD25- T cells of spleen in mice. Zhonghua Wai Ke Za Zhi 46: 217-220 (2008).

• Zhao Y, Li J, Yu K, Liu Y, Chen X. Sinomenine inhibits maturation of monocyte-derived dendritic cells through blocking activation of NF-kappa B. Int. Immunopharmacol. 7: 637-645 (2007).

• Zhu X, Yang P, Zhou H, Li B, Huang X, Meng Q, Wang L, Kijlstra A. CD4(+)CD25 (+)Tregs express an increased LAG-3 and CTLA-4 in anterior chamber-associated immune deviation. Graefes Arch. Clin. Exp. Ophthalmol. 245: 1549-1557 (2007). *

• Zimmer C, Beiderlinden M, Peters J. Lethal acute respiratory distress syndrome during anti-TNF-alpha therapy for rheumatoid arthritis. Clin. Rheumatol. 25: 430-432 (2006).

• Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Wright F, Steinberg T, Bennett W, Kam I. Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience. Transpl. Int. 20: 747-753 (2007).

• Zivkovic SA, Jumaa M, Barisic N, McCurry K. Neurologic complications following lung transplantation. J. Neurol. Sci. 280: 90-93 (2009).

• Zmora O, Khaikin M, Pishori T, Pikarsky A, Dinnewitzer A, Weiss EG, Nogueras JJ, Wexner SD. Should ileoanal pouch surgery be staged for patients with mucosal ulcerative colitis on immunosuppressives? Int. J. Colorectal Dis. 22: 289-292 (2007). *

• Zozulya AA, Gabaeva MV, Sokolov OY, Surkina ID, Kost NV. Personality, coping style, and constitutional neuroimmunology. J. Immunotoxicol. 5: 221-225 (2008).

Number of references = 1338

www psc-literature.org